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ABSTRACT 
 
PSEUDOMONAS AERUGINOSA PILIN GLYCOSYLATION: THE ROLE OF THE PILIN 
GLYCAN IN PILUS SOLUBILITY, FUNCTION, AND ASSEMBLY 
 
 
 
By 
Tara Marie Kennedy Allison 
August 2015 
 
Dissertation supervised by Dr. Peter Castric 
 Pseudomonas aeruginosa strains producing group I type IVa pili comprise over 
50% of the clinical isolate population. The pilus lateral surface of these strains is characterized 
by the attachment of an O-antigen repeating unit to each pilin monomer. O-antigen (glycan) 
structural analysis provided information on two possible characteristics, charge and size. 
Solubility experiments of fully, partially, and non-glycosylated P. aeruginosa 1244 pili showed 
that a full length glycan was required for maximum pilus solubility. Reduced solubility 
suggested an increased pilus surface hydrophobicity which was supported by protein modeling. 
While having no effect on the wild type strain, ionic strengths found at many host infection sites 
inhibited surface and subsurface twitching motility of strain 1244G7, an isogenic mutant unable 
to glycosylate pilin. This effect was reversed by mutant complementation.  
A PCR method for assigning R-type (glycan) was developed and conducted for 206 
clinical isolates. It was expected that the R-types would be evenly distributed across all isolates, 
 v 
but there was a significant prevalence for the R5 type which encodes the O6 serotype. 
Verification of the R5 strains was conducted with O6 specific antibodies confirming the genetic 
classification of these isolates. Results suggest that the increased prevalence of the R5-type as 
the pilin glycan could potentially lead to its use in a multi-component vaccine or therapeutic for 
P. aeruginosa infections.  
Clinical isolates were screened for group I pilin producing strains. Unexpectedly, strains 
producing non-glycosylated group I pilin were found, prompting the characterization of this 
altered phenotype. Sequencing and complementation results indicated that non-glycosylation was 
caused by defects in the main components of glycosylation: pilA, pilO, and the O-antigen 
biosynthesis pathway. Only one co-phenotype was found among these strains, reduced piliation. 
Additional characterization of the cause for reduced piliation showed that the presence of non-
glycosylated pilin alone was enough to reduce surface pili in these mutant clinical isolates. A 
pilO knockout was engineered which also showed a loss of glycosylation and a marked reduction 
in piliation. Providing this mutant with a functional pilO complemented both phenotypes. 
Overall, these results show that the presence of glycan is important for pilus function, solubility 
and piliation. 
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 1 
Chapter 1. Introduction 
1.1. Pseudomonas aeruginosa. P. aeruginosa is a ubiquitous Gram-negative, rod-shaped 
bacterium found naturally in soil, water, and near the rhizosphere of plants (Green, 1974). 
Additionally, this organism has been isolated in the clinical setting from faucets, sinks, mop 
buckets, catheters, ventilators, and hospital patients. This microorganism belongs to the family 
Pseudomonadaceae and like the other pseudomonads in this family, is widely adaptable to 
numerous environments and growth conditions due to its ability to grow at temperatures up to 
42
o
C, to utilize a variety of compounds as energy sources, and to be naturally resistant or quickly 
obtain resistance to many antibiotics. P aeruginosa contains a single chromosome of about 6.3 
Mb with more than 5500 predicted open reading frames (ORFs), a high G + C  content of 66.6%,  
and numerous regulatory mechanisms (LaBaer, 2004; Stover, 2000).  
This organism produces a variety of virulence factors that ultimately allow it to behave as 
an opportunistic pathogen, infecting plants, animals, and immunocompromised humans while 
less likely to infect those with intact immune systems. These virulence factors include 
lipopolysaccharide (LPS), type IV pili, proteases, exotoxins, elastases, flagella, cytotoxins, and a 
variety of others (Ballok, 2013; Lyczak, 2000; Rumbaugh, 1999) and are depicted in Figure 1.1. 
This organism is successful, due to its initial onset of virulence factors upon entering the human 
body followed by a change in expression of these and additional factors once settled in an 
infective state (Lyczak, 2000).   
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Figure 1.1. Representative image of the virulence factors produced by P. aeruginosa. 
These factors are both cell associated (pili, flagella, LPS) and secreted (alginate, exoenzymes). 
Image taken from Lee et. al. (Lee, 2015).  
 
1.2. P. aeruginosa Pathogenicity. P. aeruginosa is classified as an opportunistic 
pathogen involved in numerous hospital acquired/health-care associated infections. The 
pathogenicity of this organism fully depends on the host having a compromised immune 
condition. In the presence of a suppressed immune system, this organism is responsible for 
causing infections in patients with acute and chronic diseases/disorders including pneumonia, 
burns, urinary tract infections, keratitis, chronic obstructive pulmonary disease (COPD), and 
cystic fibrosis (Driscoll, 2007; Lyczak, 2000; Martínez-Solano, 2008; Murphy, 2008; Sadikot, 
2005; Speert, 2002; Stewart, 2011).  
Acute P. aeruginosa infections exhibit fast growth, remain motile, secrete cytotoxins, and 
progress quickly, while this bacterium in chronic infections grows more slowly, settles into a 
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biofilm, often becomes resistant to antibiotics, and persists longer than acute infections 
(Furukawa, 2006). Since P. aeruginosa produces multiple virulence factors, there are numerous 
ways for this bacterium to evade the host immune system and cause severe infections. The 
majority of these virulence factors are regulated by quorum sensing, which in turn is regulated by 
two-component systems.  
1.2.1. Quorum Sensing and Two-Component System Regulation. Quorum 
sensing is a cell density dependent means of communication that is used by multiple bacterial 
species and was first discovered in the symbiotic bacterium Vibrio fisheri for activation of 
luminescence genes (Stevens, 1997). Following this finding, numerous other bacteria were found 
to use this same type of interspecies and intraspecies communication (Lee, 2015). Quorum 
sensing involves the release of signaling molecules (acyl homoserine lactones) which diffuse 
throughout a bacterium’s local environment. In low densities of a given bacterial species, the 
signaling molecules are not received by the surrounding cells. As densities increase, more 
molecules are being released and the signal is amplified. Surrounding cells then receive the 
signal which leads to a change in gene expression depending on the signal and environmental 
conditions.  
P. aeruginosa uses this communication system to regulate a wide array of virulence 
factors associated with P. aeruginosa pathogenicity (Holm, 2014; Lee, 2015). There are four 
known quorum sensing systems in P. aeruginosa: Las, Rhl, PQS, and IQS, with the Las system 
being the first discovered in P. aeruginosa, followed by the Rhl system (Lee, 2015, 2013). Each 
of these systems is interconnected and highly regulated (Lee, 2015, 2013) (Figure 1.2).  
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Figure 1.2. Representation of the interaction and regulation of the four known 
quorum sensing systems: Las, Rhl, PQS, and IQS. The Las pathway directly regulates the 
other three quorum sensing networks. Image taken from Lee et. al. (Lee, 2015). Arrowheads 
show activating roles, while circular ended lines indicate inhibitory actions. Each system exhibits 
a variety of feedback mechanisms.  
 
Quorum sensing is regulated globally by two-component systems which help the 
bacterium to respond to varying environments and stresses. These systems are also involved in 
the transition from acute to chronic infections. Two-component systems consist of a sensor 
kinase and a response regulator. One of the earlier known two-component systems found in P. 
aeruginosa is the GacS/GacA pathway, which is involved in virulence factor expression and 
biofilm formation (Parkins, 2001). These systems work by the sensor kinase receiving a signal, 
autophosphorylation, phosphate group transfer to the response regulator which becomes active as 
a transcription factor (Mikkelsen, 2011). Numerous regulated virulence factors of both quorum 
sensing and two-component systems are toxins and proteases.  
 5 
1.2.2. Toxins and Proteases. P. aeruginosa produces multiple toxins that lead to 
severe tissue damage and cell death within the host. The delivery system for the major cytotoxins 
(or exoenzymes) is the type III secretion system or T3SS (Galle, 2012). The T3SS of P. 
aeruginosa resembles that of other bacterial species including Yersinia spp., Vibrio 
parahaemolyticus, Bordetella spp., and others (Galle, 2012; Hauser, 2009). This system is used 
to directly inject host cells with toxic enzymes, ExoS, ExoT, ExoU, and ExoY. These enzymes 
have similar but unique functions once inside the host cell. ExoS has two functions, it is able to 
activate GTPases and exhibits ADP ribosyltransferase activity (Rangel, 2014). It has been shown 
that the majority of P. aeruginosa clinical strains contain the gene that encodes the ExoS enzyme 
(Feltman, 2001). The production of this enzyme is related to persistence and virulence in a 
mouse model of pneumonia and is also involved in phagocytosis evasion (Rangel, 2014). ExoT 
has been implicated in inhibiting phagocytosis and interfering with epithelial barriers which 
allows for further dispersion of this organism to other cells in the host (Lee, 2005; Vance, 2005). 
ExoU is a phospholipase that directly and quickly leads to host cell death (Finck-Barbançon, 
1997) and is involved in severe lung injury during acute infections (Howell, 2013). The function 
of ExoY is not fully understood, but it has been shown to be involved in increasing cell 
permeability and evading phagocytosis (Hauser, 2009). Recent research shows a correlation 
between the exo genes present in Pseudomonas aeruginosa strains and its resistance to a 
category of antibiotics, fluoroquinolones (Cho, 2014). 
P. aeruginosa also produces a virulence factor called exotoxin A which is secreted 
from the type 2 secretion system and endocytosed by host cells. Once inside the host cell, the 
toxin inactivates elongation factor 2. This inactivation occurs through the ADP-ribosylation of 
elongation factor 2 which thereby prevents protein synthesis in host cells (Chung, 1977). The 
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lack of protein synthesis leads to cell death, which can occur in a variety of cells even those of 
the immune system (Hertle, 2001).  
Not only do these toxins wreak havoc on host cells and tissues, but numerous secreted 
proteases are produced to break down host defenses. These proteases include alkaline protease 
and elastase. Alkaline protease has been shown to inhibit the complement pathway which allows 
P. aeruginosa to avoid killing by neutrophils and complement mediated phagocytosis (Laarman, 
2012). Elastase has been implicated in the breakdown of human collagen and elastin (Hamdaoui, 
1987; Heck, 1986) and is regulated by the Las quorum sensing system (Lee, 2015). These 
proteases and others are involved in P. aeruginosa dissemination during infections by breaking 
down host barriers. With all P. aeruginosa infections, multiple virulence factors are produced to 
help the bacterium evade the host immune system and make the bacterium much more 
complicated to treat. Treatment of  infections is becoming more difficult as this bacterium is 
naturally resistant to numerous antibiotics and several strains are multidrug resistant (Livermore, 
2002). 
1.2.3. Antibiotic Resistance.  An area of concern in healthcare settings is that of 
antibiotic resistance. P. aeruginosa is naturally resistant to many antibiotics due to either 
exclusion and/or efflux (Livermore, 2002). The outer membrane inhibits the entrance of certain 
molecules, while efflux pumps quickly remove molecules that do enter the cell. In many cases, 
the combination of efflux and inhibition is enough to provide antibiotic resistance in the absence 
of acquiring new genetic material (El’Garch, 2007). This resistance ability and other proteins 
produced by this organism lead to its ability to evade the host immune system or use the host 
immune system to cause more damage to surrounding tissues, including the primary component 
of the outer surface of the bacterial cell, lipopolysaccharide. 
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1.2.4. Lipopolysaccharide (LPS). The outer membrane of P. aeruginosa is 
covered by LPS which aids in activation of a human Toll-like receptor, specifically TLR4 
(Amiel, 2010; Ballok, 2013; McIsaac, 2012). The composition of LPS directly causes numerous 
host responses that lead in inflammation and tissue damage (King, 2009). LPS is composed of a 
lipid A constituent (endotoxin) anchored in the membrane with the core oligosaccharide and O-
antigen repeating units extending from the cell’s surface (Figure 1.3). There are two main types 
of LPS presented at the cell surface, A-band and B-band. The A-band is composed of the neutral 
sugar D-rhamnose and is also known as the “common antigen.”  The B-band is more commonly 
known as the O-antigen. The O-antigen is utilized to classify each P. aeruginosa strain into a 
serotype(s) based on its variation (Knirel, 1990, 2006). There are 20 different serotypes, 
according to the International Antigenic Typing System (Lam, 2011; Liu, 1973; Liu, 1983).  
Additionally, P. aeruginosa isolates can exhibit two phenotypes based on the form of 
LPS being produced. LPS containing the O-antigen is considered the “smooth” phenotype while 
the absence of the O-antigen and presence of the “common antigen” represents the “rough” 
phenotype. It is the “smooth” or O-antigen containing form of LPS produced by these organisms 
that is responsible for acute virulence and is involved in protecting the bacterial cell from 
phagocytosis and complement mediated killing by host cells (King, 2009). In addition to LPS 
coating on the cell surface, this organism also produces extracellular polysaccharides 
(exopolysaccharides) such as Psl, Pel, and alginate.  These exopolysaccharides are involved in 
the mucoid phenotype and biofilm formation of this organism more commonly found in chronic 
infections such as cystic fibrosis.  
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Figure 1.3. Structure of the P. aeruginosa 1244 O7 Serotype Lipopolysaccharide 
(LPS). LPS is composed of Lipid A, an anchoring unit in the bacterial outer membrane, a 
variable length region of the core oligosaccharide, and multiple O-antigen repeating units. Image 
courtesy of Joseph Horzempa (Horzempa, 2006a).  
 
1.2.5. Mucoid Phenotype in Cystic Fibrosis and Biofilm Formation. This 
opportunist is also a major component of the microbial community in the lungs of cystic fibrosis 
patients, leading to high morbidity and mortality in this population (Hauser, 2011). P. 
aeruginosa can be found in two major forms, nonmucoid or mucoid (Speert, 2002). The mucoid 
form is especially prevalent in the lungs of cystic fibrosis patients and makes this organism 
difficult to remove because of its characteristic excessive production of alginate, inhibiting the 
ability of antibiotics to penetrate this exopolysaccharide barrier, thereby providing an additional 
layer of protection to this bacterium during more chronic infections (Govan, 1996; Pritt, 2007). 
The change from mucoid to nonmucoid in vitro is associated with the regulation of the alginate 
producing genes, specifically a mutation in algT (Devries, 1994). However, the mucoid form is 
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reversible and seems to fully depend on the in vivo setting of a chronic bacterial infection in the 
human lung to maintain mucoidy (Devries, 1994).  
The change to the overexpression of alginate and other exopolysaccharides such as Psl 
and Pel is commonly associated and required for biofilm formation (Ma, 2009; Yang, 2012). 
Biofilms develop on both biotic and abiotic surfaces (Giltner, 2006; O'Toole, 1998; Zolfaghar, 
2003). Biofilms begin when free swimming P. aeruginosa cells begin to adhere to either an 
abiotic or biotic surface. Following adherence, exopolysaccharides are produced which then 
connect multiple cells into a single layer, more cells are recruited and maturation to a 
microcolony occurs with multiple layers of cells. Finally, cells can be dispersed for re-initiation 
of this process at a different site in the human body or to colonize a new area of an abiotic 
surface (Figure 1.4). Initial stages of biofilm formation require both flagella and type IV pili 
(Klausen, 2003b; O'Toole, 1998). 
 
 
Figure 1.4. Five Stages of Biofilm Development in P. aeruginosa. This image depicts 
the 1) adherence of planktonic cells to a surface, 2) production of exopolysaccharides that encase 
multiple cells, 3) layering of cells, 4) microcolony formation, and 5) dispersal. Image modified 
from Ma et. al. (Ma, 2009). 
 10 
 
 1.3. Flagella. The flagellum of P. aeruginosa is involved in cell motility and chemotaxis 
and is a major virulence factor of P. aeruginosa. The monomer, flagellin, is expressed in two 
forms flagellin a and flagellin b, which vary in molecular weight due to the primary amino acid 
sequence and glycosylation (Brimer, 1998; Montie, 1982a). In addition, the presence of flagella 
has been implicated in increased pathogenicity in an acute pneumonia mouse model (Feldman, 
1998) and leads to an inflammatory response in human airway epithelial cells (Shanks, 2010). It 
has also been shown that non-flagellated mutant P. aeruginosa strains have reduced virulence in 
a burned mouse model (Montie, 1982b). The flagellum is a major component for mucin 
adhesion, specifically the cap protein, FliD (Arora, 1998). As mentioned, this protein is also 
glycosylated which aids in pro-inflammatory activities of P. aeruginosa (Verma, 2005). In 
combination with type IV pili, the flagellum is required for swarming motility and biofilm 
formation (Kohler, 2000; O'Toole, 1998).  
1.4. Pili. Pili are polymeric surface protein filaments that can be found at the poles of 
cells or surrounding the whole cell. The earliest identification of pili (also called fimbriae) came 
in 1949 when research by Anderson and Houwink showed cell surface appendages that differed 
from flagella (Anderson, 1949; Houwink, 1949) in Gram negative bacterial species. After the 
observation of non-flagellar bacterial appendages across numerous species of Gram negative 
bacteria, much work was done to determine how to classify the various morphologically and 
functionally diverse proteins. A well accepted classification system was established by Ottow 
(Ottow, 1975) in which he categorized pili into groups based on morphology and function. Later, 
pili were placed into categories called types which include type I (an example of chaperone/usher 
pathway pili, see Figure 1.5) and type IV pili. Almost two decades after the discovery of these 
surface appendages in Gram negative bacterial species, it was found that pili are also produced 
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by Gram positive bacteria (Yanagawa, 1968). Examples of both Gram negative and Gram 
positive pili types can be found in Figure 1.5. Amongst these non-flagellar surface appendages, 
one of the most studied is the type IV pilus which is found in numerous pathogenic bacteria 
including P. aeruginosa, Neisseria spp., and enteropathogenic E. coli (Pelicic, 2008). 
 
Figure 1.5. Bacterial Pili Types. Representative examples and background information 
for the main bacterial pili types. BFP: bundle-forming pilus, C4BP: complement-component-4-
binding protein, EPEC: enteropathogenic Escherichia coli, ND: not determined, TFP: type IV 
pilus. Image reprinted by permission from MacMillan Publishers Ltd: Nature Review 
Microbiology (Telford, 2006). http://www.nature.com/nrmicro/index.html  
 
1.5. P. aeruginosa pili/pilin proteins. Type IV pili are hair-like proteins that are ~6 nm 
in diameter and several micrometers in length (Craig, 2004; Mattick, 2002) (Figure 1.6). The 
type IV pilus is primarily composed of individual 15-16 kDa pilin monomers which are encoded 
by the pilA gene with minor pilins also associated with the pilus fiber (Giltner, 2010). Pilins can 
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be divided into two subcategories, Type IVa and Type IVb, based on the size of the full-length 
protein and the length of the leader sequences (Craig, 2004; Strom, 1993). Type IVa pilins have 
a short, 5-6 amino acid, leader sequence, a mature protein that is 150-160 amino acids, an N-
methylated phenylalanine at the N-terminus, and a 22 amino acid disulfide region (Craig, 2004; 
Pelicic, 2008). Type IVb pilins contain a longer, 15-30 amino acid, leader sequence, a mature 
protein that is 190 amino acids, an N-methylated methionine, valine, or leucine at the N-
terminus, and a 55 amino acid disulfide region (Craig, 2004).  
 
Flagellum
Cell
Pili
 
Figure 1.6. Transmission Electron Micrograph of P. aeruginosa 1244 Expressing 
Flagella and Type IVa Pili. Image was taken by Erica Jewell, Duquesne University (Jewell, 
2004). Negative staining was conducted and observations were made at 50K magnification.  
 
The secondary structures of these proteins resemble a stick-pin (Figure 1.7). In type IVa 
this structure is bent and composed of an α-helix region followed by an αβ loop continuing into 
four anti-parallel β sheets and ending in a disulfide loop region (Craig, 2004, 2003; Hahn, 1997). 
The type IVa pilins are found in P. aeruginosa, Neisseria spp., Bdellovibrio bacteriovorus, 
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Moraxella spp., Eikenella corrodens, and Dichelobacter nodosus (Craig, 2004). Type IVb pilins 
are similar in structure except that the protein is not bent and the α-helix is connected to a five-
stranded β-sheet via an additional, small α-helix (Craig, 2003). This type of pilin is found in 
Vibrio cholerae, Salmonella enterica, enteropathogenic E. coli as well as enterotoxigenic E. coli 
(Craig, 2004).  
 
Figure 1.7. Type IVa Pilin Monomer Structure. The 6 residue leader sequence is 
cleaved by PilD. The pilin monomer is composed of both alpha helix and beta sheet regions and 
always contains a disulfide loop near the C-terminus. This model was obtained from the online 
software PHYRE2 utilizing the PAK pilin protein sequence as a template.   
 
The pilin monomers are helically arranged to form the final pilus structure (Figure 1.8). 
This arrangement contains 4-5 monomers per turn and combined with minor pilins makes up the 
basic pilus fiber (Giltner, 2010, 2012). This structure and arrangements aids in the strength and 
flexibility of the pilus fiber (Nudleman, 2004) 
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Figure 1.8. Schematic of Helically Arranged Pilin Monomers in the Type IVa Pilus 
Fiber. This image depicts the size of the pilus fiber with the individual arrangement of pilin 
monomers. Image taken from Giltner et. al. (Giltner, 2012). 
 
1.6. Pilus Biosynthesis. Over 40 genes are involved in the regulation, assembly, and 
function of the pilus fiber (Giltner, 2010; Jacobs, 2003; Mattick, 2002). Each pilus is made up of 
individual protein monomers called pilin (PilA) encoded by pilA (Table 1.1). Many of the 
proteins encoded by these genes have either unknown or poorly elucidated functions. However, 
the majority appear to be associated with pilus biogenesis/assembly (Giltner, 2010; Mattick, 
2002, 1996). In many cases, genes involved in the same process such as pilus biosynthesis are 
found in gene clusters within the P. aeruginosa chromosome. As previously mentioned, there is 
a single major pilin encoding gene, pilA. The product of this gene, PilA/pilin requires 
modification by cleavage of the leader sequence and subsequent N-methylation carried out by 
PilD, a pre-pilin peptidase. The expression of pilA gene requires the presence of RpoN which is 
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an alternate sigma factor involved in the expression of multiple virulence factors and flagella. 
Furthermore, pilA is regulated by two main gene products, pilR and pilS. PilR is a transcriptional 
activator and PilS is a sensor kinase involved in signal transduction to initiate PilA biosynthesis 
(Hobbs, 1993; Ishimoto, 1992). Additionally, it has been shown that pilus assembly requires the 
minor pilin proteins: FimU, PilV, PilW, PilX, and PilE which are incorporated into the pilus 
fiber and involved in twitching motility (Alm, 1995, 1996; Asikyan, 2008; Giltner, 2010; 
Russell, 1994). Table 1.1 shows the functions or proposed functions of most of the pil genes 
involved in proper pilus assembly and function. We know that one of the basic functions of the 
type IV pilus is twitching motility, but there are numerous additional proposed and known 
functions of this protein fiber. 
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Table 1.1. Pilus Biosynthesis Genes, Proteins, and Protein Function(s). A selection of pilus 
biogenesis genes, encoded proteins, and known/putative functions. 
 
Gene Protein Protein Function 
pilA PilA, pilin Pilus monomer 
pilB PilB Pilus biogenesis motor 
pilC PilC Pilus biogenesis motor 
pilD PilD, XcpA Prepilin peptidase 
pilE PilE Assembly/Twitching 
pilF PilF Pilus assembly 
pilG PilG Twitching motility 
pilH PilH Twitching motility 
pilI PilI Twitching motility 
pilJ PilJ Twitching motility 
pilK PilK Methyltransferase 
pilL PilL, ChpA chemotactic signal transduction component 
pilM PilM Pilus assembly 
pilN PilN Pilus assembly 
pilO PilO (TfpO) Oligosaccharyltransferase 
pilO PilO Pilus assembly 
pilP PilP Lipoprotein  
pilQ PilQ Secretin protein 
pilR PilR Two-component response regulator 
pilS PilS Two-component sensor kinase 
pilT PilT Pilus retraction motor 
pilU PilU Twitching motility 
pilV PilV Assembly/Twitching 
pilW PilW Assembly/Twitching 
pilX PilX Assembly/Twitching 
pilY1 PilY1 Ca
2+
 regulation of retraction 
pilY2 PilY2 Pilus assemblytwitching motillity 
pilZ PilZ Pilus assembly 
fimT FimT Pilus assembly 
fimU FimU Assembly/Twitching 
fimV FimV Motility, putative peptidoglycan binding 
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1.7. Pilus functions. Type IVa pili are strong, protein fibers that are involved in 
numerous cellular functions that include twitching motility, adhesion, biofilm formation, DNA 
uptake, and phage sensitivity (Craig, 2004). These roles of the pilus are important for host-
pathogen interactions. Twitching motility is a flagella-independent form of motility and is the 
process by which the type IV pili extend and retract to move cells across surfaces (Burrows, 
2005, 2012). This type of motility is one of the two main ways that P. aeruginosa conducts cell 
movement, host colonization, and biofilm formation (Burrows, 2005, 2012).   
The involvement of type IV pili in twitching motility was originally determined through 
optical tweezer studies conducted on Neisseria spp. (Maier, 2002; Merz, 2000). This form of 
motility involves the extension, attachment, retraction, and release of the pilus fiber from either 
host tissues/cells or abiotic surfaces and requires gene products involved in a concerted 
polymerization and depolymerization cycle. These gene products are the extension motor PilB 
and its associated protein PilC and the retraction motors PilT and PilU (Burrows, 2005, 2012; 
Chiang, 2005; Whitchurch, 1994). Not only does twitching motility allow for the movement of 
the bacterium across multiple surfaces, but it also lends to its virulence during host-pathogen 
interactions (Comolli, 1999a; Zolfaghar, 2003). Additional research indicates that type IV pili 
are also involved other motility forms such as swarming, slingshot, and walking (Conrad, 2011; 
Gibiansky, 2010; Jin, 2011; Kohler, 2000) each of which aid the bacterium in surface 
translocation under varying conditions. 
Aside from twitching and other motilities, the type IV pilus functions in adhesion and 
biofilm formation. Adhesion, as previously mentioned, can be to both biotic and abiotic surfaces 
(Giltner, 2006; Saiman, 1990) and has been shown to be involved in P. aeruginosa virulence and 
pathogenicity (Farinha, 1994). The initial step of biofilm formation is the adherence of cells to a 
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surface. Once adherence occurs and a sufficient number of cells are present, the overproduction 
of alginate and other exopolysaccharides commences. Type IV pili are initially involved in 
biofilm formation (Deziel, 2001; Harmsen, 2010; Klausen, 2003a, b; Ma, 2009; O'Toole, 1998) 
but the expression of the type IV pilus is often down-regulated once in the chronic biofilm state 
(Sauer, 2002; Smith, 2006) 
1.8. Prokaryotic protein glycosylation. Initially, it was assumed that protein 
glycosylation did not occur in prokaryotes and was solely a modification expressed by 
eukaryotes. However, it was found that glycosylation was not strictly a eukaryotic phenomenon 
(Abu-Qarn, 2008; Castric, 1995; Mescher, 1976). The knowledge of prokaryotic protein 
glycosylation is relatively new (~30 years) and was first discovered in the archaeal S-layer 
proteins (Mescher, 1976). Additionally, our lab was one of the first to discover protein 
glycosylation in a bacterial species (Castric, 1995) which was a major factor in dispelling the 
long accepted view of protein glycosylation solely in the eukaryotic domain. Following these 
breakthrough findings of protein glycosylation in the prokaryotic world, much research has 
shown that there are numerous cases of prokaryotic protein glycosylation and a great deal of 
work has ensued to understand the purpose of this post-translational modification (Power, 2003; 
Schmidt, 2003; Szymanski, 2005). These findings show that this modification is not unique to 
eukaryotic organisms but is also equally present in archaeal and bacterial organisms. Just as in 
eukaryotic glycosylation systems, both N-linked (asparagine residue linked) and O-linked 
(serine/threonine residue linked) are present in prokaryotes.  
The N-linked glycosylation pathway of Campylobacter jejuni was the first system of its 
kind to be discovered in a bacterial species and is one of the most well characterized systems in 
prokaryotes (Szymanski, 2005, 1999). Since this finding, numerous other bacterial species have 
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been found to glycosylate their proteins, specifically through O-linked glycosylation systems 
(Abu-Qarn, 2008; Castric, 1995; Cuccui, 2013; Iwashkiw, 2013). Within these glycosylation 
systems, there is a great deal of variety in the number of sites that can be glycosylated on a given 
protein. In some cases, a single residue is modified (ex. P. aeruginosa 1244 pilin) while multiple 
residues (ex. Campylobacter jejuni flagellin) can also be modified (Castric, 1995; Thibault, 
2001).  The number of protein targets and glycans is highly variable across prokaryotes and can 
be carried out in two ways, each component is separately added (sequential) or the complete 
glycan is added in one step (en bloc) (Spiro, 2002). Of note is that many bacterial pathogens and 
opportunistic pathogens exhibit a wide array of glycosylated proteins.  
An important feature of prokaryotic protein glycosylation is that it seems to play a role in 
bacterial pathogenicity, due to the fact that many of the proteins (ex. flagella, pili, and 
outermembrane proteins) involved in host-pathogen interactions have been shown to be 
glycosylated (Ghosh, 2004; Szymanski, 2005). Other studies report that organisms, such as 
Neisseria species and Francisella tularensis, produce glycosylated pilin (Børud, 2010; Egge-
Jacobsen, 2011). At least in Neisseria species, it has been shown that the glycan is involved in 
eliciting an immune response (Børud, 2010), which also may be the case in F. tularensis (Egge-
Jacobsen, 2011; Salomonsson, 2011).  
A number of functions for prokaryotic protein glycosylation have been suggested. These 
suggestions include maintaining protein conformation, acting as surface recognition structures, 
increasing resistance to proteolytic digestion, providing enzymatic activity, aiding in immune 
evasion, and helping with cell adhesion and colonization (Nothaft, 2010; Schmidt, 2003). The 
functions of glycosylation vary greatly and are likely to be species or protein specific. My 
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research focuses on understanding the role of protein glycosylation of the P. aeruginosa group I 
pilin protein and how it affects the type IVa pilus fiber. 
1.9. Group I pilin glycosylation. Based on our lab’s research and that of Julianne Kus 
(from the lab of Dr. Lori Burrows), we can show that approximately 80% of known P. 
aeruginosa strains can be placed into one of two groups (I and II) based on type IVa pilin 
primary structure and accessory genes (Castric, 1994; Kus, 2004)(Figure 1.9). Group I pilin 
producing (GIPP) strains examined, such as 1244, have the pilO gene (Castric, 1995) which 
codes for PilO, an oligosaccharyl transferase which is potentially capable of pilin glycosylation 
(Figure 1.10). Group II pilin producing strains examined, such as PA103 or PAO1, lack this gene 
and the ability to glycosylate pilin (DiGiandomenico, 2002).  
 
 Figure 1.9. Neighbor-joining Tree of GenBank Retrieved and Sequenced Pilin 
Proteins. The majority of known pilin proteins fall within two groups (I and II). The remaining 
protein sequences fall within groups III, IV, and V. Outgroup- E. coli strain ECE24377A. 
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Figure 1.10. P. aeruginosa Pilin Biosynthesis Gene Clusters for PAO1 and 1244. The 
representative gene clusters show lack of the pilO gene in PAO1 (group II) and its presence in 
strain 1244 (group I). The pilO gene encodes PilO the oligosaccharyl transferase responsible for 
glycosylation of the group I pilin monomer. This image also shows the presence of pil gene 
operons in the P. aeruginosa chromosome. Image from a departmental presentation by 
Mohammed Qutyan. 
 
It has previously been shown that P. aeruginosa 1244 pilin is posttranslationally 
modified by the attachment of a sugar glycan identical to the O7 O-antigen repeating unit from 
the strain’s LPS to the C-terminal serine residue (Castric, 2001). This glycan is a trisaccharide 
containing pseudaminic acid, xylose, and N-acetylfucosamine (Figure 1.11). The glycan is O-
linked through covalent attachment to the -carbon of serine residue 148 which is the necessary 
pilin substrate for glycosylation (Castric, 2001; Comer, 2002; Horzempa, 2006b). 
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Figure 1.11. Structure of the P. aeruginosa 1244 Pilin Glycan/LPS O-antigen 
Repeating Unit. The pilin glycan is composed of pseudaminic acid, xylose, and N-
acetylfucosamine. This glycan is attached to serine
148
 at the C-terminus of the pilin monomer at 
the β carbon. (Castric, 2001; Comer, 2002) 
 
Furthermore, the pilin glycan of 1244 is identical to the O-antigen repeating unit of the 
O7 LPS serotype that is found on the outer membrane of P. aeruginosa (Castric, 2001). In 
addition, it was determined that only the reducing end of the O-subunit was necessary for glycan 
recognition (Horzempa, 2006c). We have also verified that the pili and LPS synthesis pathways 
share a common O-antigen biosynthesis pathway (Figure 1.12) and that PilO is the only 
necessary protein for pilin glycosylation (DiGiandomenico, 2002).  
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Figure 1.12. Proposed Mechanism for Glycosylation of the Pilin Subunit. Image 
depicting the utilization of the O-antigen biosynthesis pathway for the production of the pilin 
glycan in group I pilin producing P. aeruginosa strains. The O7 serotype O-antigen subunit of P. 
aeruginosa 1244 is N-acetylfucosamine (FucNAc), xylose (Xyl), and pseudaminic acid (Pse) 
which is transferred from undecaprenyl phosphate (Und-P) to the core oligosaccharide of LPS or 
PilO. PilO then catalyzes the addition of the O-antigen glycan to the pilin subunit. Image from 
the dissertation of Joseph Horzempa, Ph.D. (Horzempa, 2006a).  
 
Work from our lab also showed that the P. aeruginosa 1244 pilin glycan elicits an 
immune response, contributes to virulence, and provides O-antigen specific protection (Comer, 
2002; Horzempa, 2008; Smedley, 2005). Much like glycans on other surface associated proteins, 
the location of the pilin glycan along the pilus fiber allows for its interaction with the pathogen’s 
environment (ex. host cells) (Smedley, 2005). The practical application of this knowledge would 
be to introduce a specific chemotherapy or vaccination strategy for each type of infection rather 
than the general antibiotic treatment currently used. 
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1.10. Dissertation Goals. As previously mentioned, there have been numerous proposed 
roles for prokaryotic protein glycosylation. These include being involved in cell surface adhesion 
and colonization, resistance to proteolytic cleavage, maintaining protein conformation, acting as 
surface recognition structures, providing enzymatic activity, and aiding in immune evasion 
(Nothaft, 2010; Schmidt, 2003). Most recent research on type IV pilus glycosylation provides 
evidence that this modification reduces opsonization of the bacterial cell by lung phagocytes via 
surfactant protein-A (Tan, 2015). Tan and colleagues tested our laboratory strains 1244, 1244G7, 
and 1244G7pMBT100 (Tan, 2015). They found that the presence of the glycan promoted 
resistance to opsonization but only in the presence of surfactant protein-A (Tan, 2015).  
Previous research from our lab has shown that the group I pilin glycan of P. aeruginosa 
1244 is posttranslationally modified by the O-linked addition of a single repeat of the cell’s O-
antigen subunit to the C-terminal S
148
 residue (Castric, 2001; Comer, 2002; DiGiandomenico, 
2002). This glycosylation is carried out solely by the PilO protein, an oligosaccharyl transferase 
(Castric, 1995) that is located in the cytoplasmic membrane with its catalytic domain found in 
the periplasmic space (Qutyan, 2007). Research also showed that the presence of the glycan 
aided in pilus solubility, reducing hydrophobicity (Smedley, 2005). This glycosylation 
modification is not found in the other pilin producing strains except group IVs which utilize a 
different glycan and glycosylation pathway (Voisin, 2007). However, these strains are in the 
minority compared to group I pilin producing strains. Since the group I pilin producing strains 
make up the majority of clinical isolates, it is necessary to investigate why this modification is 
present for this pilin group and the potential benefit it incurs.  
Research presented in this dissertation was carried out to further understand the role of 
the group I pilin glycan in both laboratory and clinical strains of P. aeruginosa. My work seeks 
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to provide insight into the basic role of the group I pilin glycan in type IVa pilus function. 
Glycosylation in all domains of life show evidence that this modification is important or critical 
for various protein functions. However, it has never been shown that the group I pilin requires 
this modification for proper function. This would be a novel finding in our lab and would 
contribute to the overall knowledge and importance of bacterial protein glycosylation.  
My hypothesis is that group I pilin glycosylation is central to pilus function.  
 
The goals of my research detailed in this dissertation were: 
1. To further determine the influence of the group I pilin glycan on pilus solubility 
and function in laboratory strains. 
2. To determine the distribution of glycan types across a population of clinical 
Pseudomonas aeruginosa isolates. 
3. To determine the prevalence of the non-glycosylated group I pilin phenotype 
among group I pilin producing Pseudomonas aeruginosa clinical isolates. 
a. To characterize the basis for the non-glycosylated pilin phenotype. 
b. To investigate any co-phenotypes associated with non-glycosylation.  
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Chapter 2. The Group I Pilin Glycan Affects Type IVa Pilus Hydrophobicity and 
Twitching Motility in Pseudomonas aeruginosa 1244
1 
 
2.1 Abstract. Pseudomonas aeruginosa strains producing group I type IVa pili comprise 
over 50% of the clinical isolate population. The pilus lateral surface of these strains is 
characterized by the attachment of an O-antigen repeating unit to each pilin monomer along the 
fiber. The current work was conducted to investigate the pilin glycan’s effect on pilus solubility 
and function. Culture supernatant fluids containing fully, partially, and non-glycosylated P. 
aeruginosa 1244 pili were tested for solubility in the presence of ammonium sulfate. These 
experiments showed that a full length glycan was required for maximum pilus solubility. A 
representative of the P. aeruginosa producing group II pilin also showed low solubility when 
assayed under these same conditions. Reduced solubility suggested an increased pilus surface 
hydrophobicity which was supported by protein modeling. While having no effect on the wild 
type strain, ionic strengths found at many host infection sites inhibited surface and subsurface 
twitching motility of strain 1244G7, an isogenic mutant unable to glycosylate pilin. This effect 
was reversed by mutant complementation. Twitching motility of P. aeruginosa strain PA103, 
which produces group II pilin, was also inhibited by ionic strengths which influenced the mutant 
strain. We suggest that the group I pilin glycan may, therefore, be beneficial to this organism 
specifically for optimal pilus functioning at host disease sites producing comparable ionic 
strengths. 
                                               
1 In Revision for Microbiology 
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2.2. Introduction. The type IVa pilus is a protein fiber that extends from the cell surface. 
This structure, which is composed of a monomeric subunit called pilin, is an important virulence 
factor of the opportunistic pathogen Pseudomonas aeruginosa where it is has long been 
recognized as an adhesion factor (Hahn, 1997), as well as being responsible for a type of surface 
motility called twitching (Burrows, 2012). The type IVa pili of P. aeruginosa can be placed into 
one of five groupings (I through V) based on pilin primary structure and the presence of pilus-
specific accessory genes, (Castric, 1995, 1994; Kus, 2004) although the majority of isolates 
reported produce pilin belonging to groups I and II (Kus, 2004). The P. aeruginosa group I pilins 
are further characterized by the presence of a covalently attached O-antigen repeating unit  
(Castric, 2001). The addition of this structure is catalyzed by an oligosaccharyl transferase called 
PilO (aka TpfO) which is coded for by the accessory gene pilO located directly downstream 
from the pilA gene (Castric, 1995, 2001). It is interesting to note that P. aeruginosa group IV 
pilins are also glycosylated, although the glycan substrate employed in this situation is not the O-
antigen repeating unit (Harvey, 2011; Voisin, 2007).   
While a number of studies have shown that the type IVa pilus tip is important for 
adhesion to biotic and abiotic surfaces (Farinha, 1994; Fletcher, 1993; Giltner, 2006; Woods, 
1980), the influence of the lateral surface of this fiber on pilus function has not been well 
studied. The number of pili produced per cell as well as pilus length suggests the possibility of a 
significant contact between the fiber surface and the pathogen’s physical environment. Such an 
interaction could affect the pathogenicity of this organism by influencing a number of surface-
associated virulence factors including twitching motility, biofilm development, and contact with 
innate defense and target host cell surfaces.  
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The type IVa pilus exterior, as determined by protein features alone, is a mosaic of 
repeated pilin surface structures displaying identical patterns composed of ionized charges, weak 
bonds, and hydrophobic regions (Craig, 2004). Mutual attraction of these forces between fibers 
lends itself to bundle formation (Brinton, 1965; Silipigni-Fusco, 1987) which could be 
detrimental to pilus extension and retraction, a process necessary for most pilus function 
(Burrows, 2012). The P. aeruginosa 1244 pilin glycan is covalently attached through its reducing 
end to the β-hydroxyl carbon of the serine which resides at the pilin C-terminus (Castric, 2001; 
Comer, 2002). This structure is evenly distributed over the pilus surface (Smedley, 2005) and so 
would be expected to have a significant effect on the physical properties of these fibers by 
contributing charge and hydrophilicity as well as by shielding of the surface amino acid residues 
from the fiber environment. These effects would be expected to reduce the pilus-pilus attraction 
described above, thereby improving functionality.  The glycan modification of the P. aeruginosa 
type IVa pili offers an opportunity to study the effect of the pilus lateral surface on functionality 
since its presence, sugar composition, and charge can be manipulated.  
The work described in the present study suggests that the pilin glycan strongly influences 
pilus-pilus interactions. Evidence is presented that the enhanced solubility of the strain 1244 
pilus was associated with the negative charge present on the terminal oligosaccharide residue 
(pseudaminic acid). Variations in glycan composition that do not result in the addition of a 
negative charge did not improve solubility. Experiments also suggest that the presence of the 
pilin glycan influences pilus function.  An isogenic mutant of strain 1244 that lacked the ability 
to glycosylate pilin demonstrated reduced twitching motility, a trait important in virulence by 
this organism (Comolli, 1999a; Mattick, 1996; Zolfaghar, 2003), at ionic strengths associated 
with host disease sites. Results presented further suggest that the presence of the pilin glycan is 
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potentially able to suppress unfavorable pilus interaction with hydrophobic elements of the cell 
environment. 
2.3. Materials and Methods  
2.3.1. Bacterial Culture Conditions. Luria-Bertani medium (LB; 1% Tryptone, 
0.5% Yeast Extract, 1% NaCl, pH7.0) or Casamino Acids-Yeast extract medium (CAYE; 0.75% 
casamino acids, 0.15% yeast extract) (Silipigni-Fusco, 1987) broth cultures were grown at 37°C 
on a rotary shaker at 250 rpm.  Solid media were prepared with the addition of either 1.5% (LB) 
or 2.0% agar. When necessary, media were supplemented with carbenicillin (Cb) at 200 µg ml
-1
 
or gentamicin (Gm) 250 µg ml
-1
 for P. aeruginosa and 10 μg ml-1 for Escherichia coli. For 
induction of pPAC46, media were supplemented with 5mM Isopropyl-β-D-1-
thiogalactopyranoside (IPTG). See Table 2.1 for all strains and vectors used. 
Table 2.1. Strains and vectors used in this study. 
 Description
*
 
Source or 
reference 
Strains   
1244 Wild type, group I pili (Ramphal, 1984) 
1244G7 PilO-negative mutant, Gmr (Smedley, 2005) 
1244.47 PilA-negative mutant,  Hgr (Horzempa, 2006b) 
1244.2.1 Transposon mutant, incomplete pilin glycosylation, Gmr This study 
PA103 Wild type, group II pili (Liu, 1973) 
PA103∆pilA PilA-negative mutant,  Gmr (Comolli, 1999a) 
577B Wild type, group I pili (Castric, 1994) 
A031 Clinical isolate, PilO-negative. This study 
   
Vectors   
pMMB66EH Broad host range vector, Apr (Fürste, 1986) 
pMBT100 pMMB66EH with 1244 pilO (Smedley, 2005) 
pPAC46 pMMB66EH with 1244 pilAO (Castric, 1995) 
pTJS53 pUC8 containing RK2 oriT (Schmidhauser, 1985) 
pPC110 pUC7 containing a Gmr cassette (Nunn, 1990) 
pSMC900 pTJS53, Tn5, Gmr This study 
λ467 Tn5 vector, Kmr (Yelton, 1983) 
*
Gm
r
, gentamicin resistance; Hg
r
, mercury resistance; Ap
r
, carbenicillin resistance; Km
r
, kanamycin  
resistance  
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2.3.2. Production of Group I pili expressing alternate oligosaccharides. 
2.3.2.1. Pilin/D-Xyl-(β1→3)-D-FucNAc-(1→. Construction of a P. 
aeruginosa 1244 strain producing glycosylated pilin lacking pseudaminic acid involved 
engineering of a mutagenesis vector. Here, E. coli HB101 containing pTJS53 was subjected to 
transposon mutagenesis using standard protocol (de Bruijn, 1984) employing the λ::Tn5 hybrid 
vector λ467. Plasmid DNA containing λ::Tn5 was isolated from a colony kanamycin resistant E. 
coli. The Km
r
 region of the inserted λ::Tn5 was removed by digestion with BamHI and the 
remainder of the fragment was ligated with the Gm resistance (Gm
r
) cassette from pPC110 cut 
with the same restriction enzyme. This produced pSMC900 which was used in transposon 
mutagenesis of P. aeruginosa 1244.  
pSMC900 was introduced into P. aeruginosa 1244 by triparental mating (Figurski, 1979; 
Ruvkun, 1981). Gm
r
 colonies were patched to LB-Gm plates which were incubated overnight at 
37°C. Colonies were lifted using nitrocellulose membranes which were blocked and then probed 
with monoclonal 11.14 (Castric, 2001), an antibody which is specific for strain 1244 O-antigen/ 
pilin glycan. Forty-four colonies of 1771 screened were found to be non-reactive. On re-
examination, two of these clones did not react with monoclonal 11.14, but were recognized by a 
pilin-specific monoclonal antibody (results not shown). One of these strains, 1244.2.1, was used 
in the present study. Pili produced by this strain were subjected to Western blot analysis, using a 
protocol described previously (Castric, 1995) and employing a 1244-pilin specific monoclonal 
antibody 5.44 (Castric, 1994) as probe. Results indicated that this strain produced pilin of a 
reduced apparent molecular weight as compared to the wild type (Figure 2.1).  
 
 
 31 
 
 
Figure 2.1. Western blot of whole cell lysate preparations from P. aeruginosa 1244, 
1244.2.1, 1244G7, 577B, A031, PA103ΔpilA/pPAC24, and PA103ΔpilA/pPAC46. Cell 
extracts of these strains were electrophoresed and blotted to nitrocellulose paper. A) Strains 
1244, 1244.2.1, and 1244G7. B) Strains 577B, 1244G7, and A031. C) Strains 
PA103ΔpilA/pPAC24, and PA103ΔpilA/pPAC46. The blots were probed with group I pilin 
protein specific monoclonal antibody 5.44 (Castric, 2001). Images were changed to grayscale. 
 
To examine this point further, purified strains 1244 and 1244.2.1 pilin samples separated 
by SDS-PAGE were submitted to The University of Pittsburgh Genomics and Proteomics Core 
Laboratory for chymotrypsin digestion followed by mass spectrometric analysis using high 
resolution LC-MS/MS (LTQ/Orbitrap). This treatment revealed a fragment with the expected C-
terminal sequence (KPNYAPANCPKS) and a mass of 1608.61 kDa. This is consistent with the 
presence of the peptide plus FucNac and xylose, but the loss of pseudaminic acid. A similar 
analysis of strain 1244 pilin revealed a fragment with this same sequence, but a mass of 1954.89 
kDA which is consistent with the presence of the intact glycan.     
2.3.2.2. Pilin/ D-Glc-(β1→3)-L-FucNAc-(α1→3)-D-FucNAc-(β1→.  
Strain 1244 pili with the covalently attached neutral trisaccharide shown here were produced by 
expressing the functional 1244 pilAO operon in P. aeruginosa strain PA103ΔpilA. This mutant 
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lacks the ability to produce pilin (Comolli, 1999a, b) but expresses the desired O-antigen 
repeating unit (Fig 2.1).   
2.3.2.3. Pilin/ L-Rha-(α1→3)-L-FucNAc-(α1→3)-L-FucNAc-(α1→3)-
D-QuiNAc(α1→.  P. aeruginosa strain 577B (Castric, 1994) belongs to IATS serotype O4. The 
structure of the O-antigen repeating unit of this serotype has been determined to be that of the 
four sugar saccharide indicated here (Knirel, 2006).  Pili from strain A031, a clinical isolate 
which produces only nonglycosylated group I pilin due to the presence of an insertion sequence 
in the pilO gene was used as control (Figure 2.1). The sequence of the pilin from this strain is 
identical to that produced by strain 577B. 
2.3.3. Pilus preparation. Four 2% CAYE agar plates each of P. aeruginosa 
strains 1244, 1244G7, 1244.2.1, PA103ΔpilA/pPAC24, PA103ΔpilA/pPAC46, PA103, 577B, 
and A031 were inoculated with CAYE broth starter cultures and incubated 14 hours at 37
º
C. 
These cells were resuspended with CAYE broth and diluted to an equal OD650 using the same 
medium. This suspension was stirred for 30 minutes at room temperature, vortexed for 45 
seconds, and centrifuged at 11,952 x g and 4
o
C for 30 minutes. The cell pellets were discarded 
and the supernatant fractions were transferred to 15 ml glass round-bottom centrifuge tubes.  
2.3.4. Pilus Solubility Assays. Protein from each supernatant fraction was 
harvested in three sequential salt precipitations. Saturated ammonium sulfate was first added to 
each initial pilus preparation supernatant sample to a concentration of 0.1 M. This suspension 
was incubated on ice for 30 minutes then centrifuged for 30 minutes at 11,952 x g at 4
o
C. Next, 
solid ammonium sulfate was added to each of the separated supernatant fluids produced by the 
previous step to a concentration of 1.11 M. This was incubated and centrifuged as above. Lastly, 
solid ammonium sulfate precipitation (this time at a concentration of 3.95 M) of the resulting 
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supernatant fluid was repeated followed by salt dissolution, incubation on ice, and centrifugation 
as above. 
The pellets from each of these samples were dissolved in deionized water and subjected 
to (SDS) polyacrylamide gel electrophoresis using a 16% T separation gel as previously 
described (Castric, 1989). All protein samples were prepared to fit within the linear portion of a 
previously determined pilin protein calibration curve (Furst, 2005). Proteins were then 
electroblotted onto 0.45 µm nitrocellulose membranes at 100V for 20 minutes using Bio-Rad 
Mini Trans-blot system (Bio-Rad Laboratories, Hercules, CA). This treatment ensured that the 
pilin sample left the gel but did not pass through the membrane (Furst, 2005).  The membranes 
were blocked in protein solution (Sidberry, 1985) for 20 minutes and incubated overnight with 
either monoclonal antibody 5.44 (Castric, 2001), which is specific for group I pilin, or 
monoclonal 2.97 (Saiman, 1989), which recognizes P. aeruginosa PA103 pilin.  The membranes 
were washed with phosphate buffered saline three times for 10 minutes then incubated with a 
goat anti-mouse Alexa Fluor 532 labeled secondary antibody 1 hr with constant motion in 
darkness. The membranes were washed again as above in darkness and allowed to dry.  
Fluorescent protein bands were visualized using a FluorImager 595 (Molecular 
Dynamics) at 514 nm with a 570 DF30 filter. The fluorescence was then quantified using 
ImageQuant Version 5.0 software (Molecular Dynamics). All pilus solubility assays were 
conducted at least three times. The most resolved blot was used for fluorometric quantitation to 
represent the amount of protein in each assay fraction.  
2.3.5. Twitching Assays. Subsurface twitch assays (McMichael, 1992) were 
conducted as previously described (Castric, 2001). Fisherbrand 100 x 15 mm polystyrene plates 
were used for the standard subsurface assay. BD Falcon 100 x 20 mm vacuum gas plasma treated 
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polystyrene tissue culture dishes were used in all other assays.  At least 40 repeats of each 
treatment were carried out.  
Surface agar twitching (Semmler, 1999) was measured as follows. Cells were grown in 
CAYE broth to an OD650 of 0.200 (this value gave 4x10
9
 colony forming units per ml (CFUs ml
-
1
). Dilutions calculated to produce 400, 40, and 4 CFUs were spread onto 2% CAYE agar with 
and without 90.0 mM ammonium sulfate. Plates were incubated at 37
º
C for 20-26 hours. Isolated 
colonies were imaged using Leica S6D (Leica Microsystems Inc.) microscope with Spot Insight 
Color camera (Diagnostics Instruments). Multiple fields of view were observed to obtain 
representative colony morphologies. 
2.3.6. Statistical Analysis. Statistical analyses for the subsurface twitching assays 
of 1244 and 1244G7 at increasing concentrations of ammonium sulfate were conducted using 
SPSS statistical software for One-Way ANOVA followed by Bonferroni correction. Paired T-
tests were conducted for all pairwise comparisons of subsurface twitching using the online 
Graphpad QuickCalcs software.  
2.3.7. Pilin Surface Models. Pilin sequences for 1244 (group I) and PA103 
(group II) were submitted to the PHYRE2 online protein structure prediction tool (Kelley, 2009). 
Surface analysis and modeling was conducted using DS ViewerPro 6.0 software. 
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2.4. Results 
2.4.1. Influence of glycan components on pilus-pilus interaction. The P. 
aeruginosa 1244 pilin oligosaccharide (Figure 2.2a) is composed of N-acetyl fucosamine, 
xylose, and pseudaminic acid (Castric, 2001). This structure is attached, via the FucNac reducing 
end, to the β-carbon of the serine that resides at the pilin C-terminus (Comer, 2002). Solubility is 
an appropriate way to determine pilus-pilus interaction via the fiber lateral surface since it is 
known that salt precipitation produces paracrystalline structure formation by longitudinal 
alignment of these fibers (Brinton, 1965). In order to establish the influence of the components 
of this structure on pilus solubility, partially glycosylated constructs were prepared and tested. 
Solubility was determined by ammonium sulfate precipitation from sheared cell supernatant 
fluids followed by quantitative Western blot of the pellet. The pH of these supernatant fluids was 
approximately 7.9. At this pH, glycosylated and non-glycosylated strain 1244 pili as well the pili 
of strain PA103 are predicted from their primary structures to have a net negative charge.   
Figure 2.2b shows that strain 1244 pili lacking all glycan components were insoluble in 
0.1 M ammonium sulfate. The presence of Xylose-FucNAc did not allow solubility at this salt 
concentration. However, the presence of the native oligosaccharide, Pse-Xyl-FucNAc, resulted in 
pilus solubility at both 0.1 and 1.11 M ammonium sulfate with precipitation occurring at 3.95 M. 
Quantitation of these blots by fluorometric imaging confirmed these results (Figure 2.2b). In 
order to determine whether the pseudaminic acid residue influenced fiber solubility through the 
presence of its negative charge or because of the increased oligosaccharide size, pili from strain 
1244 containing three neutral sugars (Glc-FucNAc-FucNAc) were tested. Figure 2a indicates that 
this pilus form was soluble in 0.1 M ammonium sulfate suggesting that pilus solubility did not 
require a negative charge but was rather influenced by the length of the glycan.  These findings 
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were supported by the evidence that pili (isolated from P. aeruginosa 577B), composed of pilin 
which showed a 95% identity in primary structure with that from 1244 but which had a four 
sugar neutral saccharide (Rha-FucNAc-FucNAc-QuiNAc), precipitated in the presence of 3.95 
M ammonium sulfate, but not at the lower concentrations.  Pili for strain A031, which were 
made up of pilin identical with that of strain 577B, but which lacked a glycan, were insoluble in 
0.1 M ammonium sulfate (Figure 2.2a). Again, quantitation of these blots by fluorescent imaging 
confirmed these results (Figure 2.2b).  For comparison, the solubility of a naturally non-
glycosylated type IVa pilus of P. aeruginosa was carried out. Here, it was found that the pili of 
strain PA103, which belonged to group II, were insoluble in 0.1 M ammonium sulfate (Figure 
2.2, Appendix Figures 1-7 show additional results for pilus solubility experiments). 
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Figure 2.2. Pilus solubility in the presence of ammonium sulfate.  (a) Western blot 
analysis of culture supernatant ammonium sulfate precipitates containing the pilin construct 
indicated. Monoclonal antibody 5.44, which is specific for group I pilin, was used in all samples 
except for PA103 pilin which employed monoclonal 2.97. Images were produced with the use of 
fluorescently labeled secondary antibodies and captured using a fluorimager. (b) Quantitation of 
Western blot pilin reactions shown in the previous panel employed ImageQuant software. The 
values given represent the percent total antigen present in the supernatant fluid sample.  
 
 
a. 
b. 
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Overall, these results suggest that pilus solubility is enhanced by the length of the glycan 
rather than the presence of the negative charge. Such a clear effect on the interaction between the 
pilus and its local environment suggests the possibility that the presence of this oligosaccharide 
has an influence on pilus function. 
2.4.2. Predicted pilin hydrophobicity. The reduction of the P. aeruginosa 1244 
pilus solubility in the presence of elevated salts suggests that the protein portion of this pilus 
surface contains hydrophobic components. While the native structure of the P. aeruginosa strain 
1244 pilus is not known, modeling can be used to produce a representation of the fiber surface 
based on the knowledge that the β-sheet region of the subunit resides at the polymer exterior of 
type IVa pili (Craig, 2004). Figure 2.3 presents models for the group I pilin from strain 1244 and 
the group II pilus subunit of strain PA103. Here it can be seen that residues containing ionizable 
R-groups are evident as are amino acids (serine and threonine) capable of hydrogen bond 
interaction. Of particular interest are the distinctive hydrophobic areas. These residues, when 
arranged in the pilus helix, would form a repeating pattern of surface hydrophobicity that could 
potentially influence interaction with the cell’s environment. The proximity of the O-antigen 
repeating unit attachment site to this area (Figure 2.3a, red star) suggests that this oligosaccharide 
has the potential to moderate the influence of the hydrophobic region. The strain PA103 pilus 
surface also has a hydrophobic region (Figure 2.3b) which may account for the reduced 
solubility seen above (Figure 2.2a and b). 
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(a)
(b)
 
Figure 2.3. Predicted surface exposed residues of P. aeruginosa strains 1244 and 
PA103 pilin monomers. The inset figure shows the β-sheet region which exists at the pilus 
surface. Red residues are acidic while blue ones are basic. Orange residues represent amides 
while white surfaces are amino acids exposing hydroxyl groups. Black residues have 
hydrophobic side chains.  (a) Strain 1244 (star indicates the glycan attachment site) pilin 
monomer.  (b) Strain PA103 pilin monomer. 
 
2.4.3. Influence of pilus glycan on twitching motility. Twitching motility on the 
surface of agar plates is associated with the presence of flared colony edges (Henrichsen, 1972). 
This phenomenon was observed with growth of either strain 1244 or strain 1244G7 (which 
produces only non-glycosylated pilin) on CAYE agar in the absence of added ammonium sulfate 
(Figure 2.4a and b). Flared colony edges were also seen with the wild type strain growing in the 
presence of 90 mM ammonium sulfate  (Figure 2.4e) while strain 1244G7 growing on the same 
medium presented smooth edged colonies (Figure 2.4f) suggesting an inhibition of pilus-
mediated motility. Strain 1244.47, an isogenic pilA mutant (Horzempa, 2006b), growing on this 
same medium confirmed the relationship between this colony morphology and the presence of 
functional pili (Figure 2.4c).  Strain 1244.47 does not show an altered morphology when 
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growing in the presence of elevated ammonium sulfate (Figure 2.4g). Assay of culture 
supernatant fluids by quantitative Western blot indicated that strain 1244G7 produced pili at the 
same level as the wild type (Appendix Figure 8) suggesting that twitching reduction was not due 
to inhibition of piliation. Both strains carried out a normal twitching response when sucrose was 
substituted for ammonium sulfate in a concentration of 250 mM (T. M. Allison and P. Castric, 
unpublished data) which indicated that the response seen was not due to an osmotic effect.  In 
order to determine whether the salt effect on colonial morphology was due to pilin glycosylation, 
strain 1244G7 containing either an empty vector or the pilO gene under control of a tac promoter 
were tested.  As can be seen on Figure 2.4d and h, expression of this gene partially restores the 
wild type colonial morphology. These results suggested that the colonial morphology change 
seen was due to a selective salt inhibition of twitching motility mediated by non-glycosylated 
pili.  
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Figure 2.4. Influence of salt concentration on colonial morphology of P. aeruginosa 
1244, 1244G7, 1244.47, 1244G7/pMMB66EH, and 1244G7/pMBT100. All strains were 
grown on CAYE agar. Panels (a) and (e): Strain 1244. Panels (b) and (f): Strain 1244G7. Panels 
(c) and (g): Strain 1244.47. Panel (d): 1244G7/pMMB66EH.  Panel (h): 1244G7/pMBT100.  
Panels (a), (b), and (c) were grown in the absence of added salt. Panels (d) through (h) were 
grown in the presence of 90 mM ammonium sulfate. Colony images are representative of 
multiple fields of view within and between plates. 
 
To study this response further, strains 1244 and 1244G7 were tested using the subsurface 
twitching motility assay. Here, the diameter of the twitch zone was measured after approximately 
48 hrs of growth. Figure 2.5 shows that the mutant producing non-glycosylated pili showed 
progressively reduced twitching motility as the ammonium sulfate concentration of the medium 
increased with statistically significant decreases at 60 mM ammonium sulfate compared to the 
mutant at all previous ammonium sulfate concentrations. Additionally, the mutant strain 
exhibited reduced twitching compared to the wild type strain at all ammonium sulfate 
concentrations (Figure 2.5). By comparison, the wild type parent of this mutant showed no 
motility inhibition at any salt concentration tested. Analysis of these results (as indicated in the 
legend of this figure) shows them to be statistically valid. The inclusion of 250 mM sucrose to 
the assay plates did not selectively influence twitching motility by either strain, suggesting that 
 42 
the selective ammonium sulfate inhibition was not due to an osmotic pressure effect on 1244G7 
(Appendix Figure 9). 
  
 
Figure 2.5. Influence of salt concentration on subsurface twitching motility by P. 
aeruginosa strains 1244 and 1244G7.  The solid bar represents the response of strain 1244 
while the grey bar is strain 1244G7. Statistical analysis used One-Way Anova with Bonferroni 
correction.  * P <  0.0001, ** P = 0.002.   
 
Selective inhibition of 1244G7 twitching by 125 mM sodium chloride (Figure 6a) 
suggested that the effect seen with ammonium sulfate was due to ionic strength and not 
specifically to ammonium or sulfate ions. The expression of a functional pilO gene, which had 
previously been shown to complement glycosylation in 1244G7 (Smedley, 2005), reversed salt 
inhibition (Figure 2.6a) indicating that selective ammonium sulfate inhibition of twitching 
motility was not due to a secondary mutation. Figure 2.6b shows that ammonium sulfate, at a 
concentration which inhibited 1244G7 also inhibited twitching motility of P. aeruginosa PA103, 
a group II strain that produces non-glycosylated pili (DiGiandomenico, 2002). 
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** * ***
1244 + - - -
1244G7 - + + +
NaCl + + + +
pMMBEH66 - - + -
pMBT100 - - - +
PA103 + +
(NH4)2SO4 - +
1244 + -
1244G7 - +
(NH4)2SO4 + +
 
Figure 2.6. Influence of salt concentration and matrix on subsurface twitching by P. 
aeruginosa strains.  (a) Twitching response of strains 1244 (solid bar) and 1244G7 (grey bar) to 
the presence of 125 mM sodium chloride in the culture medium.  The second data set is the 
twitching response of 1244G7 containing an empty vector (solid bar) or a plasmid expressing a 
functional pilO gene (grey bar) both in the presence of 125 mM Sodium Chloride. (b) Twitching 
response of strain PA103 to the absence (solid bar) or the presence (grey bar) of 90 mM 
ammonium sulfate. (c) Unlike the previous assays described, which employed standard 
polystyrene plates, the tests here were conducted using treated polystyrene plates. The solid bar 
represents the response of strain 1244 while the grey bar is strain 1244G7. Both represent 
motility in the presence of 90 mM ammonium sulfate.  Statistical analysis used the paired T-test.  
* P <  0.0001, *** No statistical significance. 
 
The lower solubility of non-glycosylated strain 1244 pili in the presence of ammonium 
sulfate as well as estimated surface structure suggested that these fibers had an increased 
hydrophobicity. If this is the case, the reduction in twitching motility might be in part due to the 
hydrophobic interaction among non-glycosylated 1244 pili or between these pili and the external 
environment. To test whether the non-glycosylated pili were attracted to the surface of the 
polystyrene culture plates used in these assays, twitching motility was repeated using plates 
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chemically treated to reduce surface hydrophobicity. Figure 2.6c shows that, in this situation, 
there was no difference between glycosylated and non-glycosylated strain 1244 pili under 
conditions of elevated ammonium sulfate suggesting that an interaction between the pilus surface 
and the cell environment is capable of altering pilus function. Incubation times employed using 
modified test plates were approximately half that of assays used for polystyrene plates indicating 
that both 1244 and 1244G7 growing next to these surfaces had speeds approximately twice that 
of the wild type traversing the polystyrene surface.   
2.5. Discussion. The presence of the O-antigen repeating units on the exterior of the P. 
aeruginosa group I type IVa pilus has the potential for having a major influence on the physical 
surface properties of this structure. This oligosaccharide commonly adds a negative charge, 
while the variation of the O-antigen repeating unit in saccharide structure and number (Knirel, 
1990; Lam, 2011) would produce a multiplicity of distinctive pilus surfaces. In addition, the 
glycan structure, unlike the pilin protein surface, has a dynamic conformational potential and 
would be expected to move freely about the point of attachment. This means that the non-
covalent interaction between the glycan and the protein surface from which it extends is difficult 
to predict because it is likely driven by the physical and chemical make-up of the environment in 
which the cell resides. This degree of variability suggests that the pilin glycan could influence 
pilus function in a number of ways. 
The pilus solubility experiments presented in this work suggests that the pilin glycan has 
an important role in pilus-pilus interaction.  These oligosaccharides could influence solubility in 
several non-exclusive ways.  The hydrophilic nature of these structures would be expected to 
allow them to fit into the water lattice more efficiently than could many of the protein surface 
residues.  In addition, the conformational flexibility of these glycans would minimize the 
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formation of stable structures capable of interacting between adjacent fibers.  Further, the bulk of 
the typically three to four sugars present in an O-antigen repeating unit could act to shield the 
pilus protein surface from direct contact with adjacent fibers or environmental surfaces. The 
absence of such shielding would lead to an increase in lateral surface attraction such as seen with 
the type IVb pili of the enteropathogenic Escherichia coli (Ramboarina, 2005) or the 
paracrystalline structure commonly seen with aggregated type IVa pili (Brinton, 1965).  In 
addition, the O-antigen repeating unit of P. aeruginosa frequently displays a negative charge 
(Knirel, 2006) at physiological pH which would produce a zone of electrostatic repulsion on the 
fiber surface.  Our results suggest that while electrical charge may enhance pilus function, it is 
not required for optimal pilus solubility.  Rather, sugar number appears to be the key determinant 
in pilus solubility.  However, the loss of solubility protection by fibers containing only two 
sugars suggests that the O-antigen repeating unit of this organism provides the near minimum 
protection for fiber solubility. It would be interesting to see whether the solubility P. aeruginosa 
type IV pili, which are glycosylated with a non-O-antigen oligosaccharide, is influenced by the 
presence of its glycan. 
The lessening of solubility in the absence of optimal glycan number implies the presence 
of hydrophobic regions on the pilus surface, which was confirmed by examination of surface 
oriented pilin subunits using molecular modeling. Repetition of this hydrophobic region over the 
length of the pilus could result in a cumulative significant attractive force between adjacent 
fibers. Previous work (Smedley, 2005) indicated that strain 1244G7 cells had an increased 
ammonium sulfate induced agglutination response as compared to strain 1244. This suggested 
that the pilin glycan directly influenced cell-cell interaction.  
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While bundles of fibers increase the success of some bacteria (colonization by 
enteropathogenic E. coli for example (Humphries, 2010)), this type of interaction could be 
detrimental for  other organisms. Twitching motility by P. aeruginosa, which is mediated by 
extension and retraction of the type IVa pilus (Burrows, 2012), is a significant contributor to this 
organism’s virulence (Comolli, 1999a; Zolfaghar, 2003). Weak binding at multiple pilus lateral 
sites could influence the efficiency of extension or retraction processes for type IVa pilus 
function.  The present study, using both the surface and submerged twitch assays, showed that 
there was little difference between strain 1244 and the isogenic mutant 1244G7 when measured 
at low ionic strength. However, increasing ionic strength through the addition of ammonium 
sulfate selectively reduced mobility by the mutant in both types of assay. The higher ionic 
strengths used in these experiments were in the same range as those found at a variety of P. 
aeruginosa infection sites including serum (Maas, 1985) and the respiratory tract surface fluid 
(Joris, 1993; Knowles, 1997; Landry, 2001). This suggests that strains producing group I pilin 
may have a selective advantage in certain disease situations. In support of this proposal, previous 
work has shown that strain 1244G7 had reduced virulence as compared to the wild type using a 
mouse respiratory disease model (Smedley, 2005). We show in the present work that twitching 
motility of P. aeruginosa PA103, a strain which produces a non-glycosylated pilus 
(DiGiandomenico, 2002), is strongly inhibited at elevated ionic strengths. This suggests that 
strains producing glycosylated group I pili may have a selective virulence advantage under 
conditions of elevated ionic strength as compared to group II producers. Further studies will be 
required to clarify these points. Such studies could suggest that the targeting of the pilin 
glycosylation reaction is a feasible chemotherapeutic strategy.  Since much is known of the PilO 
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substrate requirements, knowledge of the PilO structure could allow design of candidate 
inhibitors. 
The absence of salt-induced 1244G7 twitch inhibition when using treated assay dishes,  
as well as the reduced solubility of this strain as compared to the wild type, indicates that an 
interaction occurred between the non-glycosylated pilus surface and the hydrophobic polystyrene 
plate surface used in the standard assay. If this is the case, it is possible that the repetitive 
hydrophobic regions of the pilus lateral surface may interact directly with the elements in the 
pathogen’s environment. For example, the pilin glycan could prevent a non-specific interaction 
between pili of the pathogen and hydrophobic host matrix proteins such as fibronectin (Singh, 
2010). In this environment an organism producing glycosylated pili would have, due to enhanced 
twitching motility and reduced non-specific lateral interactions, an advantage by enhancing pilus 
function. Alternately, the absence of the glycan from a group II surface could increase 
colonization at hydrophobic sites or on non-natural hydrophobic environment surfaces such as 
implant and catheter surfaces, leading to enhanced biofilm formation. Overall, these results 
indicate that a balance between the physical and chemical characteristics of the pilus lateral 
surface and the host colonization site is an important determinant in pathogen success. This is an 
important area of study that should be examined in future work. 
In summary, this study has presented evidence that the pilin oligosaccharide has a role in 
maintaining function by moderating fiber interaction with its environment. These results suggest 
that even though the newly synthesized O-antigen repeating unit is primarily destined to become 
lipopolysaccharide and not the group I pilus, this glycan must also be considered a functionally 
integral component of the P. aeruginosa group I pilus expresses a lowered functionality in its 
absence. Since the O-antigen repeating units are diverse in structure and physical properties, it 
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can be questioned whether certain of these oligosaccharides are preferentially utilized in the 
production of group I pilin or if any of the structural types (Knirel, 1990, 2006) are able to carry 
out the pilin glycan function. Further studies will be required to answer this question. 
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Chapter 3: Glycan Specificity of P. aeruginosa Group I Pilin Glycosylation. 
3.1. Abstract. Group I pilin producing Pseudomonas aeruginosa utilize the O-antigen 
subunit as the pilin glycan. This glycan has been shown to aid in pilus function and 
hydrophobicity. Group I pilin producing strains comprise over 50% of the clinical isolate 
population and would be expected to exhibit glycans nonspecifically across strains. The 
traditional process of serotyping Pseudomonas strains with O-antigen specific antibodies is time 
consuming and expensive. Work in this chapter provides a method for assigning basic serotype 
using PCR amplification of unique genetic regions of the 20 O-antigen biosynthesis gene 
clusters. The results are presented as R-types which were assigned to all group I and non-group I 
pilin producing isolates to differentiate between the genetic classification and the antibody 
agglutination serotyping methods. It was expected that the R-types would be evenly distributed 
across all isolates, but in fact, there was a significant prevalence for the R5 type which encodes a 
single serotype (O6). Verification of the R5 strains was conducted with O6 specific antibodies 
which confirmed the genetic classification of these isolates. Results in this chapter suggest that 
the increased employment of the O6 O-antigen as the pilin glycan could potentially lead to its 
use as a part of a multi-component vaccine or therapeutic for P. aeruginosa infections.  
3.2. Introduction. Pseudomonas aeruginosa is a Gram negative, rod-shaped bacterium 
involved in numerous hospital acquired infections. The type IVa pili of this organism are 
surface-associated protein filaments which are composed of a monomeric subunit called pilin 
(Craig, 2004; Mattick, 2002). These fibers may be placed into five groups based on subunit 
primary structure as well as the presence of pilus-specific accessory genes (Castric, 1995; Kus, 
2004). Approximately half of P. aeruginosa isolates tested produce pilin belonging to group I 
(Kus, 2004). This protein has the added characteristic of being posttranslationally modified with 
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the covalent attachment of an oligosaccharide which is identical with the O-antigen repeating 
unit of the organism’s lipopolysaccharide (LPS) (Castric, 2001).  Recent work from our 
laboratory has presented evidence that the presence of the pilin glycan influences pilus function 
(manuscript in review). Since the O-antigen repeating unit is highly variable in size, charge, and 
structure (Knirel, 1990, 2006; Lam, 2011), it is possible that specific types of O-antigen 
repeating unit have a differential influence on group I pilus function. If this is the case, selection 
might allow for dominance of particular glycan types while suppressing the presence of others. 
This would suggest the possibility that these two major P. aeruginosa virulence factors, type IV 
pili and O-antigen subunits, are linked in terms of distribution (and possibly influence) in the 
natural populations from which these pathogens come in contact with their hosts. 
While the International Antigen Typing Schema (IATS) allows LPS from this organism 
to be placed into one of 20 serotypes (Knirel, 1990, 2006; Lam, 2011), it does not readily 
provide structural information on the O-antigen repeating unit. Work by Raymond et. al. has 
shown that the variety of O-antigen types produced by P. aeruginosa are encoded by only 11 
different gene clusters (Liu, 1983; Raymond, 2002). Each of these clusters produces 
antigenically distinct, but structurally predictable O-antigen oligosaccharides (Knirel, 2006).  
The current chapter describes development of an O-antigen typing system that is based on unique 
sequences present in each of the O-antigen gene clusters. These gene clusters were retrieved 
from GenBank and aligned. Unique areas of sequence were found for each cluster which were 
considered gene cluster specific regions and primers were designed to amplify these regions. 
Further verification that the primer sequences were specific for each cluster was conducted using 
BLAST. Application of this system to a clinical isolate population indicated that while one 
particular category (referred to as R-Type) predominated in strains producing group I pilin, 
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others were rare. The results of this chapter may provide insight into targeting a specific serotype 
as a therapeutic approach to P. aeruginosa infections. Furthermore, the PCR approach would 
reduce the time, expense, and inaccuracy of the current serotyping method as it can narrow down 
the number of possible serotypes thereby reducing the quantity of required agglutination tests. 
3.3. Materials and Methods 
 
3.3.1. Bacterial Culture Conditions. LB or CAYE broth cultures were grown at 
37°C on a rotary shaker at 250 rpm. CAYE broth cultures were plated on solid CAYE medium 
consisting of 0.75% casamino acids, 0.15% yeast extract, and 2% agar (Silipigni-Fusco, 1987). 
All clinical isolates used in this study were collected from Pittsburgh Children’s Hospital.   
3.3.2. Identification of strains producing group I pilin. PCR identification was 
employed using primers (Table 3.1) against a conserved region of pilO, a group I specific gene 
(Castric, 1995). Genomic DNA was extracted using the Qiagen DNA mini kit as per the 
manufacturer’s protocol (Qiagen). Thermocycler conditions were as follows 1) 94oC- 2.5 
minutes, 2) 94
o
C- 1 minute, 3) 61.5
o
C- 45 seconds, 4) 72
o
C- 1.5 minutes, Repeat 2-4 for 30 
cycles, 5) 72
o
C 5 minutes, and 6) 4
o
C Hold (Eppendorf, MasterGradient). Figure 3.1 shows the 
specificity of the group I pilO primers. 
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Figure 3.1. Agarose gel image of pilO PCR products. 1244: group I positive control, 
6640: clinical group I strain, PA103: group II negative control, Pfl (Pseudomonas fluorescens): 
non-aeruginosa control. The first lane contains a DNA size standard. 
 
Table 3.1. Group I pilO specific PCR primers. 
Group I pilO Forward 5’- CGT TAC CTG CGT GAA CAG GGC G-3’ 
Group I pilO Reverse 5’-GCC GCC GTG GAT TTC CAG GTA GC-3’ 
 
3.3.3. Identification of strains containing specific O-antigen Biosynthesis 
Gene Clusters. Raymond et. al. showed that there were 11 gene clusters encoding the 20 IATS 
serotypes of P. aeruginosa (Raymond, 2002). The sequences for the 11 P. aeruginosa O-antigen 
biosynthesis gene clusters were obtained from GenBank and aligned using Clustal W multiple 
sequence alignment, Megalign, and Microsoft Word. Examination of these gene cluster 
alignments showed that each contained unique regions.  The alignments were then analyzed for 
unique regions that could be used to identify each cluster (Appendix Figure 10). With this 
information, specific primers (Table 3.2, Figure 3.2) for each of the 11 R-types were prepared 
and tested using standard P. aeruginosa strains producing known IATS serotypes. Genomic 
DNA was extracted as described above. Thermocycler conditions were as follows 1) 94
o
C- 3 
400 bp  
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minutes, 2) 94
o
C- 1 minute, 3) 57
o
C- 45 seconds, 4) 72
o
C- 45 seconds, Repeat 2-4 for 30 cycles, 
5) 72
o
C- 5 minutes, and 6) 4
o
C Hold (Eppendorf, MasterGradient). The reactions of these primer 
sets with the stock strains are shown in Figure 3.3.  Here it can be seen that these specific 
primers recognized DNA from their IATS targets, producing fragments of anticipated size. In 
addition, these primers produced no reaction with DNA from any of the remaining target strains 
(results not shown).  
PCR amplification using these primers were applied to DNA from the clinical isolates 
described in Appendix Table 1. Ambiguous results (reaction with more than one primer set) were 
seen in a few cases which necessitated redesign and retesting of certain primers. Ultimately, 
unambiguous results were obtained for all isolates.  
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Table 3.2. R-type specific PCR primers. 
R1 Forward 5'- CGA GCT GCC CGT TGT TCT CTA TGT TG -3' 
R1 Reverse 5'- CTG AAG CTA TTC GAA ACG AGA AGC AGC TAC A -3' 
R2 Forward 5'- GGA GTT GCC ATG CTT TGG GTC AAG CG -3' 
R2 Reverse 5'- CCA TAA AAG CTT GAC CTT TGG CGA AGA -3' 
R3 Forward 5'- GAC CCC AGC TTG TAA TCT CCG AGC ATG -3' 
R3 Reverse 5'- CGT TCC CTC GGA CTG TAC ATT TCG GG -3' 
R4 Forward 5'- CAG GCG TCT GGC TAT CGC TGG -3' 
R4 Reverse 5'- GGC AAT CAA CCA CTT CTG CCT GAG AAT A -3' 
R5 Forward 5’- GGC TGA CGC TGA ATC TCG ATA AAG TC -3’ 
R5 Reverse 5’- CTC AGT TCG GAC GCT TCT TTC AAC TC -3’ 
R6 Forward 5’- CCT TCG GTT ATA GCG TCC GAT ATC AGC C -3’ 
R6 Reverse 5’- CCA CAT CGC TAA GAG AAG GAG GTA GTA C -3’ 
R7 Forward 5’- GCT GAT CAT TGA ACG AAA GAA TCC GGC A -3’ 
R7 Reverse 5’- CTG CAC TTC CGG GCT CAT GTT C -3’ 
R8 Forward 5’- GCT CAT TCA AGG GCT CTG GTC ACA AAA G -3’ 
R8 Reverse 5’- CGA GTG CCT TCG GAC TGC AGA TTC -3’ 
R9 Forward 5’- CCT CCT GCT CTT GGG TCT ATC GAA GG -3’ 
R9 Reverse 5’- CTC ATC CGA AAG CAG ATT GCG CG -3’ 
R10 Forward 5'- GAA ACA GGA AAT CCT GGT TCT GGA AGC G -3' 
R10 Reverse 5’- CGC CAT ACA TTT CAA GCT CCT CCC C -3’ 
R11 Forward 5’- CTA TCT TTC CTT GGG TGG CGC ACG -3’ 
R11 Reverse 5’- CAT GCC GGC AGT GGA TAG AGA AAC G -3’ 
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Figure 3.2. Primer site depictions for R-typing primers. A) Sequence regions for R-
types 1-4, 7-9, and 11. PCR primers fall within the orfA and wzz genes with the exceptions of B) 
the R5 (O6) falls between wzz and wbpO genes and R10 (O12) which falls between wzz and 
wbpK. Images modified from (Lam, 2011). 
 
B. 
A. 
 56 
 
Figure 3.3. Validation of R-type PCR primer specificity using DNA from strains of 
known O-antigen serotype. A. PCR results. The serotype of the target DNA source is 
underlined in white.  Primer sets recognize only one R-type and produce the expected product 
size.  The first lane contains DNA size standard.  B.  Relationship between R-type and IATS 
serotype. 
 
3.3.4. pilA gene nucleotide sequencing. Nucleotide sequencing of DNA 
produced by PCR amplification of the P. aeruginosa pilA gene utilized primers (Table 3.3) 
specific for the group I pilin gene.  Genomic DNA was extracted as described above. 
Thermocycler conditions were as follows 1) 94
o
C- 5 minutes, 2) 94
o
C- 1 minute, 3) 54
o
C- 40 
seconds, 4) 72
o
C- 1.5 minutes, Repeat 2-4 for 33 cycles, 5) 72
o
C- 7 minutes, and 6) 4
o
C Hold 
(Eppendorf, MasterGradient). The amplified DNA was sequenced at the University of 
Pittsburgh’s Genomic and Proteomic Core facility using pilA specific primers (Table 3.3). 
Table 3.3. Group I pilA PCR primers.  
1244PilR Forward Primer 5’- TTG CCG GCA GGG GAG AGC -3’ 
R3pilO Reverse Primer 5’- CGC AGC CAT CAG CGG CAG -3’ 
 
 
 
 57 
3.3.5. Immunoblotting. 
3.3.5.1. Western blotting of whole cell lysates.  One 2% CAYE agar 
plate was inoculated with 8 hour CAYE broth starter cultures and incubated 14 hours at 37
o
C. 
Cells were resuspended with phosphate buffered saline (PBS) and normalized to an equal OD650 
using the same buffer. Samples were prepared with 5x Laemmli/10% βME and heated for 5 
minutes at 95
o
C.  All protein samples were subjected to polyacrylamide gel electrophoresis using 
a 16% T separation gel as previously described (Castric, 1989). Proteins were electroblotted onto 
0.45 µm nitrocellulose membranes at 100V for 20 minutes as previously described (manuscript 
in revision, Allison et. al.2015). The membranes were blocked in protein solution (Sidberry, 
1985) for 20 minutes and incubated overnight with monoclonal antibody 5.44 (Castric, 2001), 
which is specific for group I pilin. The membranes were washed with PBS, incubated with a goat 
anti-mouse alkaline phosphatase labeled secondary antibody for 1 hr with constant motion at 
room temperature, and washed again in PBS and 0.05M Tris/HCl ph 8.0. The colorimetric 
development of the membranes was conducted using Napthol AS/MX Phosphate (Sigma) and 
Fast Red Salt (Sigma) in 0.05M Tris/HCl ph 8.0 until desired band intensity was achieved.  
3.3.5.2. Dot blot determination of O6 serotype. Overnight broth cultures 
of all clinical isolates typed as R5, P. aeruginosa strain PAK (positive control), and P. 
aeruginosa strain 1244 (negative control) were diluted to the same OD650 using CAYE broth. 
Five microliters of each culture were then spotted onto 0.45 µM nitrocellulose membranes. The 
membranes were blocked in protein solution (Sidberry, 1985) for 20 minutes and incubated for 4 
hours in the presence monoclonal antibodies (128.1.1, 2-34-3-7, and 7-72-1) (Sadoff, 1985) 
specific for IATS serotype O6.  Membranes were then washed three times in PBS and incubated 
with a goat anti-mouse Alexa Fluor 532 labeled secondary antibody for 1 hour with constant 
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motion in darkness. They were again washed three times in PBS for ten minutes each time in 
darkness and allowed to dry. Fluorescent protein spots were visualized using a FluorImager 595 
(Molecular Dynamics) at 514 nm with a 570 DF30 filter. 
3.3.6. Twitching Assays. Subsurface twitch assays (McMichael, 1992) were 
conducted as previously described (Castric, 2001) for all isolates giving a positive PCR signal 
using pilO gene primers. Fisherbrand 100 x 15 mm polystyrene plates were used for the standard 
subsurface assay.  
3.4. Results 
3.4.1. Distribution of P. aeruginosa group I pilin producers. Two hundred and 
six P. aeruginosa isolates from defined clinical sources (chronic respiratory, acute respiratory, 
and non-respiratory) were screened for the potential to produce group I pili. This was done by 
PCR using primers specific to a conserved region of pilO (tfpO), a gene found in strains 
producing such pili (Castric, 1995) (Appendix Figure 11). The results of PCR analysis of the 
hospital strains collected are shown in Table 3.4. Several pieces of information can be obtained 
from these data. First, the frequency of the pilO gene indicates that the strains producing group I 
pilin are well represented in these clinical isolates overall with a frequency of 110/206 (53.4% of 
all isolates). Comparing the acute and chronic respiratory isolates revealed no significant 
selection by either group. The same can be said for comparison of either respiratory group with 
non-respiratory isolates. These results present evidence overall that, even though the group I 
pilin is the most common type found among P. aeruginosa clinical, no clear cut association 
between it and a specific disease site is apparent.  
Western blotting using monoclonal 5.44, an antibody recognizing a conserved group I 
pilin epitope (Castric, 1994), was carried out to confirm the PCR response and to determine 
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whether the identified strains actually produced pilin (Figure 3.4, Table 3.4, and Appendix Table 
2).  
 
 
Figure 3.4. Western blot verification of group I pilO PCR positive clinical isolates. 
Strains 1244 and G7- group I positive controls, A108-A110 and A113-A117- pilO PCR positive 
isolates. Blot was developed with group I specific, monoclonal antibody 5.44 (Castric, 2001) at a 
10
-3
 dilution. 
 
Table 3.4. Distribution of isolates potentially able to produce group I pilin. Distribution of P. 
aeruginosa clinical isolates producing group I pili among three disease categories. Pilin group 
status was determined by PCR using pilO-specific primers and by Western blot using a group I 
pilin-specific monoclonal antibody (5.44). 
 
 
PCR reaction Western blot  
Disease Category 
 
Group I/total 
 
(%) 
 
Positives/Group I 
 
(%) 
  
 
Chronic respiratory 38/82 46.5 30/38 79.0 
  
 
Acute respiratory 28/48 58.3 27/28 96.4 
  
Non-respiratory 44/76 57.4 42/44 95.5   
Total: 110/206 53.4 99/110 90.0   
 
Here it was found that none of the isolates unable to produce a PCR signal gave a 
positive Western blot reaction. Further, this work showed that out of all of these strains, only one 
acute respiratory isolate (out of 28) and two non-respiratory strains (out of 44) were not 
recognized by monoclonal 5.44. These may represent spontaneous mutations resulting in the loss 
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of pilin biosynthesis or a sequence variation resulting in loss of reactivity with the 5.44 epitope. 
This low rate of pilin variants can be compared to that seen with the chronic respiratory isolates 
where 8 of 38 PCR-positive strains did not produce a Western blot signal. These results may 
again be due to mutant selection. It is known that a high production of mutations in genes coding 
for various phenotypes (such as O-antigen production) is a characteristic of chronic P. 
aeruginosa infections of cystic fibrosis patients (Cullen, 2015; Smith, 2006). Since strains that 
produced negative Western blot reactions missed strains with the ancestral ability to produce 
group I pilin, the higher accuracy of the PCR assay is important. 
As can clearly be seen in Figure 3.4, while being a supportive measurement of strains 
producing group I pilin, the Western blot has a further use. This methodology clearly 
differentiates between glycosylated and non-glycosylated group I pilins by difference in apparent 
molecular weight. Unmodified group I pilins vary only slightly in mass which means that they 
present consistently similar electrophoretic mobilities. Although the P. aeruginosa O-antigen 
repeating unit varies in size, even the smallest one changes the apparent pilin molecular weight 
of the carrier pilin enough to easily allow detection by polyacrylamide gel electrophoresis 
followed by Western blot as seen in Figure 3.4. The absence of the glycan in strain 1244G7 was 
caused by the inactivation of the pilO gene in the parent strain 1244. The remaining eight strains 
are from the present study.   
Table 3.5 shows that 15.2% of the strains produce group I non-glycosylated pilin. 
However this frequency is consistent with the loss of other pilin-related phenotypes. The 
inability of strains that can produce group I pilin to carry out twitching motility (a test for pilus 
functionality, Appendix Table 2) is also 15.2%. These rates are not unusual for an organism that 
is known for its high mutation frequency (Mena, 2008). 
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Table 3.5. Pilin glycosylation status of group I pilin producing clinical isolates. Frequency of 
production of non-glycosylated group I pili among clinical P. aeruginosa isolates.  
 
 (Non-Glycosylated/total)  (%)  
Chronic 
respiratory  5/30 16.7  
Acute respiratory  4/27 14.8  
Non-respiratory  6/42  14.3  
Total:  15/99 15.2  
 
3.4.2. Distribution of O-antigen repeating unit genes among clinical isolates. 
Each of the eleven P. aeruginosa O-antigen biosynthetic gene clusters (Raymond, 2002) can be 
distinguished by PCR using specific oligonucleotide primers (see Materials and Methods 
section). Since these clusters each produce structurally distinct repeating units (Knirel, 2006), 
this procedure allows for a novel form of O-antigen typing as well as the prediction of the glycan 
type available for pilin glycosylation. The results of analysis of the 206 clinical isolates using 
this methodology are presented in Figure 3.5 and based upon PCR positive versus negative 
reactions (Appendix Figure 12 and Appendix Tables 3 and 4). While the entire collection of 
group I pilin producing strains could be typed, 8 of the 96 non-group I pilin producing strains 
were non-typeable, meaning that they were recognized by none of the primer sets. Repeating the 
amplification of these strains gave identical results. These non-reacting strains may contain O-
antigen gene clusters that have previously not been described or are variants of one of the 11 
known R-types.  
 Aside from these non-typeable non-group I pilin producing strains, it can be seen that 
while there is a wide distribution of R-types, those strains producing R5 are most numerous, 
while those making R10 and R11 are absent. More importantly, the isolates possessing the pilO 
gene, and therefore potentially capable of producing group I pili, show a distinctively different 
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pattern of distribution as compared to the remainder of strains. For example, group I pilin 
producing strains that express genetic information for the R5 cluster are found far more 
frequently (65/110) as compared to the R5 cluster in non-group I pilin producing isolates 
(16/88). However, R2 and R9 types were rarely found among the group I pilin producing strains 
(1 and 2/110), although well represented (16 and 23/97) among the non-group I pilin producing 
isolates. The relative frequencies of these isolates were noted to be significant (P<0.0001) in 
each case as determined by 2 x 2 contingency table analysis.  
 
 
Figure 3.5. R-type distribution of group I and non-group I pilin producing clinical 
isolates. Histogram showing R1-R11 typing, NT- nontypeable, and PT- polytypeable clinical 
isolates. *P <  0.0001.  
 
It remained to be confirmed that the strains producing a signal with the R5-specific 
primers made O-antigen of the type expected. To determine this, all of the group I, R5-positive 
strains were tested by dot immunoblot using a panel of three monoclonal antibodies specific for 
International Antigen Typing Schema (IATS, (Liu, 1983)) O6, the serotype produced by this 
gene cluster (Knirel, 2006; Lam, 2011). Table 3.6 shows that a clear majority of strains were 
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recognized by these sera (Appendix Table 5). While the pattern of reaction varied, at least 56 of 
the 65 strains tested reacted with at least one of the sera employed. Although lack of recognition 
could be due to epitope variation, 5 of the 9 non-reactors were from patients with cystic fibrosis 
suggesting the possibility of loss of this trait during chronic infection (Ernst, 1999).  
Table 3.6.  The ability of R5 clinical isolates to react with O6-specific monoclonal 
antibodies. 
 O6 O-antigen Monoclonal Antibodies 
Disease Category 128.1.1 2.34.3.7 7.72.1 
Chronic Respiratory 15/20 10/20 7/20 
Acute Respiratory 21/22 20/22 13/22 
Non-respiratory 19/23 19/23 15/23 
Controls    
Strain PAK (+) 1/1 1/1 1/1 
Strain 1244 (-) 0/1 0/1 0/1 
 
3.4.3. Influence of disease category on R-type distribution. The non-group I 
pilin producing isolates present a view of O-antigen distribution based on LPS requirement only. 
Figure 3.6 shows that R9 is a prominent type in each category of disease. R8 types are 
conspicuous in acute respiratory (6/20) and non-respiratory (6/32) strains but absent in isolates 
from patients with chronic respiratory infection. In addition, isolates from the chronic disease 
category present a distinctly different R-type pattern, especially with regards to R2, R3, and R4. 
The variance of this group of types between the chronic respiratory isolates and the acute 
respiratory or the non-respiratory strains is significant (p = 0.0009 and 0.0015 respectively) as 
determined using the 2 x 2 contingency table.   
Isolates that utilize the O-antigen repeating unit for both the LPS O-antigen and the pilin 
glycan demonstrate an R pattern that is quite uniform among all three disease types. Further, this 
distribution is distinctly unlike any of the patterns seen for strains that use the O-antigen 
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repeating unit only for LPS. Here the strong presence of R5 is a characteristic feature in all 
disease groups, as is the lack of R2 and R9.   
 
Figure 3.6. Distribution of P. aeruginosa R-types in relation to isolate source. The 
dark bars represent group I clinical isolates while gray bars represent non-group I clinical 
isolates. The three graphs show the distinctive patterns for each disease type based on group 
status. 
 
A comparison can be made of the co-frequency of R5 and group I pili in the disease 
groups. Table 3.7 shows that the number of strains expressing both R5 glycan and a group I pilin 
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is greatest among the acute respiratory strains where 22/28 (78.6%) co-expressed these traits. 
Comparing this frequency with that of the chronic respiratory and the non-respiratory groups 
using the 2 x 2 contingency table produce a P-value of 0.0279.  The P-value obtained by 
comparing the R5/group I strains associated with acute disease with these phenotypes found in 
the remaining isolates (other two disease categories) produced a P-value of 0.0211.   
Table 3.7. Frequency of R5-type O-antigen among three groups of clinical isolates and the 
co-frequency of the R5-type with presentation of group I pili within each disease category.  
 
Disease Category R5/Group I  R5 Group I’s/Total  
Chronic Respiratory  20/37 (54.1%) 20/81 (24.7%) 
Acute Respiratory  22/28 (78.6%) 22/48 (45.8%) 
Non-respiratory  23/44 (52.0%) 23/76 (31.9%) 
 
3.4.4. Influence of oligosaccharide structure on glycan selection. It is possible 
that there may be a structural reason for the predominance of particular O-antigens among the 
pilin glycans.  Examination of the oligosaccharide structures (Figure 3.7) showed that while the 
R5 type is composed of four sugars, both R2 and R9 are smaller having three sugars. R5 is 
capable of expressing a negative charge, while the R9 glycan is neutral and the R2 structure is a 
zwitterion capable of producing a net negative charge at a neutral pH.  
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 Figure 3.7. Structure and charge examples of R5, R9, and R2 O-antigen repeating 
units. Corresponding International Antigenic Typing Scheme (IATS) examples are presented.  
 
Examining the distribution of oligosaccharide size and charge produces the results shown 
in Table 3.8. It can be seen that both O-antigen repeating units expressing a negative charge at 
neutral pH and those composed of four sugars predominate among the group I pilin producing 
isolates. The asymmetrical distribution of charge among these strains was significant (P = 
0.0056) as determined by 2 x 2 contingency table analysis. The distribution of size was also 
significant (P < 0.0001) as well, using the same statistical procedure. 
Table 3.8. Distribution of predicted O-antigen charge and sugar number. 
 
 Group I Remainder 
Charge:     -1 94 60 
                   0 16 28 
Sugar:         3 15 52 
                   4 95 36 
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3.5. Discussion. One of Pseudomonas aeruginosa’s virulence factors associated with its 
success as an opportunistic pathogen is lipopolysaccharide (LPS) which coats the cell surface. P. 
aeruginosa produces 20 different LPS associated O-antigen repeating units (Liu, 1973). LPS has 
been of interest as a target for therapy for P. aeruginosa infections, but determining the serotype 
can be expensive, inaccurate, and time-consuming. Traditionally, serotyping is performed using 
a serogroup antibody agglutination test. As mentioned, the use of this method can be costly due 
to the expense of each antibody (20 antibodies total) and inaccurate due to cross-reactivity with 
the core oligosaccharide of LPS and not the O-antigen.  
In the case of group I pilin producing P. aeruginosa strains, the O-antigen repeating unit 
from LPS is utilized as the pilin glycan (Castric, 2001). Therefore, it is important to serotype 
each strain since the pilin glycan is associated with the virulence of this organism. To circumvent 
the problem of inaccuracy and time of traditional serotyping, a PCR approach was developed to 
genetically assign serotypes based on the O-antigen biosynthetic gene clusters. According to 
Raymond et. al., the 20 IATS O-antigen serotypes for Pseudomonas aeruginosa are coded for by 
11 different gene clusters (Liu, 1983; Raymond, 2002). All samples were assigned an R-type (so 
called after Raymond et. al.) and not a serotype due to the genetic establishment and not 
serogroup agglutination testing.  
Since the O-antigen repeating unit is variable in size, charge, and structure, it is possible 
that its presence influences group I pilus function. If this is the case, particular O-antigen types 
may be more compatible than others in the expression of group I pili. Data presented in this 
chapter show that in the population tested there is a statistically significant selection for the O6 
encoding gene cluster or the R5 type. It is possible that the combination of a negative charge and 
a larger oligosaccharide provide a selective benefit for the organism.  
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We have presented evidence (provided in chapter 2) that the pilin glycan increases pilus 
solubility which we suggest could enhance pilus function by preventing aggregation of these 
fibers during extension and retraction. The mechanism for the prevention of this entanglement 
could be the suppression of close pilus contact which, through the multiplicity of structures 
capable of producing weak bonds arrayed along the length of the fiber, would result in strong 
binding of adjacent fibers. The action of the glycan could be through electrostatic repulsion 
produced by the uniform negative surface charge produced by the glycan. This protection could 
also be brought about by a shielding effect produced by the physical presence of the 
oligosaccharide. Here the more bulky four sugar glycan might produce a superior protection as 
compared to the smaller repeating unit. If this is the case, the R5 glycan may be the optimal 
glycan type, while R2 and R9 are poorly protective. Clearly, further work will be required to 
explore these possibilities. 
Overall, the data presented strongly suggest that there is a selective process which results 
in the observed distribution of pilin and O-antigen repeating unit type. A part of this process 
likely occurs in nature (the P. aeruginosa reservoir) resulting in selected types coming in contact 
with potential hosts. The results also suggest that there is a selection occurring based on disease 
environment. Here the combination of R5 LPS and group I pilin produce a generally more 
effective pathogen, particularly with regards to acute respiratory disease. Unfortunately the 
limited number of samples tested prevents more specific conclusions. However, the results do 
support the need for further research. The knowledge that specific disease types may be 
associated with particular LPS and pilin combinations would allow for focused intervention 
strategies. For example, we have shown that the group I pilin glycan is immunogenic and 
produces a protective LPS-based response (Horzempa, 2008). A group I, pilin-based vaccine 
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containing an R5 oligosaccharide might specifically protect individuals (such as those with 
COPD or the elderly) who are susceptible to acute respiratory disease. This would be a novel 
approach for treating P. aeruginosa infections in a more targeted fashion as current treatment 
involves antibiotic therapy that is becoming less useful as the bacterium becomes resistant to 
more antibiotics. 
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Chapter 4. The Pseudomonas aeruginosa Pilin Glycan Influences Piliation 
4.1. Abstract. The group I pilin protein of Pseudomonas aeruginosa has been shown to 
be posttranslationally modified with the addition of a single O-antigen subunit at the C-terminal 
serine residue. Research from our lab has shown that the presence of the glycan is beneficial for 
this organism. If beneficial, it would stand to reason that non-glycosylated group I pilin 
producing strains would not be prevalent in the environment (eg. clinical isolates). In screening 
clinical isolates for group I pilin producing strains, we found that non-glycosylated pilin 
producing strains were naturally present and at a higher than expected rate. In finding these 
strains, it was necessary to characterize the cause of this altered phenotype. Sequencing and 
complementation results indicated that non-glycosylated group I pilin producing strains were 
caused by defects in the known components of the glycosylation pathway: pilA, pilO, and the O-
antigen biosynthesis pathway. Furthermore, only one co-phenotype was found among these 
strains, a reduction in piliation. Additional characterization of the cause for reduced piliation 
showed that the presence of non-glycosylated pilin alone was enough to reduce the amount of 
surface pili in these mutant clinical isolates. To confirm this finding, a pilO knockout was 
engineered from the glycosylated group I pilin producing clinical isolate, A074. The knockout 
showed a loss of glycosylation and a marked reduction in piliation. Providing this mutant with a 
functional pilO complemented both glycosylation and piliation levels. A previously evaluated 
laboratory engineered mutant did not show this reduced piliation in the absence of glycosylation 
which led to experiments to evaluate the role of protein charge on pili levels as this was the only 
difference exhibited between the clinical mutants and the laboratory engineered mutant. Overall, 
work in this chapter provides evidence that non-glycosylated group I pilin producing strains are 
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naturally found in the environment and exhibit a reduction in surface pili that can be attributed to 
the absence of the pilin glycan and potentially associated with pilin charge.  
4.2. Introduction. Pseudomonas aeruginosa produces type IVa pili, which are polar, 
protein fibers extending from the cell surface. The fiber is comprised of monomers called pilin. 
These protein monomers can be placed into one of five groups (I through V) based on pilin 
primary structure and the presence of pilus-specific accessory genes (Castric, 1995, 1994; Kus, 
2004). The majority of known strains can be placed into the first two groups (I and II), with 
group I’s making up over fifty percent of the clinical isolate population. Group I pilin producing 
strains are posttranslationally modified by the addition of a covalently attached O-antigen 
repeating unit (Castric, 2001) catalyzed by an oligosaccharyl transferase called PilO (TpfO) 
encoded by the accessory gene pilO located directly downstream from the pilA gene (Castric, 
1995, 2001).  
The role of the group I pilin glycan is not fully understood. Previous research based on 
Pseudomonas aeruginosa 1244 indicated that the presence of the glycan was beneficial for 
solubility and pathogenesis (Smedley, 2005). Recently submitted work also indicates that the 
glycan benefits this organism in high ionic strength environments and that solubility is increased 
by the presence of a full length glycan in the case of strain 1244 (manuscript in revision, Allison 
et.al. 2015). In the absence of this glycan, solubility was reduced and twitching motility was 
inhibited at high ionic strengths. These studies were all conducted with glycosylated and non-
glycosylated laboratory strains of Pseudomonas aeruginosa, but it was unclear as to whether 
both phenotypes were present in the natural environment. Having determined that the loss of the 
pilin glycan interfered with pilus function, our goal was to establish if the non-glycosylated pilin 
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phenotype could be found in the clinical setting and if it had any effect on pilus function or 
piliation in the natural setting.  
The results described in this present study show that while the majority of group I pilins 
are glycosylated, non-glycosylated group I pilins are also produced by P. aeruginosa in the 
natural environment. The data show that the non-glycosylated pilin phenotype is caused by 
defects within the pathway for glycosylation, specifically in the pilA gene, pilO gene or the O-
antigen biosynthesis pathway. Complementation of these defects recovers glycosylation in many 
but not all mutant strains possibly indicating secondary mutations. In addition to the loss of 
glycosylation among these mutants, they all exhibit a marked reduction in piliation. With 
glycosylation recovery, an increase in surface piliation is often but not always seen. This 
corresponds with the variation in piliation seen among glycosylated group I pilin producing 
clinical isolates. The work described in the present study suggests that the pilin glycan may play 
a major role in the full piliation of these strains.  
4.3. Materials and Methods 
4.3.1. Bacterial Culture Conditions. LB or CAYE broth cultures were grown at 
37°C on a rotary shaker at 250 rpm. Solid CAYE medium consisting of 0.75% casamino acids, 
0.15% yeast extract, and 2% agar (Silipigni-Fusco, 1987). When necessary, media were 
supplemented with tetracycline (Tc) at 75 µg ml
-1
, carbenicillin (Cb) at 200 µg ml
-1
 or 
gentamicin (Gm) at 250 µg ml
-1
 for P. aeruginosa and 10 μg ml-1 for Escherichia coli. For 
induction of pPAC24, media was supplemented with 0.5 mM Isopropyl-β-D-1-
thiogalactopyranoside (IPTG). For induction of pBAD constructs, medium was supplemented 
with 0.25% arabinose. Information for clinical isolates used in this chapter can be found in 
Tables 1 and 7 in the Appendix. 
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4.3.2. Pilin Analysis 
4.3.2.1. Pilin sample preparation 
4.3.2.1.1. Whole Cell Lysate. One 2% CAYE agar plate each was 
inoculated with 8 hour CAYE broth starter cultures and incubated 14 hours at 37
o
C. Cells were 
resuspended with phosphate buffered saline (PBS) and normalized to an equal OD650 using the 
same buffer. Samples were prepared with 5x Laemmli/10% βME and heated for 5 minutes at 
95
o
C.  
 4.3.2.1.2. Cell and Supernatant Fraction Piliation Assays. 
Three 2% CAYE agar plates each were inoculated with 8 hour CAYE broth starter cultures and 
incubated 14 hours at 37
o
C. Cells were resuspended with CAYE broth and diluted to an equal 
A650 using the same medium. The cell suspensions were sheared 10 times through an 18 gauge 
needle attached to a 10 ml syringe. Suspensions were centrifuged at 11,952 x g and 4
o
C for 30 
minutes. The cell pellets were resuspended to original A650 values with CAYE broth and the 
supernatant fractions were transferred to 15 ml glass round-bottom centrifuge tubes.  
Polyethylene glycol (PEG) 8000 to 3% and NaCl to 0.5 M was added to each pilus 
supernatant sample. This suspension was incubated on ice for 2 hours then centrifuged for 30 
minutes at 11,952 x g at 4
o
C. Pellets were resuspended with CAYE medium to equal optical 
densities and prepared in sample buffer as previously noted. 
4.3.2.2. SDS-PAGE. All protein samples were subjected to 
polyacrylamide gel electrophoresis using a 16% T separation gel as previously described 
(Castric, 1989). 
4.3.2.2.1. Protein staining. Protein samples were prepared as 
previously described with precipitation using ammonium sulfate followed by microdialysis 
 74 
(manuscript in revision, Allison et. al. 2015). Samples were run on a 16% T separating gel, fixed 
with 7.5% HAc/10% methanol, washed in 200mM Na2CO3, rinsed with deionized water, 
incubated in Deep Purple, and washed in 7.5% HAc. The signal was then imaged with the 
FluorImager595 at 514 nm with a 610 RG filter. 
4.3.2.3. Western blotting. Proteins were electroblotted onto 0.45 µm 
nitrocellulose membranes at 100V for 20 minutes as previously described (manuscript in 
revision, Allison et. al. 2015). The membranes were blocked in protein solution (Sidberry, 1985) 
for 20 minutes and incubated overnight with monoclonal antibody 5.44 (Castric, 2001), which is 
specific for group I pilin. The membranes were washed with PBS three times for 10 minutes then 
incubated with a goat anti-mouse alkaline phosphatase labeled secondary antibody for 1 hr with 
constant motion at room temperature. The membranes were washed twice as above and a third 
time with 0.05M Tris/HCl ph 8.0. The colorimetric development of the membranes was 
conducted using Napthol AS/MX Phosphate (Sigma) and Fast Red Salt (Sigma) in 0.05M 
Tris/HCl ph 8.0 until desired band intensity was achieved. Membranes were then dried, imaged, 
and annotated.  
For quantitative analysis, the membranes were incubated with a goat anti-mouse Alexa 
Fluor 532 labeled secondary antibody for 1 hour with constant motion in darkness. Membranes 
were washed three times in PBS for ten minutes each time in darkness and allowed to dry. 
Fluorescent protein bands were visualized using a FluorImager 595 (Molecular Dynamics) at 514 
nm with a 570 DF30 filter. The fluorescence was then quantified using ImageQuant Version 5.0 
software (Molecular Dynamics). The averages of three band measurements were utilized for 
analyses.  
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4.3.2.4. Isoelectric focusing and immunoblotting. Three 2% CAYE agar 
plates were inoculated and incubated as above. The cell suspensions were sheared 10 times 
through an 18 gauge needle attached to a 10 ml syringe. Suspensions were centrifuged at 11,952 
x g and 4
o
C for 30 minutes and the supernatant fractions transferred to 15 ml glass round-bottom 
centrifuge tubes. Solid ammonium sulfate was added to each sample to 75% saturation. After the 
salt was in solution, this suspension was incubated on ice for 30 minutes and then centrifuged for 
30 minutes at 11,952 x g at 4
oC. Pellets were resuspended with 60 mM β-Octyl Glucoside 
(βOG). Samples were then run on a pH 3-9.5 isoelectric focusing Phastgel containing 30 mM 
βOG using the Phastgel electrophoresis system.  Protein was then transferred to a 0.45 µM 
nitrocellulose membrane by diffusion. The membranes were blocked in protein solution 
(Sidberry, 1985) for 20 minutes and incubated overnight with monoclonal antibody 5.44 
(Castric, 2001), which is specific for group I pilin. The blot was developed as described for the 
Western blot. 
4.3.3. pBAD Constructs 
4.3.3.1. Constructs. Primers (Table 4.1) were designed to amplify the pilA 
gene and the pilAO operon from strain A074. These primers incorporated a forward EcoRI and 
reverse HindIII enzyme cut sites. PCR amplified DNA were mixed with the pCR 2.1 TOPO 
cloning vector following the TOPO TA Cloning Kit protocol (Life Technologies). 
Transformation of TOP10 chemically competent E. coli cells was conducted as per 
manufacturer’s protocol (TOPO TA cloning kit).  
Insert presence was verified with digestion using EcoRI and HindIII enzymes. 
TOPOpilA
1244
, TOPOpilA
A074
, TOPOpilAO
A074
, and pBAD DNAs were digested with EcoRI and 
HindIII enzymes. The digested pBAD, pilA
1244
, pilA
A074
, and pilAO
A074
 were all extracted using 
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Qiagen’s Gel Extraction Kit as per the manufacturer’s protocol (Qiagen). pBAD plasmid DNA 
was combined with pilA
1244
,  pilA
A074
 or pilAO
A074
 and lyophilized. Ligation reactions were set 
up for each combination using T4 ligase. Samples were kept at 14
o
C overnight in a thermocycler 
to maintain consistent ligation temperature. TOP10 chemically competent E. coli cells were 
transformed with the ligation products following the TOPO TA cloning kit transformation 
protocol. Colonies were chosen and PCR verification of inserts was conducted using the same 
primers for previous gene/operon amplification.  DNA sequencing verified the gene and operon 
presence in the pBAD construct. These constructs are referred to as pBADpilA
1244
, 
pBADpilA
A074
, and pBADpilAO
A074
.  
Table 4.1. Strain 1244/A074 pilA and A074 pilAO primers for pBAD vector cloning. 
F1EcoRIpilA Forward 5’- GAA TTC CAA CCT GCT TTG AAG G -3’ 
R1HindIIIpilA Reverse 5’- GAA GCT TCT GCT GGT CAT GCC AGT T -3’ 
F1EcoR1pilAO Forward 5’- GAA TTC CAA CCT GCT TTG AAG G -3’ 
R1HindIIIpilO Reverse 5’- GAA GCT TGG GAA GGT ATC ACT CGG -3’ 
 
4.3.3.2. Plasmid DNA Extraction and Recombination Verification. 
Plasmid DNA was extracted according to the manufacturer’s protocol (Stratagene Plasmid Mini 
Prep Kit) with a single change for Pseudomonas strains. After addition of solution 3, all samples 
were centrifuged at 14,500 rpm for 30 minutes instead of 5 minutes. This is due to the lack of 
strong pelleting by Pseudomonas aeruginosa strains with this kit.  
 Following plasmid DNA extraction of both empty vector and gene containing plasmid 
samples, 1% agarose gels were run to determine plasmid DNA presence. Plasmid DNA was then 
subjected to either enzyme digestion or polymerase chain reaction (PCR) analysis to further 
verify the presence of the expected insert followed by DNA sequencing for newly engineered 
constructs.  
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4.3.4. Cell Transformation  
4.3.4.1. Electrocompetent Cells. Strains selected for complementation by 
electroporation were grown overnight at 37°C on a rotary shaker at 250 rpm. Cultures were made 
electrocompetent as per the protocol of Choi (Choi, 2006).  
4.3.4.2. Transformation of Mutants, PAO1, PA103, and 1244.47 Cells. 
Transformation of competent cells was conducted through electroporation. Empty vector or 
complimenting plasmids were combined with 1 tube each of electrocompetent cells. Settings for 
electroporation were 2.5 kV, 200 Ohms, and 25 Capacitance. Following electroporation, cells 
were incubated at 37
o
C and 250 rpm for 2 hours. 
Cells were then plated on LB containing the desired antibiotic for each transformation. 
Plates were dried at room temperature and incubated at 37
o
C until individual colonies were 
present (24-36 hours). Colonies from each transformation were then picked and grown in LB 
broth containing the desired antibiotic overnight at 37
o
C and 250 rpm. A 1 ml aliquot was 
removed from each culture for plasmid DNA extraction. A 50% glycerol solution was added to 
each remaining culture and mixed. Stocks were aliquotted and stored at -80
o
C.  
4.3.5. A074 PilO
- 
Strain Construction. pilO gene replacement for strain A074 
was conducted using the previously described pGIL300 plasmid (Smedley, 2005). Strain A074 
was complemented with this plasmid by triparental mating (Figurski, 1979) and subjected to the 
previously described methods of gene replacement verification (Smedley, 2005). This 
transformant is referred to as A074TK3.  
4.3.6. Twitching Assays. Subsurface twitch assays (McMichael, 1992) were 
conducted as previously described (Castric, 2001). Fisherbrand 100 x 15 mm polystyrene plates 
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were used for the standard subsurface assay. Surface twitching assays were conducted as 
previously described (manuscript in revision, Allison et. al., 2015) in the absence of 90.0 mM 
ammonium sulfate. For surface corrosion assays, cells were prepared as for surface twitching 
assays except colonies were washed away from the plate surface with deionized water and the 
agar surface was imaged for pitting/corrosion. 
4.3.7. Protease Activity. Three 2% CAYE agar plates supplemented with 2.5% 
glucose each of A074, A074TK3, and 1244.47/pBAD (induced with 0.25% arabinose to mimic 
complementation assays) were prepared as noted in Pilin Analysis. The supernatant fraction from 
1244.47/pBAD was aliquotted into two fractions, 5 ml of protease containing supernatant and 5 
ml for heat killed (HK) supernatant (95
o
C for 1 hour). Supernatant fractions from A074 and 
A074TK3 were subjected to two precipitations with 3% PEG 8000 and 0.5 M NaCl. Pellets were 
resuspended with deionized water and combined with CAYE broth, supernatant from 
1244.47/pBAD, or heat killed supernatant from 1244.47/pBAD. All samples were incubated at 
37
o
C for 0, 3, and 6 hours or 0, 7, and 14 hours. Samples were run on a 16% T separating PAGE 
gel and electroblotted as described earlier. Quantitation was conducted as previously mentioned. 
4.4. Results 
4.4.1. Isolation and characterization of pilin glycosylation defective strains. 
Our lab has provided evidence that the P. aeruginosa 1244 pilin glycan is important for pilus 
solubility and function and that the non-glycosylated group I pilin producing strain 1244G7 has 
reduced solubility and pilus function (manuscript in revision). In order to determine if this non-
glycosylated pilin phenotype is present in a natural environment, screening for P. aeruginosa 
clinical strains which produced non-glycosylated pilin was conducted. Western blotting of whole 
cell lysates revealed that 15.2% of group I pilin producing isolates examined showed a reduction 
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in apparent pilin mass compared to wild type 1244 suggesting that these were pilins lacking a 
glycan. Five representative strains, 1631, 3778, A031, A033, and A107, (Figure 4.1) were 
selected for further study.   
 
 
 Figure 4.1. Western blot of whole cell lysates of controls and clinical isolates. 1244 
(glycosylated control), 1244G7 (non-glycosylated control), and 5 representative non-
glycosylated clinical isolates (A031, A033, A107, 1631, and 3778). 
 
The components of the pilin glycosylation pathway of these isolates were examined for 
possible defects, which would further indicate that pilin from these strains was non-glycosylated. 
Sequence data for the pilA gene of strain 3778 revealed a single nucleotide variation that resulted 
in a proline rather than a serine occupying the pilin C-terminus, thus eliminating the 
glycosylation site (Castric, 2001; Comer, 2002) (Appendix Figure 13). While sequencing of 
strains A031 and 1631 showed intact pilA genes, an insertion sequence was found in each pilO 
gene which would prevent expression of glycosylation activity (Appendix Figures 14 and 15. 
Complementation of these strains with a functional pilO gene shows an increase in apparent 
molecular weight indicating a recovery of glycosylation (Figure 4.2).  
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 Figure 4.2. Western blot of whole cell lysates showing complementation of mutant 
strains 1631 and A031 with pUCP26pilO. Whole cell lysate preparations of empty vector 
(pUCP26) and a functional pilO containing vector (pUCP26pilO) for non-glycosylated clinical 
isolates 1631 and A031. Increase in apparent molecular weight indicates restoration of 
glycosylation.  
 
Sequencing of the pilA and pilO genes from strains A033 and A107 revealed no defects. 
Complementation of these strains with a plasmid containing a functional O-antigen repeating 
unit gene cluster, pLPS2 (Goldberg, 1992), increased pilin molecular weight, indicating recovery 
of pilin glycosylation (Figure 4.3). This suggested that a defect here was within the O-antigen 
biosynthesis pathway which produces the O-antigen repeating unit for both lipopolysaccharide at 
the cell surface and for pilin glycosylation (Castric, 2001). Appendix Table 6 shows the 
summary of glycosylation defects for the 5 mutant isolates described above.  
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Figure 4.3. Western blot showing complementation of group I mutant strains A033 
and A107 with pLPS2. pLPS2 contains the O11 O-antigen gene cluster. pLAFR1 is the empty 
vector control. 
 
Overall, the pilA and pilO sequence analysis and complementation data confirmed the 
non-glycosylated pilin phenotype and suggested that these strains arose spontaneously. This 
could be inferred from the results showing that all non-glycosylated pilin producing strains 
contain different defects within the known glycosylation pathway. Furthermore, these results 
indicated that strains producing non-glycosylated group I pilin occur among clinical isolates at a 
significant rate.   
In order to further characterize these strains, it was necessary to evaluate potential co-
phenotypes associated with the loss of glycosylation. Therefore, pilus related functional assays 
were conducted. These included subsurface twitching and agar corrosion assays. Subsurface 
twitching of these strains showed that wild type levels of motility (Figure 4.4) were present for 
all mutants and agar corrosion assays verified these results (Figure 4.5). Combined, these results 
provide evidence for full pilus function.  
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Figure 4.4. Subsurface twitching assays for controls and mutants. A) 1244 (twitch 
positive control), B) 1244.47 (twitch negative control), C) 3778, D) 1631, E) A031, F) A033, G) 
A107. 
 
 
 
 
 
 Figure 4.5. Agar corrosion assays for mutant strains. A) 1631, B) 3778, C) A031, D) 
A033, E) A107, F) 1244.47 (non-piliated control), G) 1244 (piliated control). Images were 
changed to grayscale. Pitting indicates functional pili and is evident by indentations in the agar 
after the colony has been removed (also shown by James Smedley (Smedley, 2001)).  
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Further characterization was done to test whether these non-glycosylated group I pilin 
producing mutants showed the same piliation levels as a laboratory engineered non-glycosylated 
mutant. The expected result was wild type piliation levels. Western blot analysis of pili produced 
by cell shearing was carried out to determine the amount of pili present on the cells’ surfaces of 
the selected five isolates. Although all strains showed similar amounts of cell bound pilin, it was 
seen that all consistently exhibited reduced pili sheared from the cell surface (Figure 4.6).  
 
 
Figure 4.6. Cell bound and sheared pili controls and non-glycosylated clinical 
strains. A) Cell bound pili were obtained from the initial cell pellet, B) Sheared pili from the cell 
surface.  Strains 1244 and 1244G7 were diluted 1:100 to obtain resolvable bands. Strain A020 
was removed from both blot images as it was no longer being studied. * A band is present in 
original blot but scanner resolution did not show. 
 
The amount of sheared pili was then quantified to determine the average reduction of 
protein compared to 1244. Quantitative western blot analysis showed a 77 fold reduction in 
surface pili for non-glycosylated strains compared to strain 1244 (Table 4.2). Additionally, 
western blotting showed that all other non-glycosylated pilin producing strains isolated also 
A 
B 
Cell Bound Pili 
Sheared Pili 
* 
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exhibited this loss of piliation. These results were confirmed by ELISA using whole cells as 
antigen (Figure 4.7).  
Table 4.2. Quantitation values and percent piliation compared to 1244. Percent total piliation 
are in comparison to the 1244 glycosylated control.  
 
Strain 
Quantitated Pili Protein 
(Fluorescence Area * 10
5
) 
 
% Piliation 
1244  24.0  N/A 
1244G7  19.0  79.2 
A031 0.56  2.3 
A033 0.22  0.92 
A107 0.52  2.2 
1631 0.34  1.4  
3778 0.20  0.83 
 
 
 Figure 4.7. Graph of ELISA results for a glycosylated group I pilin producing 
clinical isolate (A074) and non-glycosylated group I pilin producing clinical isolates (A107, 
1631, 3778, A031, and A033) piliation. Each dilution was conducted in triplicate for each 
strain. The averages were then plotted against the absorbance at A405.  
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The initial characterization of these strains indicated that the reduction in surface piliation 
amongst non-glycosylated group I pilin producing strains did not alter pilus function (Figures 4.4 
and 4.5). Knowing that the non-glycosylated group I pilin producing clinical isolates exhibited 
reduced piliation but maintained pilus function, it was then necessary to evaluate the piliation 
levels of glycosylated group I pilin producing clinical isolates for comparison. The analysis of 
sheared pili of randomly chosen group I glycosylated pilin producing clinical strains and strain 
1244 indicated that, while there is an extreme variation in piliation among these strains (Figure 
4.8), many isolates produce as much or more pilus associated pilin as the wild type control, strain 
1244. Overall, these results suggested that the non-glycosylated pilin phenotype was associated 
with a reduction in piliation and required further investigation.  
 
 Figure 4.8. Protein stained SDS-PAGE of 1244 and group I glycosylated pilin 
producing clinical isolates surface fraction pili. Image shows a high degree of variation 
amongst all samples after normalization to the same optical density. The arrow indicates the 
electrophoretic mobility of pilin under the described PAGE conditions. 
 
 86 
4.4.2. The influence of pilin glycosylation state on piliation. Strains 1631 and 
A031 were examined further to determine whether they had additional defects in pilin 
glycosylation.  To do this, these isolates were complemented with a plasmid (pUCP26pilO) 
containing a functional pilO gene. While it has already been shown that this complementation 
resulted in pilin glycosylation (Figure 4.2), it was surprising to also find a dramatic increase in 
piliation (Figure 4.9).  
 
 Figure 4.9. Piliation assays for empty vector and complemented A031 and 1631 
strains. Sheared pili fractions were obtained for A) A031 pUCP26 (empty vector) and A031 
pUCP26pilO and B) 1631 pUCP26 (empty vector) and 1631 pUCP26pilO (Appendix Figures 16 
and 17). Complemented pili for both strains show increased amounts of protein compared to 
empty vector controls. 
A. B. 
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To confirm if there was a relationship between a functional pilO gene and piliation level 
in these mutant clinical isolates, an isogenic mutant of a glycosylated group I pilin producing 
clinical isolate was engineered (Appendix Figure 18). The construction of this mutant was 
necessary to make a more direct comparison among clinical isolates. Western blotting of pili 
prepared from the parent strain (A074) and the isogenic mutant (A074TK3) showed a loss of 
pilin glycosylation in addition to strongly reduced piliation (Figure 4.10). Complementation of 
this mutant with a functional pilO gene not only resulted in return of pilin glycosylation, but also 
restored piliation (Figure 4.10). These results provide evidence that the loss of glycosylation 
directly led to a loss in surface piliation.  
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 Figure 4.10. Western blot showing piliation of A074, A074TK3, and 
A074TK3/pUCP26pilO. Sheared pili fraction preparations for A074, A074TK3, and 
complemented A074TK3 strains. The complemented strain shows an increase in the amount of 
pilin protein as compared to the engineered mutant.  
 
4.4.3. The basis for reduced piliation in the absence of pilin glycosylation. A 
potential reason for the reduction of pili in the experiments described above is that the strains 
examined produced proteolytic activity which selectively digested non-glycosylated pili. To test 
this, purified glycosylated and non-glycosylated strain A074 pili were tested for sensitivity to 
strain 1244.47 culture supernatant fluids. Figure 4.11 shows that both glycosylated and non-
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glycosylated forms of these pili are degraded as compared to heat-killed controls.  However, no 
selective protection is shown by the glycosylated form. Repeat experiments and differing time 
points (0, 7, and 14 hour) showed the same results. It could then be concluded that proteolytic 
activity of secreted proteases was not responsible for reduced piliation in the absence of 
glycosylation.  
 
 
Figure 4.11. Protease assay of strains A074 and A074TK3 pili. Pili from strains A074 
and A074TK3 were incubated at 37°C with supernatant and heat killed (95°C for 1hr) 
supernatant from 1244.47pBAD for 0 hrs, 3 hrs, and 6 hrs. A quantitative western blot was run 
for all samples and the average total area for each strain/time point was graphed. Image shows 
that non-glycosylation does not increase proteolytic degradation of pilin protein. 
 
Since the reduction of surface pili was not due to proteolytic activity, it was important to 
return to our initial knowledge of glycosylation and piliation based on strain 1244G7. The 
expression of piliation in the absence of PilO in P. aeruginosa strain 1244G7 (Smedley, 2005) 
suggests that this protein is not required as a positive regulator in pilus formation. In addition, the 
piliation by this organism also suggests that non-glycosylated PilA is not a negative regulator in 
this process. With this in mind, experiments were carried out to see if the reduction in piliation 
was due simply to the physical presence of non-glycosylated pilin.  To do this, plasmids 
 90 
containing either functional pilA or pilAO from strain A074 under a controllable promoter were 
expressed in P. aeruginosa 1244.47, a strain in which the pilA gene had been inactivated. Results 
in Figure 4.12A and B indicate that expression of the construct containing both operon 
components produced vigorous piliation composed of glycosylated pilin. In contrast, pili 
expressed from the plasmid containing only the pilA gene were non-glycosylated and present at 
markedly reduced levels. An additional characteristic to note is that a second band (above the 
non-glycosylated pilin band) can be seen in the pilA only containing strain. This band is likely 
glycosylated pilin since pre-pilin is unable to form pili (Nunn, 1990). The presence of this band 
indicates that the 1244.47 background is not strictly regulated. Based on these results, most of 
the pilin produced is not converted to the glycosylated form and therefore increased piliation is 
not observed. 
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Figure 4.12. Western blot of cell bound and sheared pili from complemented 
1244.47 cells. A) Cell bound pilin from strain 1244.47pBAD (negative control), 
1244.47pBADpilA
A074
, and 1244.47pBADpilAO
A074
. B) Sheared surface pilin from strain 
1244.47pBAD (negative control), 1244.47pBADpilA
A074
, and 1244.47pBADpilAO
A074
. Cell 
bound protein showed reduced apparent molecular weight with the single gene versus the 
operon. Sheared surface protein showed an increase in the amount of pili present with the operon 
compared to the single gene complement. Duplicate lanes were cropped from the image.  
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Overall, 1244.47 cells containing pilA
A074
 showed a 3.4x increase of the pilin protein over 
the pilAO
A074
 containing cells. This suggests that periplasmic pilin is accumulating which 
indicates that the defect in piliation is likely due to some step in pilus formation rather than pilin 
biosynthesis or one of the other above possibilities.  Also, the cells containing the pilAO
A074
 
operon produce pili showing a 200x increase over the amount of pili produced by the pilA
A074
 
cells. Quantitation of these assays is shown in Table 4.3.  
Table 4.3. Quantitative values for 1244.47pBADpilA
A074
 and 1244.47pBADpilAO
A074
 cell 
bound pilin and sheared surface pilin amount.  
 
Strain/Pili Location 
Quantitated Pili Protein 
(Fluorescence Area * 10
4
)
 
1244.47 pilA
A074
/cell bound 17.6 
1244.47 pilAO
A074
/cell bound 5.16 
1244.47 pilA
A074
/sheared 3.44 
1244.47 pilAO
A074
/sheared 686.7 
 
 
In order to see if this reduction of piliation was due to a possible structural defect in the 
pilA
A074
 containing plasmid, nucleotide sequencing of the upstream and pilA structural regions of 
these two constructs was performed. Here it was seen that these regions of the two plasmids were 
identical. To examine this point further, the construct containing only the pilA gene was 
complemented in trans using a vector expressing a functional pilO gene (pUCP26pilO). In this 
situation the pilin produced was glycosylated and piliation again occurred at a high level 
(Appendix Figure 19). Altogether, these results indicated that this construct was fully functional 
and, therefore, suggested that the presence of non-glycosylated pilin could potentially act to 
directly inhibit pilus formation.  
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4.4.4. Charge characteristics of group I pilins. We have previously shown in 
our lab that strain 1244G7 does not have reduced piliation in the absence of glycosylation 
(Smedley, 2005). However, results presented in this chapter for non-glycosylated group I pilin 
producing clinical isolates indicate that in the absence of glycosylation, there is a significant 
reduction in surface pili. The only difference seen between the pilins of strain 1244G7 and the 
clinical isolates (specifically A074) is a single base change in the pilin gene sequence that leads 
to a single amino acid change in the pilin protein sequence. In 1244G7, the pilin protein exhibits 
a net negative charge, while the pilin proteins from the mutant clinical isolates show a positive 
charge.  
 Since this introduction of electronegativity could have an influence on pilus function and 
biosynthesis, the distribution of group I pilin protein charge status was examined. Forty-one 
group I pilin producing strains examined were found to fall into five nearly homologous 
subgroups based on primary structure (Figure 4.13). Comparison of the PilA variable portion of 
sequences representative of each group reveals that while group I-specific regions are present, a 
clear degree of variation is seen among these subgroups. More importantly, even though certain 
charged residues are conserved as to relative position, a marked difference in distribution and 
type of most of the ionized amino acids is seen (Figure 4.14A and B). 
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 Figure 4.13. Neighbor-joining tree of five group I pilin subgroups. Group I pilins can 
be placed into five subgroups based in primary amino acid sequences. PilA sequences were 
retrieved from GenBank or were sequenced from clinical isolates. Outgroup- PAO1 (group II 
strain).  
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Even with this variation, the prediction of an isoelectric point for each of these proteins 
reveals that they are all nearly identical with a pI of approximately 8.2 (Figure 4.14B). This 
suggests that a pilus composed of group I pilins in the absence of posttranslational modification 
would have a net positive charge at a physiological pH, an unusual situation for a bacterial 
surface protein. By comparison, the primary structure of 14 group II P. aeruginosa pilins 
examined has a predicted average pI of 5.8 while 7 group III pilins give a value of 4.73. 
 
 
 
 
Figure 4.14. Representative group I pilin sequences with pI and charge distribution. 
A) Partial primary sequences for 5 group I pilin subgroups. Red letters indicate positively 
charged residues; Blue letters indicate negatively charged residues. B) Charge distribution and 
pIs for pilin subgroups.  
 
 
 
 
 
A. 
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To test the influence of the pilin oligosaccharide on the protein isoelectric point, pilin 
monomers of known sequence bearing glycans of predicted charge type were analyzed by 
isoelectric focusing in the presence of a non-ionic detergent.  Figure 4.15, lane 1 shows that a 
mutant strain (A074TK3), which lacks a functional pilO gene and is unable to glycosylate pilin, 
produces protein with an isoelectric point of approximately 8.2. This is consistent with the value 
predicted by the protein primary structure. The strain producing this pilin types as R5 which 
predicts that its glycan bears a net negative charge.  
Figure 4.15, lane 3 shows that pilin from this strain had a pI of approximately 6.5, a value 
consistent with this protein modified with single negative charge. Additionally, the pilin band at 
pH 8.2 in lane 3 is not unexpected as this glycan type can be found in an uncharged form in a 
small fraction of the O-antigen produced (Knirel, 1990). Expressing the pilAO operon in P. 
aeruginosa strains producing heterologous O-antigens, as well as non-group I pili, results in pilin 
glycosylation using the host repeating unit as oligosaccharide (DiGiandomenico, 2002). The R2 
gene cluster produces a zwitterionic repeating unit with a net single negative charge at neutral 
pH (Raymond, 2002). P. aeruginsa strain PAO1 contains this gene cluster and makes a non-
group I pilus (Lam, 2011). Expression of the strain A074 pilAO operon in strain PAO1 results in 
the production of A074 pilin with a pI of 6.5 (Figure 4.15, lane 2) suggesting the acquisition of a 
net negative charge. The R9 cluster produces a neutral oligosaccharide. P. aeruginosa strain 
PA103 contains this gene cluster and produces a non-group I pilus (Goldberg, 1992). Expression 
of the strain A074 pilAO operon in strain PA103 results in production of A074 pilin with a pI of 
8.2 (Figure 4.15, lane 4) indicating that this saccharide does not influence pilin charge.  
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 Figure 4.15. Isoelectric focusing immunoblot of strains A074, A074TK3, and 
pilAO
A074
 expressing PAO1 and PA103. The IEF shows that the presence of the glycan as well 
as the charge of the glycan alters pilin protein pI. (Also see Appendix Figure 20) 
 
4.4.5. Effect of Pilin Charge on Piliation. All of the non-glycosylated pilin 
producing clinical isolates exhibit low piliation in the absence of glycosylation. However, the 
laboratory engineered isogenic mutant 1244G7 produces wild type levels of pili in the absence of 
the pilin glycan. The only difference between the pilA gene of strain 1244G7 and the pilA gene 
of the sequenced clinical isolates (specifically strain A074)  is a single nucleotide change which 
leads to an amino acid change at residue 98 (Appendix Figure 21). In strain 1244G7 this residue 
is glutamine, while in all other strains sequenced, this residue is a lysine. This K98Q change 
leads to an overall negative charge of the pilin protein in strain 1244G7. In order to test if this 
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alteration leads to increased piliation, the pilA gene from strain 1244 was cloned into the pBAD 
vector and expressed in 1244.47 (pilA negative mutant). The results appeared to show an 
increase in the amount of non-glycosylated pilin (Appendix Figure 22). With the expression of 
1244 pilA in 1244.47 cells, we again see an additional glycosylated band verifying what was 
previously seen with 1244.47 expressing the pilA from A074. Although direct comparisons 
cannot be made between blots, initial results seem to show that the 1244 PilA expressing cells 
may be making more non-glycosylated pilin protein than the A074 PilA producing cells. In order 
to determine if there is a difference in the amount of non-glycosylated pilin produced by these 
strains, it is necessary to do a direct comparison and quantitation of the amount of pilin protein 
expressed. Pili precipitations for strain 1244.47 expressing the PilA from strain A074 or 1244 
were prepared (1244.47/pBADpilA
A074
 and 1244.47/pBADpilA
1244
) and quantitative 
immunoblotting was conducted. The results of this experiment showed similar amounts of cell 
bound pilin protein being produced by both strains (Figure 4.16). However, pilin protein from 
the sheared surface fraction showed that there was 14x more pilin protein produced by the 1244 
PilA expressing strain as compared to the A074 PilA producing strain (Figure 4.16). This 
experiment provides initial evidence for the effect of pilin protein charge on piliation (Figure 
4.16).  
 99 
 
 Figure 4.16. Western Blot of 1244.47 Cells Expressing 1244 and A074 pilA. The cell 
bound pilin fractions show similar amounts of protein while there is a clear difference between 
the sheared surface pili.   
 
4.5. Discussion. Based on the results we have presented thus far, pilin non-glycosylation 
is due to defects within the glycosylation pathway. Furthermore, piliation is altered by the loss of 
glycosylation. However, the results suggest that the presence or absence of PilO is not the key to 
this change in piliation levels as the laboratory strain 1244G7 does not have reduced piliation in 
the absence of PilO and many glycosylated group I pilin producing clinical isolates maintain low 
piliation in the presence of PilO.   
Since the presence or absence of PilO was not responsible for decreased piliation, surface 
pili loss could be attributed to possible proteolytic activity. If non-glycosylated pili are 
detrimental to the bacterium, proteases could be employed to reduce the number of pili presented 
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at the surface. However, results from a basic protease experiment to determine the effects of 
potential secreted proteases on the glycosylated and non-glycosylated forms of pilin from A074 
showed that protease activity was more prevalent for the glycosylated pilin producing strain than 
the non-glycosylated pilin producing strain which does not account for the reduction of pili seen 
with the non-glycosylated pilin phenotype. The apparent targeting of glycosylated pili may be 
due the fact that more pili are presented at the surface which provides more substrate for 
proteolysis. 
Since proteases were determined not to be the cause of reduced piliation, the reason for 
this change in phenotype still had to be investigated. Again, for many of the studied strains the 
loss of glycosylation led to a loss in piliation. Upon restoration of glycosylation, some strains 
produced higher levels of surface pili while others appear to have additional defects that allow 
complementation of glycosylation but interfere with piliation. This is consistent with the 
variation in piliation seen among the glycosylated group I pilin producing clinical isolates. Strain 
A033 falls within the latter category with the recovery of glycosylation but not piliation while 
the laboratory mutant 1244G7 maintains wild type piliation in the absence of glycosylation. This 
anomaly in 1244G7 may be due to a single residue change in the pilin of strain 1244G7 that 
alters the protein’s charge to an overall negative at neutral pH. However based on sequence 
analysis, the majority of group I pilin producing strains do not have this negatively charged pilin 
and show reduced piliation in the absence of glycosylation. The effect of this single amino acid 
change in the pilin protein of 1244G7 may prove to influence piliation in the absence of the 
glycan. Replacing the pilA gene from 1244 in strain 1244G7 with the pilA gene from A074 
should provide a more definitive answer for how pilin protein charge may affect piliation levels. 
This will be an area of future research. 
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Chapter 5. Discussion. With the finding that prokaryotes are able to glycosylate a variety of 
proteins with an even greater variety of glycans, much work has been conducted to determine the 
purpose of bacterial and archaeal protein glycosylation and its mechanisms. In all cases, 
glycosylation is either N-linked or O-linked and many of the genes involved in prokaryotic 
protein glycosylation show homology across genus and species levels. The first glycosylated 
prokaryotic protein to be discovered was that of the archaeal S-layer proteins (a loosely 
associated glycocalyx). In addition, one of the most studied glycosylation pathways is that of C. 
jejuni. Our lab also contributed to one of the first discoveries of prokaryotic protein 
glycosylation when the pilO gene of P. aeruginosa 1244 was observed in an operon with the 
pilin protein encoding gene, pilA (Castric, 1995). Within the last ~30 years, it has become widely 
accepted that prokaryotes produce glycosylated proteins, but our understanding of the 
purposes/functions of this modification are still limited.  
Initial work in our lab showed that the pilin glycan of P. aeruginosa strain 1244 is a 
single O-antigen repeating unit that is normally associated with the cell surface LPS structure 
(Castric, 2001). This glycan was shown to be added to the pilin monomer through an enzymatic 
reaction catalyzed by the oligosaccharyl transferase, PilO at the S
148
 residue at the C-terminus 
(Castric, 1995; Comer, 2002). Further study of the P. aeruginosa group I pilin model in our lab 
provided interesting and novel findings for the purpose and effect of the group I pilin on pilus 
function and bacterial virulence. Using the laboratory strain 1244 and its isogenic mutant 
(1244G7), it was shown that the presence of the glycan led to an increase in pilus solubility. 
Furthermore, evidence from an acute respiratory mouse model demonstrated that the presence of 
the glycan enhanced bacterial survival.  
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Results from this dissertation provide even more evidence of the importance of the group 
I pilin glycan showing that it has a specific related function and is not simply a decorative 
attachment. As previously mentioned, original research from our lab showed that the solubility 
of the pilus was influenced by the presence of the group I pilin glycan. However, it was unclear 
as to whether the whole glycan was necessary for this solubility. Experiments were conducted 
using the wild type 1244, a two sugar mutant (1244.2.1), 1244G7, PA103 expressing group I 
pilin with a single sugar, PA103 expressing group I pilin with a neutral three sugar glycan, and 
wild type PA103 (group II pilin). Ammonium sulfate precipitations at 0.1 M, 1.11 M, and 3.95 
M were conducted for all strains. Results from the quantitation of the cuts from these samples, 
indicated that the full glycan with a negative charge was necessary for increased solubility. In the 
absence of a charge and the full length pilin glycan, pilus fibers aggregate and precipitate from 
the supernatant at low levels of ammonium sulfate (AS, 0.1M or 2.5% saturation).  
However, it was later determined that PA103/pPAC46 was producing sufficient levels of 
wild type group II pili which interfered with the solubility of the group I pili. Further 
experiments had to be conducted to again evaluate whether the negative charge was required for 
pilus solubility. These experiments utilized strain PA103ΔpilA/pPAC46. In the absence of the 
interfering group II pilin protein, the results of these solubility assays in combination with those 
of glycosylated and non-glycosylated strains provided us with a different answer regarding the 
glycan’s effect on pilus solubility. Based on these experiments, it was concluded that the full 
length glycan was necessary for pilus solubility and was not specifically related to the negative 
charge associated with the glycan. 
Additionally, the absence of glycosylation leads to a reduction in the major pilus 
function, twitching motility, at high ionic strengths (90.0 mM AS or 125 mM NaCl). This 
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motility is unaffected by the presence of 250 mM sucrose indicating that ionic strength and not 
osmotic pressure is responsible for this alteration of function. Through complementation of 
glycosylation of the mutant, recovery of twitching is seen both at the surface and subsurface 
level. Furthermore, there is no difference between wild type and mutant twitching when 
conducted on treated petri plates that reduce surface hydrophobicity. These results suggest that 
the absence of the glycan contributes to an increase in protein hydrophobicity which interferes 
with pilus function depending on the local environment. Protein modeling supported this 
observation as shown by the presence of surface exposed hydrophobic residues in the absence of 
glycosylation.  
Work from chapter 2 provided insight into the role of the group I pilin glycan on 
solubility and pilus function. The glycan exhibits two main properties, varying sugar number and 
charge. We had seen in chapter 2 that the glycan size affects pilus solubility. This may provide a 
benefit to this organism for dissemination in particular disease conditions. The take home 
message of chapter 2 is that the pilus does not function optimally without the glycan. This 
sparked more interest in determining the glycan characteristics of our collection of clinical 
isolates.  
Since the glycan is identical to the O-antigen repeating unit of LPS, it was necessary to 
type our collection of clinical isolates. However, traditional serotyping methods are expensive, 
time-consuming, and often inaccurate. Therefore, it was necessary to determine the glycan 
assignment using a different methodology. Experiments in chapter 3 show a technique for the 
genetic assignment of the cell’s O-antigen type that is less time consuming than traditional 
serotyping methods. 
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 The 20 O-antigen biosynthesis gene clusters were retrieved from GenBank and aligned 
using a Clustal W multiple alignment online program. Using a PCR method, strains were 
assigned to an R-type (Raymond type) based on unique regions of the O-antigen biosynthesis 
clusters of all 20 IATS serotypes. Each strain could be placed into 1 of the 11 R-types. The 
structure and potential charge (based on known modifications) could then be attributed to each 
strain. The results from the R-typing showed that the majority of group I pilin producing P. 
aeruginosa clinical isolates were found to produce the R5 type which is solely associated with 
the O6 serotype. Based on the known composition of the O6 O-antigen, all strains in this group 
would produce a 4 sugar, negatively charged glycan. Additionally, there were two statistically 
significant R-types found amongst non-group I strains, R2 (O2, O5, O16, O18, and O20) and R9 
(O11). The R2 type adds a single negative charge to the pilin protein while the R9 type does not 
add any charge. Since these same R-types are not found to be expressed by group I pilin 
producing strains, it may show that the 4 sugar, negatively charged glycan is the most beneficial 
in this case.  
Furthermore, the distribution of R-types varies between group I and non-group I pilin 
producing strains. The distinct distribution of types across disease categories is also evident and 
may be beneficial for this organism in specific infections. Over 50% of clinical isolates produce 
group I pilin and the majority of those strains contain the R5-type (O6 O-antigen repeating unit). 
This information can be used to develop new vaccine or chemotherapeutics directed specifically 
at this glycan/pilin combination and aid in the fight against Pseudomonas aeruginosa infections. 
Additionally, the finding that 15.2 % of the clinical isolates did not contain a pilus glycan further 
influenced investigation of the role of the glycan on pilus function and maintenance. 
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The fact that non-glycosylated group I pilin producing clinical isolates were found in the 
natural environment led to further research and characterization of these strains. In all cases, the 
non-glycosylated pilin phenotype was attributed to defects within the glycosylation pathway. 
This loss of glycosylation did not interfere with pilus function as twitching motility was 
unaffected. Piliation assays showed an unexpected result for these non-glycosylated pilin 
producing mutants. Evidence presented in chapter 4 showed that in the absence of glycosylation, 
piliation was greatly reduced. This was unexpected since previous results showed that the 
laboratory engineered non-glycosylated group I pilin producing strain (1244G7) expressed wild 
type levels of pili. However, in all non-glycosylated group I pilin producing clinical isolates, full 
piliation could be complimented by providing functional components of the defect described for 
each mutant strain.  
To determine if the reduction in piliation was due to proteolytic activity targeting non-
glycosylated pilin, protease assays were conducted with supernatant from a PilA- strain against 
A074 (WT glycosylated) and A074TK3 (PilO-, engineered mutant). These strains were 
incubated in the supernatant for 0, 3, and 6 hours at 37°C. Quantitative western blots showed that 
there was not a proteolytic targeting of non-glycosylated pili. Since proteases were determined 
not to be responsible for the reduction in piliation seen with non-glycosylated pilin producing 
isolates, additional experiments had to be conducted to establish the cause for this change in 
phenotype. 
The next step was to evaluate whether the loss of piliation was due to the loss of 
glycosylation. Again, strain A074TK3 was utilized. This engineered mutant also exhibited the 
reduction in piliation and could be complimented to full piliation with the reintroduction of a 
functional pilO gene. Results presented in chapter 4 showed that full piliation occurs only when 
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the pilin subunit is glycosylated. The only atypical strain found thus far is 1244G7 which 
exhibits full piliation in the absence of pilin glycosylation. Knowing that this same change is 
present in the wild type parent strain potentially indicates a prior adaptation acquired to 
counteract reduced or loss of surface pili. This could allow optimal pilus function and ultimately 
be beneficial for exploring and inhabiting new niches both in the environment and clinical 
setting. Interesting future research would include collecting and sequencing additional clinical 
isolates to look for this K98Q change or any other PilA sequence variation that may lead to an 
overall negative protein. Studying any strains exhibiting this alteration could provide evidence 
for a pre-glycosylation adaptation. This change may have led to a functional adaptation in 
acquiring the glycosylation enzyme encoding gene, pilO, which would work to reduce 
hydrophobicity in the presence of increased numbers of non-glycosylated protein fibers further 
benefitting this organism in all settings. This could explain why group I pilin producing strains 
are glycosylated and why the group I pilin glycan has become an integral component of the pilus 
fiber.  
This research provides interesting insight into how the group I pilin glycan is beneficial 
for this organism. First of all, this modification is necessary for pilus solubility and function. 
Second, there appears to be a selective pressure for specific pilin-glycan combinations. Finally, 
the glycan is necessary for full piliation. Overall, the evidence presented in this dissertation 
supports my initially stated hypothesis of group I pilin glycosylation being central to pilus 
function.  
The research conducted in our lab and detailed in this dissertation has expanded the basic 
knowledge of prokaryotic protein glycosylation that has applications beyond our model system. 
This research provides evidence that the group I pilin glycan is a necessary component for proper 
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pilus function and supports full piliation and protein solubility. This provides a novel 
characterization of the pilin glycan. Instead of a simple decoration of the pilin protein, this 
modification appears to be an integral constituent of the group I pilin protein. Based on the 
research presented here, the glycan exhibits characteristics similar with a protein domain. In the 
absence of this domain functionality, piliation, and solubility are all decreased.  
Since we know that the majority of P. aeruginosa clinical isolates produce group I pilin, 
the practical application of this knowledge would be to introduce a specific chemotherapy or 
vaccination strategy for each type of infection rather than the general antibiotic treatment 
currently used. The group I pilin monomer in combination with the R5 glycan could be utilized 
in a multi-component vaccine platform. Additionally, non-group I pilin monomers could be 
combined with the R2 or R9 glycans for most other infection types. Since many pathogens 
exhibit posttranslational modifications which have been implicated in altering the virulence 
properties of these organisms, this type of system could potentially be interchanged with other 
pathogenic components providing a basic tool for a vaccine design against numerous bacterial 
infections. 
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Appendices 
Appendix I- Chapter 2 Supplemental Images 
 Pilus Solubility 
 
 
 
Appendix Figure 1. PA103 expressing group I pili with either a single sugar or 
neutral three sugar glycan. PA103 wbjE::aacC1 and PA103/pPAC46 both show low pilin 
solubility. This is due to the co-expression of wild type pilin protein influencing solubility. 
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Appendix Figure 2. Western blot showing expression of 1244 pilAO in the group II 
strain PA103. The left side of the blot was probed with 2.97 (group II pilin specific antibody) 
and the right side was probed with 5.44 (group I pilin specific antibody). The Western blot 
indicates that both wild type (group II) and expressed (group I) are produced by this strain. This 
explains the solubility seen in appendix figure 1 and opposes the solubility results seen with 
PA103ΔpilA/pPAC46 in figure 2.2a.  
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 Appendix Figure 3. A033pLAFR1 and A033pLPS2 pilus solubility. A) Western blot 
image of ammonium sulfate cuts for strains A033pLAFR1 (empty vector) and A033pLPS2 (O11 
O-antigen gene cluster containing plasmid). Protein precipitations were conducted at 0.1M, 
1.11M, and 3.95M. The blot was developed with AlexaFluor 532-conjugated secondary antibody 
and quantitated using a Fluorimager595 and ImageQuant software. B) Percent total protein based 
on fluorescent quantitation. These strains were initially run to replace those from appendix figure 
1 for the first manuscript. Based on ambiguous results, these strains were replaced with 577B, 
A031, and PA103ΔpilA/pPAC46. 
A. 
B. 
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Appendix Figure 4. Western blot showing pilus solubility of A074 pilAO expressing PAK 
and PA103. Strain PAK/pBADpilAO
A074
 produces group I pilin with a charged glycan while 
PA103/pBADpilAO
A074
 a neutral glycan. These strains were run to further evaluate if glycan 
charge influenced solubility. The solubility of both strains did not provide an unambiguous result 
for the effect of glycan charge. As previously mentioned, the production of wild type pilin from 
each of these strains has the potential to interfere with the solubility of the expressed group I 
protein.  
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 Appendix Figure 5. Pilus solubility of A074 and 577B. Strain A074 produces a 
negatively charged, four sugar glycan while 577B produces a neutral, four sugar glycan. The 
solubility of both A074 (charged, four sugar) and 577B (neutral, four sugar) at 3.95 M indicates 
that charge is not the defining glycan characteristic for pilus solubility. 
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 Appendix Figure 6. A074 and A074TK3 pilus protein solubility. Ammonium sulfate 
precipitations of partially purified pili. Strain A074 exhibits increased solubility over its non-
glycosylated isogenic mutant, strain A074TK3.  
 
 
 
 
 Appendix Figure 7. 577B and A031 pilus protein solubility. Ammonium sulfate 
precipitations of partially purified pili. Strain 577B exhibits increased solubility over its non-
glycosylated homologous clinical isolate, strain A031. 
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 Piliation of 1244 and 1244G7 
 
 
 
 
 
Strain 
Average Protein Amount 
(Fluorescence Area) 
1244 2.40 x 10
6
 
1244G7 1.90 x 10
6
 
 
Appendix Figure 8. 1244 and 1244G7 (G7) piliation and quantitation. A) Both the 
cell and supernatant (surface pili) fractions are presented. Fractions were obtained after partial 
pili purification,  B) Quantitation of supernatant fractions were obtained with ImageQuant 
software. The average amount of protein per sample shows a 1-fold reduction for G7 compared 
to 1244.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1244 
 
1244 
 
G7 
 
G7 
 
A. 
B. 
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Subsurface Twitching Assays on Media +/- 250 mM Sucrose 
 
 
 
  
Appendix Figure 9. 1244 and G7 subsurface twitching assays with 250 mM sucrose. 
The average subsurface twitching zone area for strains 1244 and G7 in the absence or presence 
of 250 mM sucrose is shown. Twelve replicates were conducted for each condition. No 
statistically significant differences are seen between the strains under the two conditions.  
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Appendix II- Chapter 3 Supplemental Images 
 
Appendix Table 1: Children’s Hospital Isolate Data. Information on pickup date, strain, 
isolation source, CF and mucoid status.  
 
Pickup date Strain Source CF Mucoidy 
9/17/2010 A001 Trach 
  9/17/2010 A002 Ear 
  9/17/2010 A003 Trach 
  9/17/2010 A004 
 
CF mucoid 
9/17/2010 A005 Trach 
  9/17/2010 A006 Ear 
  9/17/2010 A007 Trach 
  9/17/2010 A008 Trach 
  9/17/2010 A009 
 
CF 
 9/17/2010 A010 
 
CF mucoid 
9/17/2010 A011 
 
CF 
 9/17/2010 A012 Trach 
  9/30/2010 A013 BAL - bronchoalveolar lavage 
  9/30/2010 A014 
 
CF 
 9/30/2010 A015 
 
CF mucoid 
9/30/2010 A016 
 
CF mucoid 
9/30/2010 A017 Trach 
  9/30/2010 A018 Ascites Fluid 
  9/30/2010 A019 Bile Drainage 
  9/30/2010 A020 Urine 
  9/30/2010 A021 Urine 
  9/30/2010 A022 Ear Drainage 
  9/30/2010 A023 Peritoneal 
  9/30/2010 A024 Blood 
  9/30/2010 A025 Bile Drainage 
  9/30/2010 A026 Mediport Device 
  9/30/2010 A027 Trach 
  9/30/2010 A028 ear 
  9/30/2010 A029 Blood 
  9/30/2010 A030 Peritoneal 
  9/30/2010 A031 ear 
  9/30/2010 A032 ear 
  9/30/2010 A033 ear external 
  9/30/2010 A034 
 
CF mucoid 
9/30/2010 A035 
 
CF 
 9/30/2010 A036 
 
CF mucoid 
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9/30/2010 A037 Trach 
  9/30/2010 A038 Blood 
  9/30/2010 A039 Appendiceal 
  9/30/2010 A040 ear 
  9/30/2010 A041 ear 
  10/12/2010 A042 Trach 
  10/12/2010 A043 Right Ear 
  10/12/2010 A044 Left Ear 
  10/12/2010 A045 Renal 
  10/12/2010 A046 Left Ear 
  10/12/2010 A047 Left Ear 
  10/12/2010 A048 Inner Ear 
  10/12/2010 A049 Left Ear 
  10/12/2010 A050 Leg 
  10/12/2010 A051 Trach 
  10/12/2010 A052 Leg 
  10/12/2010 A053 Trach 
  10/12/2010 A054 WND 
  11/9/2010 A055 Blood 
  11/9/2010 A056 Ear 
  11/9/2010 A057 Ear 
  11/9/2010 A058 Trach 
  11/9/2010 A059 Trach 
  11/9/2010 A060 Trach 
  11/9/2010 A061 Trach 
  5/23/2011 A062 Throat CF 
 5/23/2011 A063 Peritoneal Fluid 
  5/23/2001 A064 Trach 
  5/23/2011 A065 Sputum 
  5/23/2011 A066 Sputum 
  5/23/2001 A067 Endotraceal Aspirate 
  5/23/2011 A068 Sputum 
  6/7/2011 A069 Trach 
  6/7/2011 A070 Throat CF 
 6/7/2011 A071 Sputum CF 
 6/7/2011 A072 Trach 
  6/7/2011 A073 Sputum CF 
 6/7/2011 A074 Sputum 
  6/7/2011 A075 Nasal Wash 
  6/7/2011 A076 Trach 
  6/7/2011 A077 Sputum CF 
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6/7/2011 A078 Trach 
  6/7/2011 A079 Throat CF 
 6/7/2011 A080 Trach 
  6/7/2011 A081 Trach 
  6/15/2011 A082 Urine 
  6/15/2011 A083 
 
CF 
 6/15/2011 A084 Urine 
  6/15/2011 A085 
 
CF mucoid 
6/15/2011 A086 
 
CF mucoid 
6/28/2011 A087 Sputum CF mucoid 
6/28/2011 A088 Throat CF mucoid 
6/28/2011 A089 Throat CF 
 6/28/2011 A090 Sputum CF 
 6/28/2011 A091 Right Ear 
  6/28/2011 A092 Throat CF 
 6/28/2011 A093 Sputum CF 
 6/28/2011 A094 Throat CF 
 6/28/2011 A095 Sputum CF 
 6/28/2011 A096 Right Arm 
  7/11/2011 A097 ABD. WND- abdominal wound 
  7/11/2011 A098 Trach 
  7/11/2011 A099 Ear 
  7/11/2011 A100 Trach 
  7/11/2011 A101 Trach Aspirate 
  7/11/2011 A102 Trach 
  7/11/2011 A103 Cerebral spinal fluid 
  7/11/2011 A104 No site labeled 
  
7/11/2011 A105 
PICC site-area of skin around where the line is inserted in the vein, 
PICC catheter- intravenous line  
7/11/2011 A106 Blood 
  7/11/2011 A107 Trach 
  8/7/2012 A108 wound 
  8/7/2012 A109 ear 
  8/7/2012 A110 respiratory 
  8/7/2012 A111 sputum 
  8/7/2012 A112 respiratory 
  8/7/2012 A113 stool 
  8/7/2012 A114 blood 
  8/7/2012 A115 respiratory 
  8/7/2012 A116 ear 
  8/7/2012 A117 urine 
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8/7/2012 A118 trach 
  8/7/2012 A119 wound G tube- gastrostomy feeding tube 
  8/7/2012 A120 respiratory/trach culture 
  8/7/2012 A121 ear 
  8/7/2012 A122 urine 
  8/7/2012 A123 urine 
  8/7/2012 A124 no site labeled 
  8/7/2012 A125 stool 
  8/7/2012 A126 trach wash 
  8/7/2012 A127 1st isolate CF 
 8/7/2012 A128 urine 
  8/7/2012 A129 ear 
  8/7/2012 A130 wound 
  8/7/2012 A131 urine 
  8/7/2012 A132 respiratory 
  8/7/2012 A133 urine 
  8/7/2012 A134 trach 
  8/7/2012 A135 PTC drainage- peritoneal tube 
  8/23/2012 A136 Throat CF mucoid 
8/23/2012 A137 Throat CF 
 8/23/2012 A138 Sputum CF 
 8/23/2012 A139 Throat CF 
 8/23/2012 A140 Sputum CF 
 8/23/2012 A141 Sputum CF 
 8/23/2012 A142 Throat CF 
 8/23/2012 A143 Throat CF 
 8/23/2012 A144 Throat CF 
 8/23/2012 A145 Sputum 
  8/23/2012 A146 sputum CF 
 8/23/2012 A147 Throat CF mucoid 
8/23/2012 A148 Throat CF 
 8/23/2012 A149 Throat CF 
 8/23/2012 A150 sputum 
  8/23/2012 A151 Throat CF 
 8/23/2012 A152 Sputum CF mucoid 
8/23/2012 A153 Sputum CF 
 9/12/2012 A154 
 
CF 
 9/12/2012 A155 
 
CF 
 9/12/2012 A156 
 
CF 
 9/12/2012 A157 
 
CF 
 9/12/2012 A158 
 
CF 
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9/12/2012 A159 
 
CF mucoid 
9/12/2012 A160 Urine 
  9/12/2012 A161 
 
CF 
 9/12/2012 A162 Urine 
  9/12/2012 A163 
 
CF 
 10/18/2012 A164 Throat CF 
 10/18/2012 A165 G. tube drain 
  10/18/2012 A166 Throat CF 
 10/18/2012 A167 Throat CF 
 10/18/2012 A168 Urine 
  10/18/2012 A169 subglottis lesion- around vocal cords 
  10/18/2012 A170 r tip subclavian- catheter tip in subclavian vein 
  10/18/2012 A171 subclavian tip- catheter tip in subclavian vein 
  11/8/2012 A172 
 
CF 
 11/8/2012 A173 
 
CF mucoid 
11/8/2012 A174 
 
CF mucoid 
11/8/2012 A175 
 
CF 
 11/8/2012 A176 
 
CF 
 11/8/2012 A177 
 
CF 
 11/8/2012 A178 
 
CF 
 11/8/2012 A179 
 
CF 
 11/8/2012 A180 Ear 
  11/8/2012 A181 
 
CF 
 11/8/2012 A182 urine 
  11/8/2012 A183 
 
CF 
 11/8/2012 A184 
 
CF 
 11/8/2012 A185 
 
CF 
 11/8/2012 A186 
 
CF 
 11/8/2012 A187 
 
CF 
 11/8/2012 A188 
 
CF 
 11/8/2012 A189 
 
CF mucoid 
11/8/2012 A190 urine 
  11/8/2012 A191 urine 
  11/8/2012 A192 
 
CF 
 11/8/2012 A193 
 
CF 
 11/8/2012 A194 chest tube drainage 
  12/7/2012 A195 
 
CF 
 12/7/2012 A196 ear 
  12/7/2012 A197 ear 
  12/7/2012 A198 
 
CF 
 12/7/2012 A199 Sputum 
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12/7/2012 A200 
 
CF 
 12/7/2012 A201 
 
CF 
 12/7/2012 A202 stool 
  12/7/2012 A203 wound- umbilical 
  12/7/2012 A204 
 
CF 
 12/7/2012 A205 
 
CF 
 12/7/2012 A206 
 
CF 
 12/7/2012 A207 
 
CF 
 12/7/2012 A208 
 
CF 
  
  
Based on information provided by the Microbiology Unit of Children’s Hospital, it is 
unlikely that any of the collected clinical samples are re-isolates of the same bacterial strain. The 
isolation frequency is every 6 months per patient. In some cases, two strains of different 
phenotypes are isolated from the same patient.  
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Sequence Alignment and Primer Sites for R-typing 
 
O1        CGGTCCATTCGGATATTGGAGTCTTCATGCTTTGGATAAGGCGCATACTGCTGATGGGTG 
O9        CCGGCCATTATGATACTGGAGTCTTCATGCTTTGGATCAGGCGTGCCTTGATGGCGATTG 
O7        GGTTCGATC--AATAGAGGGAATATCATGCAATGGTTTAAGCGATTTGCTGCTATAGCGG 
O8        GGTTCGATC--AATAGAGGGAATATCATGCAATGGTTTAAGCGATTTGCTGCTATAGCGG 
FO2       TGCCTTGTTCAGATGTTGGAGTTGCCATGCTTTGGGTCAAGCGTACGTTAATGGCGGTGG 
FO5       TGCCTTGTTCAGATGTTGGAGTTGCCATGCTTTGGGTCAAGCGTACGTTAATGGCGGTGG 
F018      TGCCTTGTTCAGATGTTGGAGTTGCCATGCTTTGGGTCAAGCGTACGTTAATGGCGGTGG 
FO20      TGCCTTGTTCAGATGTTGGAGTTGCCATGCTTTGGGTCAAGCGTACGTTAATGGCGGTGG 
F016      TGCCTTGTTCAGATGTTGGAGTTGCCATGCTTTGGGTCAAGCGTACGTTAATGGCGGTGG 
O6        GGCAGATAC----GA-GGTTTTTTCAATGCAATGGCTCGGGCGGATTTTGACTGCTGTGT 
O13       GGCGGCGATTAAGAG-GGAGTTTTCCATGCGATGGTTCAGACGGATTTTGACTGCGGTGG 
O14       GGCGGCGATTAAGAG-GGAGTTTTCCATGCGATGGTTCAGACGGATTTTGACTGCGGTGG 
FO4       CTGAAACATGTTAT-TAGGAGTCTTTATGCTTC---TCAGGCGTCTGGCTATCGCTGGCT 
O12       TTCAACCATATCACATTGGAGTCTTAATGCTTTGGATCAAGCGTGTATTACTAGGGTGCG 
O12b      TTCAACCATATCACATTGGAGTCTTAATGCTTTGGATCAAGCGTGTATTACTAGGGTGCG 
O11       TTGACCTGCTTGGTATGGAGGTATTCATGCGCACGCTTAAAAGAATGCTTGTTGGGCTAC 
017       TTGACCTGCTTGGTATGGAGGTATTCATGCGCACGCTTAAAAGAATGCTTGTTGGGCTAC 
O3        TCGATCAGCGTTATAGAGGGATTTCCATGCAATGGTTCAGGCGATCTGCCGCTGTAGCGG 
O15       TCGATCAGCGTTATAGAGGGATTTCCATGCAATGGTTCAGGCGATCTGCCGCTGTAGCGG 
O10       TCGATCAGCGTTATAGAGGGATTTCCATGCAATGGTTCAGGCGATCTGCCGCTATAGCGG 
O19       TCGATCAGCGTTATAGAGGGATTTCCATGCAATGGTTCAGGCGATCTGCCGCTATAGCGG 
 
 
O1        GAGTGCTGTTTATCGCTCTTCTCGTAGTAGTTATGGTATTGGAAAACCGGCAGGTTACTC 
O9        GAGTGCTGCTTGTAGCTCTTTTCATGATCGTGGCTGTTCTGGAAAACCAGCAAACCACTC 
O7        TTCTGCTAGTGGTATCTATCGCGGTCGTGGCATTCGTTCTGGAGAATCAGGGGCTGGTCC 
O8        TTCTGCTAGTGGTATCTATCGCGGTCGTGGCATTCGTTCTGGAGAATCAGGGGCTGGTCC 
O2        GGCTGTTAGTTGTCGCCCTTTTCATGATTGTGGTTGCTTTGGAGAACCGGCAAAGCGTCA 
O5        GGCTGTTAGTTGTCGCCCTTTTCATGATTGTGGTTGCTTTGGAGAACCGGCAAAGCGTCA 
018       GGCTGTTAGTTGTCGCCCTTTTCATGATTGTGGTTGCTTTGGAGAACCGGCAAAGCGTCA 
O20       GGCTGTTAGTTGTCGCCCTTTTCATGATTGTGGTTGCTTTGGAGAACCGGCAAAGCGTCA 
016       GGCTGTTAGTTGTCGCCCTTTTCATGATTGTGGTTGCTTTGGAGAACCGGCAGAGCGTCA 
O6        TTGTGTTGGTGGTTGCGCTGGTGGTCCTGGTTTTCGTATTGGAAAATCAGAATAGCGTCA 
O13       TTGTACTGATGGTTGCGCTGACGGTCATCATTTTTGTCTTGGAAAATCAAAGTGGTGTCA 
O14       TTGTACTGATGGTTGCGCTGACGGTCATCATTTTTGTCTTGGAAAATCAAAGTGGTGTCA 
O4        TTTTTTTCCTATTGGCGCTTATAGTCATTGTCTTCGTATTGGAGAATCTTGACAGTAGTC 
O12       GGCTTTTATTCGTCGCTCTTTTTGTTATTTTGCTGACGGTCGAGAATCAGCAGACTACAC 
O12b      GGCTTTTATTCGTCGCTCTTTTTGTTATTTTGCTGACGGTCGAGAATCAGCAGACTACAC 
O11       TGATAGTGGTTGTGGCCTTGTCGGCAATTATTTTTACTTTGGAAAATCGTGCTCTTATCC 
017       TGATAGTGGTTGTGGCCTTGTCGGCAATTATTTTTACTTTGGAAAATCGTGCTCTTATCC 
O3        TTCTACTGGTGGTATCTATCGCAGTCGTGGTTTTCGTGCTGGAAAACCAAGGAGTGGTCC 
O15       TTCTACTGGTGGTATCTATCGCAGTCGTGGTTTTCGTGCTGGAAAACCAAGGAGTGGTCC 
O10       TTCTGCTAGTGGTATCTATCGTAGTTGTGGTTTTCGTTCTGGAGAATCAGGGGCTGGTTC 
O19       TTCTGCTAGTGGTATCTATCGTAGTTGTGGTTTTCGTTCTGGAGAATCAGGGGCTGGTTC 
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FO1       ATTTCGAACTGTTCGGTTTGCTTACCCCCGAGCTGCCCGTTGTTCTCTATGTTGCCTTGG 
O9        ACCTCGAACTCTTTGGTTTAAGCTCCCCGGAATTCCCTGTTGTCCTCTATCTCGCCTTGG 
O7        GGCTGGCCCTCCTCGGTTCCCAGTCTCCTCAATGGCCTTTGGCTATCTATCTCATTGCTG 
O8        GGCTGGCCCTCCTCGGTTCCCAGTCTCCTCAATGGCCTTTGGCTATCTATCTCATTGCTG 
O2        GCTTTGAACTCTTTGGTCTTGCCACGCCAGATTTACCTGTGGTCCTTTATGTTGCGTTAG 
O5        GCTTTGAACTCTTTGGTCTTGCCACGCCAGATTTACCTGTGGTCCTTTATGTTGCGTTAG 
018       GCTTTGAACTCTTTGGTCTTGCCACGCCAGATTTACCTGTGGTCCTTTATGTTGCGTTAG 
O20       GCTTTGAACTCTTTGGTCTTGCCACGCCAGATTTACCTGTGGTCCTTTATGTTGCGTTAG 
016       GCTTTGAACTCTTTGGTCTTGCCACGCCAGATTTGCCTGTGGTCCTTTATGTTGCGTTAG 
O6        GCCTTGCCTTCCTTGGGTGGCACACTCCTGACGGTCCGCTTTCTCTCTTCGTGTCTCTGG 
FO13      ATCTATCTTTCCTTGGGTGGCGCACGCCTGAGGGGCCATTATCCTTGTTTGTATCTTTAG 
FO14      ATCTATCTTTCCTTGGGTGGCGCACGCCTGAGGGGCCATTATCCTTGTTTGTATCTTTAG 
O4        ATGTGACGTTTTTGGGGAGGCAGTCTCCTGAATTTCCTTTGGTGCTCTTGCTGCTATCGT 
O12       ATTTCAAACTGCTTGGTTTTTACAGTCCTGAATTCTCGATTGTACTTTATATGACCTTGG 
O12b      ATTTCAAACTGCTTGGTTTTTACAGTCCTGAATTCTCGATTGTACTTTATATGACCTTGG 
O11       AATTTTCCTTCTTGGGGTGGGAGACGCCTGCGATTCCGAGTGCATTGTTATTTTCATTGG 
017       AATTTTCCTTCTTGGGGTGGGAGACGCCTGCGATTCCGAGTGCATTGTTATTTTCATTGG 
O3        AGTTGGCCTTCCTTGGAGTCCAGTTTCCTCAATGGCCTCTGGCCGTCTATATCATCATTG 
O15       AGTTGGCCTTCCTTGGAGTCCAGTTTCCTCAATGGCCTCTGGCCGTCTATATCATCATTG 
O10       AGGTGGCCTTCCTCGGTCTTCAGTCTCCTCAGTGGCCCCTGGCCGTCTATCTCATCACAG 
O19       AGGTGGCCTTCCTCGGTCTTCAGTCTCCTCAGTGGCCCCTGGCCGTCTATCTCATCACAG 
 
 
 
O1        TGTTCATCTTGGGTGGTTTCATTGGCCTATTGGC-------------------------- 
O9        GATTCATCCTGGGTGGTGTTATCGGTTTGCTGGT-------------------------- 
O7        CCTTTGTCCTAGGTGGACTCCTGGCGCTGGCTAT-------------------------- 
O8        CCTTTGTCCTAGGTGGACTCCTGGCGCTGGCTAT-------------------------- 
O2        CATTTATTGCTGGCGGTATTATTGGTATGTTGAT-------------------------- 
O5        CATTTATTGCTGGCGGTATTATTGGTATGTTGAT-------------------------- 
018       CATTTATTGCTGGCGGTATTATTGGTATGTTGAT-------------------------- 
O20       CATTTATTGCTGGCGGTATTATTGGTATGTTGAT-------------------------- 
016       CATTTATTGCTGGCGGTATTATTGGTATGTTGAT-------------------------- 
O6        CTTTCATCCTCGGTGGGCTCGGTGGGTTGTTGAG-------------------------- 
O13       CCTTTGTTCTCGGTGGTTTAGGTGGAGTACTCAG-------------------------- 
O14       CCTTTGTTCTCGGTGGTTTAGGTGGAGTACTCAG-------------------------- 
O4        CTTTTGTTATGGGGGGGCTGCTTGTTCTACTAATGAGTCTTCCTGGCTACATGCGCACAC 
O12       CCTTTGTTTTAGGTGGGTTTTTTGGTCTCTTGAT-------------------------- 
O12b      CCTTTGTTTTAGGTGGGTTTTTTGGTCTCTTGAT-------------------------- 
O11       TGTTTGTTGCGGGCGGTCTGCTCGGTTGGTTTTTTGGAGTTTTTG--------------- 
017       TGTTTGTTGCGGGCGGTCTGCTCGGTTGGTTTTTTGGAGTTTTTG--------------- 
O3        CCTTCATCCTTGGTGGGTTGCTGGGACTGGCTGC-------------------------- 
O15       CCTTCATCCTTGGTGGGTTGCTGGGACTGGCTGC-------------------------- 
O10       CCTTTGTCCTTGGTGGACTCCTGGGGTTGGCCAT-------------------------- 
O19       CCTTTGTCCTTGGTGGACTCCTGGGGTTGGCCAT-------------------------- 
 
 
 
 
 
 
 
 
 
 
 
 
 145 
O1        -CGGTTCATCACTTTTAGCGCGAGCTAATATACGTATCAAGGCAATCGAGAAGGATCTTG 
O9        -CAGTGTCCCTATTCTCGCTCGTCTCCATATCCAGCTCAGGTCTACGAGAGATGATCTGT 
O7        -CCAACTGCCTTCCCTAGCTATCTCGCGTGCTCGAGCCAGTGGCCTGCGCGCGGAGCTTA 
O8        -CCAACTGCCTTCCCTAGCTATCTCGCGTGCTCGAGCCAGTGGCCTGCGCGCGGAGCTTA 
O2        -CAGCGTGCCTCTTCTGGCTCGTGCCAAAGTGCGTCTCAGATCTGCAAGATCTGATCTGT 
O5        -CAGCGTGCCTCTTCTGGCTCGTGCCAAAGTGCGTCTCAGATCTGCAAGATCTGATCTGT 
018       -CAGCGTGCCTCTTCTGGCTCGTGCCAAAGTGCGTCTCAGATCTGCAAGATCTGATCTGT 
O20       -CAGCGTGCCTCTTCTGGCTCGTGCCAAAGTGCGTCTCAGATCTGCAAGATCTGATCTGT 
016       -CAGCGTGCCTCTTCTGGCTCGTGCCAAAGTGCGTCTCAGATCTGCAAGATCTGATCTGT 
O6        -TGGGGCATTGCTTC----------------------------------GTTTGAGGGGG 
O13       -CGGCATGTGGCTCC----------------------------------GTTTGATAGGT 
O14       -CGGCATGTGGCTCC----------------------------------GTTTGATAGGT 
O4        GCAGCATGCTTTCTGGCTTGCGTACGGAAG-------TGGCGAAGCTAAGGACAAGTCCG 
O12       -CGGCATGCCTCTTGTTGCGCGGATGAGAGTTCGCCTTGGGGCAATAAGAAAAGAGCTAG 
O12b      -CGGCATGCCTCTTGTTGCGCGGATGAGAGTTCGCCTTGGGGCAATAAGAAAAGAGCTAG 
O11       -----------CAGGCTTTGCGCATCATAAGTCGTCAAGACAACCTTC------------ 
017       -----------CAGGCTTTGCGCATCATAAGTCGTCAAGACAACCTTC------------ 
O3        -CCAGCTACCGTTCCTGACCATATCGCGTGTGCGAGCCAGTAGCTTGCGCGCCGAGCTTG 
O15       -CCAGCTACCGTTCCTGACCATATCGCGTGTGCGAGCCAGTAGCTTGCGCGCCGAGCTTG 
O10       -CCAACTGCCTTCCCTGGCTATCTCGCGTGCACGAGCCAGTGGCCTGCGCGCGGAGTTGG 
O19       -CCAACTGCCTTCCCTGGCTATCTCGCGTGCACGAGCCAGTGGCCTGCGCGCGGAGTTGG 
 
 
O1        CCAAGGCTCGGAAAGAGAGAGATTCCTTACTTGCTCGGCTTTC----------------- 
O9        CTCGCCTTCGCAATGGGATGGATTCCCGA------CAGCTTGC----------------- 
O7        TGCAGGCCCGTAAAGAAGTCGAAGCCTTGCGGATGGAGTCTTCGAAAGCCTCTTGAGTCT 
O8        TGCAGGCCCGTAAAGAAGTCGAAGCCTTGCGGATGGAGTCTTCGAAAGCCTCTTGAGGCT 
O2        CTCGTACTCGAAAAGAACTCGCAGTATCTCAGTCTACCGCCCTGCGGTGAGGTCTGCTCG 
O5        CTCGTACTCGAAAAGAACTCGCAGTATCTCAGTCTACCGCCCTGCGGTGAGGTCTGCTCG 
018       CTCGTACTCGAAAAGAACTCGCAGTATCTCAGTCTACCGCCCTGCGGTGAGGTCTGCTCG 
O20       CTCGTACTCGAAAAGAACTCGCAGTATCTCAGTCTACCGTCCTGCGGTGAGGTCTGCTCG 
016       CTCGTACTCGAAAAGAACTCGCAGTATCTCAGTCTACCGCCCTGCGGTGAGGTCTGCTCG 
O6        C-----GTCGACAAAAATCTCT--------------TCGCTCTGAATCAACCTCTCTATA 
O13       TCCGTATCCAAAGGCCATCTGC--------------CAGTTCGTCGTGAAGCTATGAAAT 
O14       TCCGTATCCAAAGGCCATCTGC--------------CAGTTCGTCGTGAAGCTATGAAAT 
O4        CTGGATCACTAAAGGCGG------------------------------------------ 
O12       CCAAGGCTCAAAGGGAGAGTGACCTTCTCCAGGCTAAGCTCATAGCTTATAGTGGAGGTA 
O12b      CCAAGGCTCAAAGGGAGAGTGACCTTCTCCAGGCTAAGCTCATAGCTTATAGTGGAGGTA 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        TACAAGCTCGTAAAGAGGTCGACACCTTGCGCGCGGAACCTTCGAAAGTTTCCTGAAACT 
O15       TACAAGCTCGTAAAGAGGTCGACACCTTGCGCGCGGAACCTTCGAAAGTTTCCTGAAACT 
O10       AGCAGGCTCGTAAAGAGGTTGACAGCTTGCG---GGTGCCTTCCAGTTCATCCTG--ACT 
O19       AGCAGGCTCGTAAAGAGGTTGACAGCTTGCG---GGTGCCTTCCAGTTCATCCTG—ACT 
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O1        ------TTCATCGAGTGATGGGGGGGGCTGACAATGGCCTGAGGCGCAAGGACTCATAGC 
O9        ------TTC---------------------TGGACAGCCCGAGAAGTAGAG--------- 
RO7        GGGGTGTTCCTGCTTGGATTTCAGCGGAGAGGAAGGAGGCGAGCGGAGGCAACTAATCGT 
RO8        GGGGTGTTCCTGCTTGGATTTCAGCGGAGAGGAAGGAGGCGAGCGGAGGCAACTAATCGT 
O2        AGTCCCTGCCT---GGTCTTTGTGGG---------------------------------- 
O5        AGTCCCTGCCT---GGTCTTTGTGGG---------------------------------- 
018       AGTCCCTGCCT---GGTCTTTGTGGG---------------------------------- 
O20       AGTCCCTGCCT---GGTCTTTGTGGG---------------------------------- 
016       AGTCCCTGCCT---GGTCTTTGTGGG---------------------------------- 
O6        AGTTCGTCCCTTCCGAACTAATTGCG---------------------------------- 
O13       AGCTCTACTCCTC---------TGCG---------------------------------- 
O14       AGCTCTACTCCTC---------TGCG---------------------------------- 
O4        ----CGGAAAGGCTTTGCCGGGAGGGTGATTGCTCGAGGGGTGTAAGGGG---------- 
O12       CGGTCAACTCGCCTTTATCGGGCGAAAGTGTATAAAAAGTGTATAAACAGCTTCATATTC 
O12b      CGGTCAACTCGCCTTTATCGGGCGAAAGTGTATAAAAAGTGTATAAACAGCTTCATATTC 
O11       ----CGTGTAGAACTTGTCGGGGA------------------------------------ 
017       ----CGTGTAGAACTTGTCGGGGA------------------------------------ 
O3        GATATTTCTGCTTGGCTTGAAACGCGCATTTCAGCGGTAGGCGCCGGAGAGAA------- 
O15       GATATTTCTGCTTGGCTTGAAACGCGCATTTCAGCGGTAGGCGCCGGAGAGAA------- 
O10       GCTTTTCTATTTCGGTTCGAGTAAGGCATTTGGAGGCGGGAGCGGTGAACGAA------- 
O19       GCTTTTCTATTTCGGTTCGAGTAAGGCATTTGGAGGCGGGAGCGGTGAACGAA------- 
 
 
O1        GGATCGACTGGTTAGAGTGGCCTTCCATCTTGATTGCGTTCTGCCATCATTTTGCTTGTT 
O9        ----------------------------CTTGTCCAGGTCTGGTCAGGAGCTGGCATAT- 
O7        TAGCCGC---------------------TCTGTCTACTTTCAGTCGCTCCTTTGC----- 
O8        TAGCCGC---------------------TCTGTCTACTTTCAGTCGCTCCTTTGC----- 
O2        ----------------------------CTCGAGTGCTATTCGCATCTAGATGACTACAC 
O5        ----------------------------CTCGAGTGCTATTCGCATCTAGATGACTACAC 
018       ----------------------------CTCGAGTGCTATTCGCATCTAGATGACTACAC 
O20       ----------------------------CTCGAGTGCTATTCGCATCTAGATGACTACAC 
016       ----------------------------CTCGAGTGCTATTCGCATCTAGATGACTACAC 
O6        ----------------------------TGCCAGC--------TCCGCAGTGGGTCTCTT 
O13       ----------------------------TTTCAGTTGATGATATCCCTTGCTATTTTCAC 
O14       ----------------------------TTTCAGTTGATGATATCCCTTGCTATTTTCAC 
O4        -CGGAGGAAACTAACCTTCTGTGTGGTTGTCTATGCATGTTGAGCTATTTATCTCGACA- 
O12       TCCGCCGGAACTAAACTTTACAATGGAGGTCTA---AGGCCAAGCGATTTTTTTTGAAAA 
O12b      TCCGCCGGAACTAAACTTTACAATGGAGGTCTA---AGGCCAAGCGATTTTTTTTGAAAA 
O11       --------------------TCGTGGTGTCCAACCCATCTTGTTGGGCTTTTCCCCTGA- 
017       --------------------TCGTGGTGTCCAATATATCTTGTTGGGCTTTTCCCCTGA- 
O3        ----------------------------GGCAACTAATTGTGGGGCGTCCTGTCTACTCA 
O15       ----------------------------GGCAACTAATTGTGGGGCGTCCTGTCTACTCA 
O10       ----------------------------AGCAACTAATCATTGTTCGCTCTGTCTACTGA 
O19       ----------------------------AGCAACTAATCATTGTTCGCTCTGTCTACTGA 
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O1        ACCTCCGGGCTTTT------------------TCTTTGAAGCTGTTTCGCGATTTGAATC 
O9        ---TCCGCGCTTGC------------------TCGATAGGCGGAGGGAACTGTTGGAAGG 
O7        ------------------------------------------------GATGAAGGACCA 
O8        ------------------------------------------------GATGAAGGACCA 
O2        AATGCTTGGAAGGT------------------CGGGTGGGATGGGTGTCCTGTTAGAGGG 
O5        AATGCTTGGAAGGT------------------CGGGTGGGATGGGTGTCTTGTTAGAGGG 
018       AATGCTTGGAAGGT------------------CGGGTGGGATGGGTGTCTTGTTAGAGGG 
O20       AATGCTTGGAAGGT------------------CGGGTGGGATGGGTGTCCTGTTAGAGGG 
016       AATGCTTGGAAGGT------------------CGGGTGGGATGGGTGTCCTGTTAGAGGG 
O6        CTTGCTGAAAAGGG------------TTGCTGCCGGCGGGTCGTAACCTCTCGTGGAAGG 
RO13      TTCGTTGAGCGAGGGCGTTTCTCTATCCACTGCCGGCATGCTGTTGACGGTGGGAAAGGA 
RO14      TTCGTTGAGCGAGGGCGTTTCTCTATCCACTGCCGGCATGCTGTTGACGGTGGGAAAGGA 
O4        --------CTGTCG--------------------------------------------GA 
O12       CCGTTTGGACACCA--------------------------------------------CA 
O12b      CCGTTTGGACACCA--------------------------------------------CA 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        GATTCTTCATTC-T--------------------------------ATGATGAAGGACCT 
O15       GATTCTTCATTC-T--------------------------------ATGATGAAGGACCT 
O10       GATTCTTCACTTAA--------------------------------AAGGCGAAGAGGCA 
O19       GATTCTTCACTTAA--------------------------------AAGGCGAAGAGGCA 
 
 
O1        GTATGC---------TCAGCTGTACTGAGCGA----------------GCAATCAGTCTT 
O9        GTGTGCGATCTGACATAGGTCGTATCTGGCGA----------------CTTGTAATATCG 
FO7       GCATGCCATCTACCTTCGGTTATAGCGTCCGATATCAGCCTGTAGTCTCCGGTTAGGCTG 
FO8       GCATGCCATCTACCTTCGGTTATAGCGTCCGATATCAGCCTGTAGTCTTCGGTTAGGCTG 
O2        ------------------------------GGTGCTGAGTTACCATGTCTTACTGGTTTG 
O5        ------------------------------GGTGCTGAGTTACCATGTCTTACTGGTTTG 
018       ------------------------------GGTGCTGAGTTACCATGTCTTACTGGTTTG 
O20       ------------------------------GGTGCTGAGTTACCATGTCTTACTGGTTTG 
016       ------------------------------GTTGCTGAGTTACCATGTCTTACTGGTTTG 
O6        TATCCTCTGGCCTGCTTGACCCCATTTTTCTGCTGTGGGCACTAATCTCTGACTGTCTTG 
O13       AG----------------------------AGGGGCGGCAACTAATTTCTAGCTAGAATG 
O14       AG----------------------------AGGGGCGGCAACTAATTTCTAGCTAGAATG 
O4        TGAAAGGGCTTGTCGAAGGAGGCTTTCGGTTCGTACTCCTTGTATTCTCGAGTCATGCTG 
O12       TGGTACAGTTTGTGAATGTAAA------------------TAGAGGTTTAACTTTACCTG 
O12b      TGGTACAGTTTGTGAATGTAAA------------------TAGAGGTTTAACTTTACCTG 
O11       ----------------------------------------TAGAGTTTCCGATTGGACTG 
017       ----------------------------------------TAGAGTTTCCGATT-GACTG 
FO3       GCATGCCAGCACCCGATGGCCATGGAGCGCGACCCCAGCTTGTAATCTCCGAGCATGCTG 
FO15      GCATGCCAGCACCCGATGGCCATGGAGCGCGACCCCAGCTTGTAATCTCCGAGCATGCTG 
O10       GCATGCTCGTACCC-CCGGGCTCATGGGGCGACATCAGTTTGTAATCTAAAGACAGGGTG 
O19       GCATGCTCGTACCC-CCGGGCTCATGGGGCGACATCAGTTTGTAATCTAAAGACAGGGTG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 148 
O1        CAGAAAACTAAAATACTTCTTACGGAACTGAGGCGTGTTCTTGGCTGTCT---------- 
O9        CAAAGGGTTGGCACAATGTGCCAGCCCTCGGGG--------------------------- 
O7        TCAAGATATGGTCTATATCAGGCTGACCTAGGG--------------------------- 
O8        TCAAGATATGGTCTATATCAGGCTGACCTAGGG--------------------------- 
O2        GCTGGAG------------TCTTTAGATGGAGGCTTGGTTCATGGCATCGTGTCGCTCCC 
O5        GCTGGAG------------TCTGTAGATGGAGGCTTGGTTCATGGCATCGTGTCGCTCCC 
018       GCTGGAG------------TCTGTAGATGGAGGCTTGGTTCATGGCATCGTGTCGCTCCC 
O20       GCTGGAG------------TCTGTAGATGGAGGCTTGGTTCATGGCATCGTGTCGCTCCC 
016       GCTGGAG------------TCTGTAGATGGGGGCTTGGTTCATGGCATCGTGTCGCTCCC 
O6        TCTAACA-TACGTCCGTGCATCCTGAATCGCGAGCTAGGCTCTGTTATCA---------- 
O13       TCTAAAAGGGCTGCGGTATACCCTGCTTAGGAGGGTGTGCCATG----CA---------- 
O14       TCTAAAAGGGCTGCGGTATACCCTGCTTAGGAGGGTGTGCCATG----CA---------- 
O4        GCAAAATGCAGTA----------------------------------------------- 
O12       GCGAGGCTTGGTT----------------------------------------------- 
O12b      GCGAGGCTTGGTT----------------------------------------------- 
O11       ATGATGGACTGAA----------------------------------------------- 
017       ATGATGGACTGAA----------------------------------------------- 
O3        TCAGAATGCGATCCATTT------------------------------------------ 
O15       TCAGAATGCGATCCATTT------------------------------------------ 
O10       TCAGAATACGTTTCATTT------------------------------------------ 
O19       TCAGAATACGTTTCATTT------------------------------------------ 
 
 
O1        ------------ATCGTAGAATTCCTTGTACAGATAATCTCTGGCACAGGGTGTGCTACT 
O9        -------------------------TCGTAGGGTTTACCTATGGCGAGGCCTGAAACAGA 
O7        ------------------------------------------------------------ 
O8        ------------------------------------------------------------ 
RO2       GGTTGGTCTTCGCCAAAGGTCAAGCTTTTATGGAACTACTTTCGTTTCTGATGGTCAAGA 
RO5       GGTTGGTCTTCGCCAAAGGTCAAGCTTTTATGGAACTACTTTCGTTTCTGATGGTCAAGA 
R018      GGTTGGTCTTCGCCAAAGGTCAAGCTTTTATGGAACTACTTTCGTTTCTGATGGTCAAGA 
RO20      GGTTGGTCTTCGCCAAAGGTCAAGCTTTTATGGAACTACTTTCGTTTCTGATGGTCAAGA 
R016      GGTTGGTCTTCGCCAAAGGTCAAGCTTTTATGGAACTACTTTCGTTTCTGATGGTCAAGA 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        ------------------------------------------------------------ 
O15       ------------------------------------------------------------ 
O10       ------------------------------------------------------------ 
O19       ------------------------------------------------------------ 
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O1        TGAGGAGGCGTCGAGATATGTCATGTTTTTTATATGCACTCTCTTTGTCTTGGTGATAAT 
O9        TGAAACGGACCTGTCGTGACTGAAAATCGCTATTCCCGCC-------------------- 
O7        ----------------------------------------------GCCAGTGGAATATC 
O8        ----------------------------------------------GCCAGTGGAATATC 
O2        TGCATTGAGGCTTTTGGCGGAGAGTTACATGTATTGCTTGCACGTAATTCATCCTGTTGA 
O5        TGCATTGAGGCTTTTGGCGGAGAGTTTCATGTATTGCTTGCACGTAATTCATCCTGTTGA 
018       TGCATTGAGGCTTTTGGCGGAGAGTTTCATGTATTGCTTGCACGTAATTCATCCTGTTGA 
O20       TGCATTGAGGCTTTTGGCGGAGAGTTTCATGTATTGCTTGCACGTAATTCATCCTGTTGA 
016       TGCATTGAGGCTTTTGGCGGAGAGTTTCATGTATTGCTTGCACGTAATTCATCCTGTTGA 
O6        ------GCGATTGGTGCGCTGAAGGTGTTTGCGTCGTATCC--------CTATCTCCTGG 
O13       ------GTTGTTGTCGGCATCCAGTCGCTAGTGCTGATTGC--------CGACCC----A 
O14       ------GTTGTTGTCGGCATCCAGTCGCTAGTGCTGATTGC--------CGACCC----A 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        ------------------------------------------------------------ 
O15       ------------------------------------------------------------ 
O10       ------------------------------------------------------------ 
O19       ------------------------------------------------------------ 
 
 
RO1       GCACATCGGTGGAGTTGTAGCTTCTCGTTTCGAATAGCTTCAGTTCGGGGCTTGCGTGAG 
O9        ------------------------------------------------------------ 
O7        AAAAAACGGTAAAAATGGGTTGTATTGTGACTAACGGCATTGGCTCGAG----------- 
O8        AAAAAACGGTAAAAATGGGTTGTATTGTGACTAACGGCATTGGCTCGAG----------- 
O2        GTTCGCTGTCGGTAATGTGTCTTCTGGGCGCTCTGTCTTTCCCTTGCTAGTGTGTAAAAA 
O5        GTTCGCTGTCGGTAATGTGTCTTCTGGGCGCTCTGTCTTTCCCTTGCTAGTGTGTAAAAA 
018       GTTCGCTGTCGGTAATGTGTCTTCTGGGCGCTCTGTCTTTCCCTTGCTAGTGTGTAAAAA 
O20       GTTCGCTGTCGGTAATGTGTCTTCTGGGCGCTCTGTCTTTCCCTTGCTAGTGTGTAAAAA 
016       GTTCGCTGTCGGTAATGTGTCTTCTGGGCGCTCTGTCTTTCCCTTGCTAGTGTGTAAAAA 
O6        AGTCGATGGTCGCGACCGTGCGGCTTGTAATCTCGTAGCATGC-TGTCAAAATGCAGCAG 
O13       GATCGGTAGCAGCGGTGTAACTGCTTGTAATCTTGGAGCATGC-TGTCAAAATGCAGCAG 
O14       GATCGGTAGCAGCGGTGTAACTGCTTGTAATCTTGGAGCATGC-TGTCAAAATGCAGCAG 
O4        --------------------------------------------GCTTGGAGAGCATGGA 
O12       --------------------------------------------CATTAATCTGGATGAC 
O12b      --------------------------------------------CATTAATCTGGATGAC 
O11       --------------------------------------------TGTGAATAAGCAGAAT 
017       --------------------------------------------TGTGAATAAGCAGAAT 
O3        ------------------------------------------------------------ 
O15       ------------------------------------------------------------ 
O10       ------------------------------------------------------------ 
O19       ------------------------------------------------------------ 
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O1        CTATAGAAGACAGATTATGGAGTTC----------------------------------- 
O9        ------------------------------------------------------------ 
O7        ------------------------------------------------------------ 
O8        ------------------------------------------------------------ 
O2        CTTCTAATTAAAAATTGGCTAATT------ATAATTGGTTTTCAATGATTGGCCGGAAGA 
O5        CTTCTAATTAAAAATTGGCTAATT------ATAATTGGTTTTCAATGATTGGCCGGAAGA 
018       CTTCTAATTAAAAATTGGCTAATT------ATAATTGGTTTTCAATGATTGGCCGGAAGA 
O20       CTTCTAATTAAAAATTGGCTAATT------ATAATTGGTTTTCAATGATTGGCCGGAAGA 
016       CTTCTAATTAAAAATTGGCTAATT------ATAATTGGTTTTCAATGGTTGGCCGGAAGA 
O6        CTTC--CTGATGCATCTCCACGTCAGGAGGGGGGCTGCCGCATGATGACTCCTTAACCCA 
O13       CTTCAGCCCATAGCTTTGCTCATGCTGCTGGTGATTTCCGCCAACCAATC---------- 
O14       CTTCAGCCCATAGCTTTGCTCATGCTGCTGGTGATTTCCGCCAACCAATC---------- 
O4        GCTGGAGAACGATTTCTGCCTTTGATCGGAACTCCT------AACCAAAATCAAGTGATG 
O12       ATATAAGAATTTTTTCGGTTTCTTTCTAAGAGTTACCCAGAATATTGATATGGAATAAAA 
O12b      ATATAAGAATTTTTTCGGTTTCTTTCTAAGAGTTACCCAGAATATTGATATGGAATAAAA 
O11       TCTT-------------------------------------------------------- 
017       TCTT-------------------------------------------------------- 
O3        ------------GCCAGGCGGGTTTC-AGGGCTTTTAGTGGCTTACCACAAAACAGTGAA 
O15       ------------GCCAGGCGGGTTTC-AGGGCTTTTAGTGGCTTACCACAAAACAGTGAA 
O10       ------------GCCAGGCTGGCTTCGGGGGCCTCTAGCTGCATATCAT-AAACAGCGAA 
O19       ------------GCCAGGCTGGCTTCGGGGGCCTCTAGCTGCATATCAT-AAACAGCGAA 
 
 
O1        -----------------CGATAATGGTAGCGTTGAAAGAAGAAAAAAACGGTGGCGGTGA 
O9        --------------------------------------------AAGATGCAGATGGTGA 
O7        ---------------------------------------AAAACAATCGAAAGATTACGA 
O8        ---------------------------------------AAAACAATCGAAAGATTACGA 
O2        GTAGCTGGACTTTTCGATGACTGACGAAA---TACAAAAGCACGGCGGTGTAGCTGGCGA 
O5        GTAGCTGGACTTTTCGATGACTGACGAAA---TACAAAAGCACGGCGGTGTAGCTGGCGA 
018       GTAGCTGGACTTTTCGATGACTGACGAAA---TACAAAAGCACGGCGGTGTAGCTGGCGA 
O20       GTAGCTGGACTTTTCGATGACTGACGAAA---TACAAAAGCACGGCGGTGTAGCTGGCGA 
016       GTAGCTGGACTTTTTGATGACTGACGAAA---TACAAAAGCACGGCGGTGTAGCTGGCGA 
O6        AGAATTGGATCCGTTG-TGACAGAAAAAAATTTTCCCTCCTATAAAGCCAAGAGCGGCGA 
O13       AAAGACGGACTAGTTG-TGACAGAAGAAACCTTTTTCCAGCGCGTGGCCAAAAATGAAGA 
O14       AAAGACGGACTAGTTG-TGACAGAAGAAACCTTTTTCCAGCGCGTGGCCAAAAATGAAGA 
O4        GATGCATTG--------TGACCACAGAAAGATCACCCCGTGTTGTCCCTATTGATGGGCA 
O12       AATGTCCGA--------TAAGCAGA-------------GTAGTGAAGCGGTTAATTATGA 
O12b      AATGTCCGA--------TAAGCAGA-------------GTAGTGAAGCGGTTAATTATGA 
O11       --------------------------------------CTTTGATGACGGCTGATGGTGA 
017       --------------------------------------CTTTGATGACGGCTGATGGTGA 
O3        GAGTATAGGTTGAACTGTGACAGACGGCATTGACTCGCGACAGATGTCCAAGCGTAACGA 
O15       GAGTATAGGTTGAACTGTGACAGACGGCATTGACTCGCGACAGATGTCCAAGCGTAACGA 
O10       GAATATAGGTTGAACTGTGACTGACGGTATTGACTCGCGACAGACGTCCAAGCGTAACGA 
O19       GAATATAGGTTGAACTGTGACTGACGGTATTGACTCGCGACAGACGTCCAAGCGTAACGA 
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O1        AATTGATCTCGTAAGACTTTTTCAGATTCTATGGAAGGGAAAGTGGATTATCCTGGTCGT 
O9        AATTGACTTGCTGGCGTTGGTGCAAGGGCTGTGGGCTGGAAAATGGATCATAGTGGGAAC 
O7        AATTGATGTGTTGGAGCTCGTTCGAGGGATATGGTCCCGGAAGTGGCTTGTCATTTCAGG 
O8        AATTGATGTGTTGGAGCTCGTTCGAGGGATATGGTCCCGGAAGTGGCTTGTCATTTCAGG 
O2        TATCGATCTGGTTGAGCTGGTTCGAGGATTATGGGAGGAGAAGTGGATAGTTCTTATATT 
O5        TATCGATCTGGTTGAGCTGGTTCGAGGATTATGGGAGGAGAAGTGGATAGTTCTTATATT 
018       TATCGATCTGGTTGAGCTGGTTCGAGGATTATGGGAGGAGAAGTGGATAGTTCTTATATT 
O20       TATCGATCTGGTTGAGCTGGTTCGAGGATTATGGGAGGAGAAGTGGATAGTTCTTATATT 
016       TATCGATCTGGTTGAGCTGGTTCGAGGATTATGGGAGGAGAAGTGGATAGTTCTTATATT 
O6        GTTCGATCTGATAGAGATTATGAGTGGGTTGTGGTCCCTGAGATGGCTGATTGCTTTGCT 
O13       GTTCGATCTGATAGGGCTTTTACGAGGCTTGTGGGCTGAAAAGTGGCTGATAGCTTGTAT 
O14       GTTCGATCTGATAGGGCTTTTACGAGGCTTGTGGGCTGAAAAGTGGCTGATAGCTTGTAT 
RO4       GATCGACCTCGTTGAACTTGCACAAGGTATTCTCAGGCAGAAGTGGTTGATTGCCTCT-TT 
O12       AGTGGATTTTATGGAGTTGATACGTGAGCTCTGGAAAAGCCGGTGGCTTGTTGTTCTAAG 
O12b      AGTGGATTTTATGGAGTTGATACGTGAGCTCTGGAAAAGCCGGTGGCTTGTTGTTCTAAG 
O11       GGTTGACCTGGTGAAGCTGGTCAAGGAGCTTTGGGTTAACAAGGTTCTGATTCTTCTGAC 
017       GGTTGACCTGGTGAAGCTGGTCAAGGAGCTTTGGGTTAACAAGGTTCTGATTCTTCTGAC 
O3        AATCGACTTTATCGAGCTCATTCAAGGGCTTTGGGCACAGAAATGGCTCGTCCTTTCCCT 
O15       AATCGACTTTATCGAGCTCATTCAAGGGCTTTGGGCACAGAAATGGCTCGTCCTTTCCCT 
FO10      AATCGATTTTATCGAGCTCATTCAAGGGCTCTGGTCACAAAAGTGGCTCGTTTTTTCCCT 
FO19      AATCGATTTTATCGAGCTCATTCAAGGGCTCTGGTCACAAAAGTGGCTCGTTTTTTCCCT 
 
 
O1        AGCTCTTATATTTGGCATTGTTGCTGCTATATATGCCTATACAAGTAAGCCGGTTTATGA 
O9        TGCAGCCGTAGTGACATTGCTAGCAGTTGTATATGCAGTTTTGAAGGAGCCAGTTTATGA 
O7        GACTGCTCTTGGGGCGGTTCTGGCCGCGGCTTATGCATTTTTCAGCGAGCCGGTATATGA 
O8        GACTGCTCTTGGGGCGGTTCTGGCCGCGGCTTATGCATTTTTCAGCGAGCCGGTATATGA 
O2        TTCTTTGCTAGGTATTTTGTTTGCAGCTATCTACGCTTTTCTCAGTACTCCTGTCTATGA 
O5        TTCTTTGCTAGGTATTTTGTTTGCAGCTATCTACGCTTTTCTCAGTACTCCTGTCTATGA 
018       TTCTTTGCTAGGTATTTTGTTTGCAGCTATCTACGCTTTTCTCAGTACTCCTGTCTATGA 
O20       TTCTTTGCTAGGTATTTTGTTTGCAGCTATCTACGCTTTTCTCAGTACTCCTGTCTATGA 
016       TTCTTTGCTAGGTATTTTGCTTGCAGCTATCTACGCTTTTCTCAGCACTCCTGTCTATGA 
O6        GGCAGTGTTGCCGGTGTTGTTGGCTATTGTTTATCTATTCATCACCAAGCCCGTCTATGA 
O13       AACGATATTGACTACATCCTTGGTCGGGACATATGCCTTTTTAAGTAAGCCGGTTTATGA 
O14       AACGATATTGACTACATCCTTGGTCGGGACATATGCCTTTTTAAGTAAGCCGGTTTATGA 
O4        TTTTCTTCTTGCAACGGCCCTCGCCGTTGTTTATGCATTTTATAGTCGGCCAATCTATGA 
O12       TGGGTTCTTTTTAGGGCTTTTAGCGGCGCTCTATGCCTATTTAAGTAAGCCTGTCTATGA 
O12b      TGGGTTCTTTTTAGGGCTTTTAGCGGCGCTCTATGCCTATTTAAGTAAGCCTGTCTATGA 
O11       TACTCTTCTTGCATTAATCGGGTCTTTTACCTATGCGTATCTGAGTAAGCCTGTATATGA 
017       TACTCTTCTTGCATTAATCGGGTCTTTTACCTATGCGTATCTGAGTAAGCCTGTATATGA 
O3        GACCTTTCTAGGTGCGGTTCTGGCGGGGAGCTATGCATTTCTAAGCAAGCCTGTATACGA 
O15       GACCTTTCTAGGTGCGGTTCTGGCGGGGAGCTATGCATTTCTAAGCAAGCCTGTATACGA 
O10       GACTTTTCTAGGTGCTGTTCTGGCGGGGAGCTATGCATTTTTAAGCAAGCCAGTCTACGA 
O19       GACTTTTCTAGGTGCTGTTCTGGCGGGGAGCTATGCATTTTTAAGCAAGCCAGTCTACGA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 152 
O1        AGCCAGTATCGCCGTGTTGCCACCCTCGCTGAGCAATGTTGCCGGTTTTAACCAGGGGCG 
O9        ATCCAAAATTACGCTTCTTCCTCCTCCGCTAAGTGCCGTGGCGGGATTCAATATCGGGCG 
RO7       GTCGCGAGTGGCGGTACTACCTCCTTCTCTTAGCGATGTGGCGGGATTCAATATCGTTCG 
RO8       GTCGCGAGTGGCGGTACTACCTCCTTCTCTTAGCGATGTGGCGGGATTCAATATCGTTCG 
O2        GGCCCGCATAGCGATTTTGCCTCCGTCGTTGAGTGATGTGGCAGGTTTCAATCAGGGACG 
O5        GGCCCGCATAGCGATTTTGCCTCCGTCGTTGAGTGATGTGGCAGGTTTCAATCAGGGACG 
018       GGCCCGCATAGCGATTTTGCCTCCGTCGTTGAGTGATGTGGCAGGTTTCAATCAGGGACG 
O20       GGCCCGCATAGCGATTTTGCCTCCGTCGTTGAGTGATGTGGCAGGTTTCAATCAGGGACG 
016       GGCCCGCATAGCGATTTTGCCTCCGTCGTTGAGTGATGTGGCAGGTTTCAATCAGGGACG 
O6        GGCTCGTGTCTCGACGCTGCCTCCTTCACTCAGCGATATAGCTGGTTTCAACTTGGGAAG 
O13       GGCACGTATAGCGGTACTCCCTCCATCATGGAGCAGTATTGCAGGATTTAATTTGGGGCG 
O14       GGCACGTATAGCGGTACTCCCTCCATCATGGAGCAGTATTGCAGGATTTAATTTGGGGCG 
O4        GGCTCGAGCTTCTGTTTTGCCCCCTTCCTTAAATGAAATATCTGGTTTTAATCTTGGGCG 
O12       GGCTCGAGTTATTGTACTGCCTCCTTCGTTAAGCAGCGTTGCAGGCTTCAACCAGGGGCG 
O12b      GGCTCGAGTTATTGTACTGCCTCCTTCGTTAAGCAGCGTTGCAGGCTTCAACCAGGGGCG 
FO11      ATATAGGGTTGCAGTAGTACCTCCTGCTCTTGGGTCTATCGAAGGTTTCAATATTGGTAG 
F017      ATATAGGGTTGCAGTAGTGCCTCCTGCTCTTGGGTCTATCGAAGGTTTCAATGTTGGTAG 
O3        GGCTCGGGTTGCCGTTTTGCCGCCATCCCTTAGCGATGTTGCGGGGTTCAACATCGCGCG 
O15       GGCTCGGGTTGCCGTTTTGCCGCCATCCCTTAGCGATGTTGCGGGGTTCAACATCGCGCG 
O10       GGCTCGGGTTGCTCTTCTACCGCCATCCCTTAGCGATGTTGCCGGGTTCAACATTGCCCG 
O19       GGCTCGGGTTGCTCTTCTACCGCCATCCCTTAGCGATGTTGCCGGGTTCAACATTGCCCG 
 
 
O1        TA------CCAAGGAGTCGGGTCTTCAGGCATTTAAAGTTCAGGATGTCTATTCCGTGTT 
O9        TACGCGTTCTGAAGGGTTGGCCCCT------TTTACCGTTTCTGATGTCTATAGGGTTTT 
O7        CG------GAAAGGATAGTGGCCTTCCTCCTTTTACTGTCAGTCAGGTTTATTCGGTGTT 
O8        CG------GAAAGGATAGTGGCCTTCCTCCTTTTACTGTCAGTCAGGTTTATTCGGTGTT 
O2        TA------CCAGGGAAACCGGGCTTGGTCCCTTCAAGGTCCAGGATGTGTACTCTGTTTT 
O5        TA------CCAGGGAAACCGGGCTTGGTCCCTTCAAGGTCCAGGATGTGTACTCTGTTTT 
018       TA------CCAGGGAAACCGGGCTTGGTCCCTTCAAGGTCCAGGATGTGTACTCTGTTTT 
O20       TA------CCAGGGAAACCGGGCTTGGTCCCTTCAAGGTCCAGGATGTGTACTCTGTTTT 
016       TA------CCAGGGAAACCGGGCTTGGTCCCTTCAAGGTCCAGGATGTGTACTCTGTTTT 
O6        AT------CG---GAAAACGGGCTTCCCGCGTTTTCGGCAAATGGTGTCTATTCAATCTT 
O13       AG------CC---GAGAATGGATTAACCACATTCTCCGTTAATGATGTTTATTCCGTTTT 
O14       AG------CC---GAGAATGGATTAACCACATTCTCCGTTAATGATGTTTATTCCGTTTT 
O4        A---------AAAGAGAGTGACCTGGGAGTCTTTTCTGTCAAGGATATATATGACGTCTT 
O12       AA------CTAGTGATTCTGGATTGCAGCCTTTCAAGGTTCAAGACGTTTATTCGGTTTT 
O12b      AA------CTAGTGATTCTGGATTGCAGCCTTTCAAGGTTCAAGACGTTTATTCGGTTTT 
O11       A---------AGGGAGAATGGCCTAGATGCATATACTGTTAGAAGTATCTATGCGATCTT 
017       A---------AGGGAGAATGGCCTAGATGCATATACTGTTAGAAGTATCTATGCGATCTT 
O3        CA------GTCGAGACAGCGGTCTTCCACCTTTTACCGTTAGCCAGGTTTACTCGGTGTT 
O15       CA------GTCGAGACAGCGGTCTTCCACCTTTTACCGTTAGCCAGGTTTACTCGGTGTT 
O10       TG------GCCGAGACAGCGGTCTTCCACCTTTTACTGTGAGCCAAGTTTATTCTGTATT 
O19       TG------GCCGAGACAGCGGTCTTCCACCTTTTACTGTGAGCCAAGTTTATTCTGTATT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 153 
O1        CTTGCGCAATCTTCAAGCTGATGAGACTCGGCACCGCTTCTT----CGAGAATGTCTACT 
O9        CACTCGCAACCTGGAGGCTGACGAGAATCGGCGTGCTTTCTTTCGCCTGTATTATCTTCC 
O7        TATACGAAACTTACAGTCTGAAGGTACTCAGAGACGATTCTTTCGCGAGATATATCTACC 
O8        TATACGAAACTTACAGTCTGAAGGTACTCAGAGACGATTCTTTCGCGAGATATATCTACC 
O2        TGTTCGCAACCTGCAGGCTGATGGAACTCGTCATCGTTTTTTCAATGAGACCTATTTGCC 
O5        TGTTCGCAACCTGCAGGCTGATGGAACTCGTCATCGTTTTTTCAATGAGACCTATTTGCC 
018       TGTTCGCAACCTGCAGGCTGATGGAACTCGTCATCGTTTTTTCAATGAGACCTATTTGCC 
O20       TGTTCGCAACCTGCAGGCTGATGGAACTCGTCATCGTTTTTTCAATGAGACCTATTTGCC 
016       TGTTCGCAACCTGCAGGCTGATGGAACTCGTCATCGTTTTTTCAATGAGACCTATTTGCC 
O6        CGTGCGAAATCTCCAGTCCGAAGAGACTCGCCGTCAGTTCTTTCGAGATGTATATATTCC 
O13       TTTGCGAAATCTTTTAGCTGAAGAGACTCGGAGAAATTTTTTTCGCGAAGTTTATCTGCC 
O14       TTTGCGAAATCTTTTAGCTGAAGAGACTCGGAGAAATTTTTTTCGCGAAGTTTATCTGCC 
O4        TATCAGGAATTTGATGGCTGAAGAGACACGGCAGAATTTCTTCAAGGAAAAGTATCTACC 
O12       TATTCGGAATCTTCAGTCTGATGAATCGCTTCGCCGATTTTTTGAGAATATTTATTTGCC 
O12b      TATTCGGAATCTTCAGTCTGATGAATCGCTTCGCCGATTTTTTGAGAATATTTATTTGCC 
RO11      TTCGCGCAATCTGCTTTCGGATGAGAATAAAAAAGAGTTCTTCTATAAGATATACCTTCC 
017       TTCGCGCAATCTGCTTTCGGATGAGAATAAAAAAGAGTTCTTCTATAAGATATACCTTCC 
RO3       CACCCGAAATCTACAGTCCGAGGGAACGCGACGGCAGTTTTTTCGCGAGGTATATCTGCC 
RO15      CACCCGAAATCTACAGTCCGAGGGAACGCGACGGCAGTTTTTTCGCGAGGTATATCTGCC 
RO10      CACTCGGAATCTGCAGTCCGAAGGCACTCGGAGGCAGTTTTTTCGCGAAGTTTATTTGCC 
RO19      CACTCGGAATCTGCAGTCCGAAGGCACTCGGAGGCAGTTTTTTCGCGAAGTTTATTTGCC 
 
 
O1        TGCCGTCGCTAGGAGGT---GAGAGGCCGGCGTCGCGCGATAGTCTCTATAGGGTATTTA 
O9        TACTCTTGAT-GAAAGC---GATCGCAAAGGGCCGCAGGATGGGCTTTACAGACGTTTCA 
O7        TTCTCTTCAG----------CAGAGTGAAGGATCGATGGACGTCTTATACAGAGCATTTT 
O8        TTCTCTTCAG----------CAGAGTGAAGGATCGATGGACGTCTTATACAGAGCATTTT 
O2        TTCTTTGGAT-GAAGAG---CTTCGTTCGGTTTCGCGTGATGCGCTCTATAAAAGGTTCA 
O5        TTCTTTGGAT-GAAGAG---CTTCGTTCGGTTTCGCGTGATGCGCTCTATAAAAGGTTCA 
018       TTCTTTGGAT-GAAGAG---CTTCGTTCGGTTTCGCGTGATGCGCTCTATAAAAGGTTCA 
O20       TTCTTTGGAT-GAAGAG---CTTCGTTCGGTTTCGCGTGATGCGCTCTATAAAAGGTTCA 
016       TTCTTTGGAT-GAAGAG---CTTCGTTCGGTTTCACGTGATGCGCTCTATAAAAGGTTCA 
O6        TTCCTTGGAG-GAGGGG---GCTTCTGTTGGTTCGCGGGATCAGCTTTATGCGCTTCTCA 
O13       TTCCTTGAGT-GAAAAC---GAGCGCTCTGGTTCGAAAGATCGTCTTTATTCGAATCTTT 
O14       TTCCTTGAGT-GAAAAC---GAGCGCTCTGGTTCGAAAGATCGTCTTTATTCGAATCTTT 
O4        GACCTTGGGA-GACAAA---GGG---------------GCGGAATCTCTTGATGCATTAT 
O12       GTCTCTAACT-GATGCA---GAACGGTCAGAGTCGCGCGAGAAACTTTTTCGCTCCTTCA 
O12b      GTCTCTAACT-GATGCA---GAACGGTCAGAGTCGCGCGAGAAACTTTTTCGCTCCTTCA 
O11       CCAAGTGGGT-GAGGGAGCGGAAAGCGAAGATGAGCAGGAGGAGTTTTATAAGAAGTTCT 
017       CCAGGTGGGT-GAGGGAGCGGAAAGCGAAGATGAGCAGGAGGAGTTTTATAAGAAGTTCT 
O3        CTCCCTTGAA----------GAGCGAGTGGGCTCGGTGGATGGGCTGTACAGGGCGTTTT 
O15       CTCCCTTGAA----------GAGCGAGTGGGCTCGGTGGATGGGCTGTACAGGGCGTTTT 
O10       CTCCCTTGAG----------GAGCGAAAGGGCTCAATTGATGGCCTCTATAGGGCGTTTT 
O19       CTCCCTTGAG----------GAGCGAAAGGGCTCAATTGATGGCCTCTATAGGGCGTTTT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 154 
O1        ATGAAAAGATCAGTATTACTCTGCCAGACAAGACCCAGCCGAGT---------CGCTATC 
O9        ACGAAATATTTACCATCAAAGTTCCCGATAAG---CAGCAGCCT---------GGCTATA 
O7        CAGAGGACTTGAGGGTCGTGCCGCCAACCAAGGAGTTGCCGGAG---------CGTTATA 
O8        CAGAGGACTTGAGGGTCGTGCCGCCAACCAAGGAGTTGCCGGAG---------CGTTATA 
O2        CTGATCAGATAAGTATTAGTTTGCCGGGGAAAGACTTTCCGGGT---------CGTTATC 
O5        CTGATCAGATAAGTATTAGTTTGCCGGGGAAAGACTTTCCGGGT---------CGTTATC 
018       CTGATCAGATAAGTATTAGTTTGCCGGGGAAAGACTTTCCGGGT---------CGTTATC 
O20       CTGATCAGATAAGTATTAGTTTGCCGGGGAAAGACTTTCCGGGT---------CGTTATC 
016       CTGATCAGATAAGTATTAGTTTGCCGGGGAAAGACTTTCCGGGT---------CGTTATC 
O6        TGAATTCGGTAACTATTCAGAAGCCTAGCAAAGAGGATAGCGAG---------CGCTACA 
O13       CTGAAGAAATGGAAATACAGAGACCTAGTAAGGATGAGCGTGAG---------CGCTACA 
O14       CTGAAGAAATGGAAATACAGAGACCTAGTAAGGATGAGCGTGAG---------CGCTACA 
O4        ATAATAAGTTCAATGATGAATTGCAGATCAAAGCATCGGTGGATGGTTCAGGGCGCTATT 
O12       GTAAGCAGATAAGCATTAGTCTGCCGGATAGAGCGCAGCCTGAT---------CGATATT 
O12b      GTAAGCAGATAAGCATTAGTCTGCCGGATAGAGCGCAGCCTGAT---------CGATATT 
FO11       CCAAAGAGGTAAAGATTGATCCTGCTAACAAGCCAGATGCAGAC---------CGTTATA 
F017       CCAAAGAGGTAAAGATTGATCCTGCTAACAAGCCAGATGCAGAC---------CGTTATA 
O3        CCGACGATGTGAGCGTGAATCAGCCGACCAAGGAGCTACCGGAG---------CGGTACA 
O15       CCGACGATGTGAGCGTGAATCAGCCGACCAAGGAGCTACCGGAG---------CGGTACA 
O10       CAGATGATGTAAGTGTTAATCGGCCGTCGAAGGACTTGCCTGAG---------CGGTATA 
O19       CAGATGATGTAAGTGTTAATCGGCCGTCGAAGGACTTGCCTGAG---------CGGTATA 
 
 
O1        GGCTAACAGTAGAACAGGAAGATCCTGAGCTGGCCGCTGAGTGGATCCGTCGCTATCTTG 
FO9       CGCTGATCATTGAACGAAAGAATCCGGCAGAGGCCGCTGACTGGGTTCAGAAATATGTGC 
O7        CTGTGGTGTTGAATCGCCATGATCCTCAAGAAGCTGCGAGGTGGGCCAAGCAATATATCG 
O8        CTGTGGTGTTGAATCGCCATGATCCTCAAGAAGCTGCGAGGTGGGCCAAGCAATATATCG 
O2        TTGTTGCGATTGAACAGGAGGATCCGGAGCGTGCGGCGAGTTGGGTTCGTCGGTATATAG 
O5        TTGTTGCGATTGAACAGGAGGATCCGGAACGTGCGGCGAGTTGGGTTCGTCGGTATATAG 
018       TTGTTGCGATTGAACAGGAGGATCCGGAACGTGCGGCGAGTTGGGTTCGTCGGTATATAG 
O20       TTGTTGCGATTGAACAGGAGGATCCGGAGCGTGCGGCGAGTTGGGTTCGTCGGTATATAG 
016       TTGTTGCGATTGAACAGGAGGATCCGGAGCGTGCGGCGAGTTGGGTTCGTCGGTATATAG 
O6        CTGTCGTCATCGAGCGGCATGATCCTTCGCAGGCGGCGGAGTGGGGCGAGAAATATATAG 
O13       CCGTGATCTTTGAAAAGCACGATCCCGGTCAGGCGGCTGACTGGGGGCGTAGATATATAA 
O14       CCGTGATCTTTGAAAAGCACGATCCCGGTCAGGCGGCTGACTGGGGGCGTAGATATATAA 
O4        TGATTTCTGCTGTAGCTCATGAGTCGGATACAGCAGCTTATTTAGTTGACTCTTATATTG 
O12       TAATAGTAGCTAGGCAAGGTAATCCAGAGTTAGCTGCTGAGTGGGTAAAAAAATATCTTG 
O12b      TAATAGTAGCTAGGCAAGGTAATCCAGAGTTAGCTGCTGAGTGGGTAAAAAAATATCTTG 
RO11       CGGTAATTGTGGAGGGCACGAAGCGAGAGGTTCTTGCTACATGGGCACAAGCTTTCGTGC 
R017       CGGTAATTGTGGAGGGCACGAAGCGAGAGGTTCTTGCTACATGGGCACAAGCTTTCGTGC 
O3        CCGTTGTGTTTGACCGACACGATCCTGAACAAGCTGCAAAATGGGCGAAACAATACATCG 
O15       CCGTTGTGTTTGACCGACACGATCCTGAACAAGCTGCAAAATGGGCGAAACAATACATCG 
O10       CTGTCATCCTCAACCGACAGGATCCTGAGCAGGCCGCAAAATGGGCTAAGCAATACGCCG 
O19       CTGTCATCCTCAACCGACAGGATCCTGAGCAGGCCGCAAAATGGGCTAAGCAATACGCCG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 155 
O1        CCGATACGGCCGAACATTCCGTCCAAGAAATGGTTAAGAATGCGCACCGTGAGATAGAGG 
O9        AGATGGTGGCGAAGCAGTCTATCGATGAAATGCTTCAGAATGCCCGACGCGAACTAGACG 
O7        ATCTCGCTGCTCAGCGCTCGATGGATGAAATGCGAGGGAACGCTCAGCGTGAACTTGAAG 
O8        ATCTCGCTGCTCAGCGCTCGATGGATGAAATGCGAGGGAACGCTCAGCGTGAACTTGAAG 
O2        CTGATGCGGCCGAGATTTCTATTCAGGAAATGTTGAACAATGCGCATCGCGAGATTGAGG 
O5        CTGATGCGGCCGAGATTTCTATTCAGGAAATGTTGAACAATGCGCATCGCGAGATTGAGG 
018       CTGATGCGGCCGAGATTTCTATTCAGGAAATGTTGAACAATGCGCATCGCGAGATTGAGG 
O20       CTGATGCGGCCGAGATTTCTATTCAGGAAATGTTGAACAATGCGCATCGCGAGATTGAGG 
016       CTGATGCGGCCGAGATTTCTATTCAGGAAATGTTGAACAATGCGCATCGCGAGATTGAGG 
O6        GAATTGCAGTCAAGCGTTCCATGCAGGAAATGCAAGAAGGAGTACGCCGCGAGTTTCAAG 
O13       AGCTGGCTGCCGAAGGCTCCATGAAGGAAATGCAAGACGCCGTGCAGCGAGAGTTTGAGG 
O14       AGCTGGCTGCCGAAGGCTCCATGAAGGAAATGCAAGACGCCGTGCAGCGAGAGTTTGAGG 
O4        AAATGGTCGCCGGAATATCCAAGAATGAAATGCTCAAAAATATTAAAAGAGACTTGCATG 
O12       CCGACGCAGCTGATCGGTCTCTGCAGGAGATGATGGCTAATGCATACCGTGAGATTGAGG 
O12b      CCGACGCAGCTGATCGGTCTCTGCAGGAGATGATGGCTAATGCATACCGTGAGATTGAGG 
O11       GTTTGGCTGCGGATCGGGCCGTGCATGAGGTTATTGATAGTGCAGGTAGAGATTTCCAGG 
017       GTTTGGCTGCGGATCGGGCCGTGCATGAGGTTATTGATAGTGCAGGTAGAGATTTCCAGG 
O3        AACTGGCCGCCCAGCGTTCGATGGATGAAATGCGCGGCAATGCCCAGCGCGAGCTCGAGG 
O15       AACTGGCCGCCCAGCGTTCGATGGATGAAATGCGCGGCAATGCCCAGCGCGAGCTCGAGG 
O10       ATCTAGCTGCTCTGCGCTCGATGGATGAAATGCGAGGTAATGCTCAGCGCGAACTTGAGG 
O19       ATCTAGCTGCTCTGCGCTCGATGGATGAAATGCGAGGTAATGCTCAGCGCGAACTTGAGG 
 
 
O1        TCAAGGCTCGGGATGTCGATCAGCGGATCCAAACGCTACGTGAAACTGCTAAGTTACGCC 
O9        TGAAAGCAAGAAACATGCGTCAGCAGGTAGATATTCTCAAGGAGAGTGCCAAGGAACGTC 
O7        TGAAGGGACGTAACATTCAGCAGCAGATAGACACCTTGCGGCAGGTAGTCAAGGAGCGTC 
O8        TGAAGGGACGTAACATTCAGCAGCAGATAGACACCTTGCGGCAGGTAGTCAAGGAGCGTC 
O2        TCAAGGCTCGAGATATTGAGCAGCGCATACAGAACTTGCGAGAGAATGCCAAGGCAAGAC 
O5        TCAAGGCTCGAGATATTGAGCAGCGCATACAGAACTTGCGAGAGAATGCCAAGGCAAGAC 
018       TCAAGGCTCGAGATATTGAGCAGCGCATACAGAACTTGCGAGAGAATGCCAAGGCAAGAC 
O20       TCAAGGCTCGAGATATTGAGCAGCGCATACAGAACTTGCGAGAGAATGCCAAGGCAAGAC 
016       TCAAGGCTCGAGATATTGAGCAGCGCATACAGAACTTGCGAGAGAATGCCAAGGCAAGAC 
O6        TGAAGAATCGCAATATACAGCAACAGATCGACATCTTGCGTGAAACTGCGAAGGCTCGCC 
O13       TAAAAAGTCGGAATATTCAGCAACAGATAGATATTTTGCGCGATGCGGCGAAGGCGCGTC 
O14       TAAAAAGTCGGAATATTCAGCAACAGATAGATATTTTGCGCGATGCGGCGAAGGCGCGTC 
O4        TAAAAAGTGTGAATCTAGAGCAGCAGATAAATATCATGAGGGCAATGGCCAAGACTCGCA 
O12       TTAAAGCTAGGGATGTTGAACGACGCATTTATGTTTTGCGTGAAACTGCAAAACTGCGTC 
O12b      TTAAAGCTAGGGATGTTGAACGACGCATTTATGTTTTGCGTGAAACTGCAAAACTGCGTC 
O11       TAAGAAATGCTGCAATGCAGAGCCGCATAACCGTGCTGCAGAATATGGCGAAGGGCCGCC 
017       TAAGAAATGCTGCAATGCAGAGCCGCATAACCGTGCTGCAGAATATGGCGAAGGGCCGCC 
O3        TGAAGAGTCGCAACATCCAGCAGCAGATCGACACTCTACGGCAGGTGGTCAAGGAGCGAC 
O15       TGAAGAGTCGCAACATCCAGCAGCAGATCGACACTCTACGGCAGGTGGTCAAGGAGCGAC 
O10       TGAAGAGCCGCAATATTCTGCAGCAGATCGACACCCTGCGGCAGGTGGTCAAAGAGCGTC 
O19       TGAAGAGCCGCAATATTCTGCAGCAGATCGACACCCTGCGGCAGGTGGTCAAAGAGCGTC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 156 
O1        GTGAAGATAGAATTGTGCAACTTAGAGAGGCTCTAAAAGTCGCGGATGCTGTGGGGTTGG 
O9        GTGCGGACCGAATTACTCAGCTCAAGGAAGCTCTGGCCATCGCCAAGGCTTTGAATCTTG 
O7        GTACTGACCGCATCGCTCGATTAAAAGAAGCCTTGCAGGTCGCGGAAGCAATAGGTGTGG 
O8        GTACTGACCGCATCGCTCGATTAAAAGAAGCCTTGCAGGTCGCGGAAGCAATAGGTGTGG 
O2        GTGAAGATCGTATTGTTCAGCTCAAGGAGGCGTTGAAGGTCGCGGGTGCGCTGAAATTGG 
O5        GTGAAGATCGTATTGTTCAGCTCAAGGAGGCGTTGAAGGTCGCAGGTGCGCTGAAATTGG 
018       GTGAAGATCGTATTGTTCAGCTCAAGGAGGCGTTGAAGGTCGCAGGTGCGCTGAAATTGG 
O20       GTGAAGATCGTATTGTTCAGCTCAAGGAGGCGTTGAAGGTCGCAGGTGCGCTGAAATTGG 
016       GTGAAGATCGTATTGTTCAGCTCAAGGAGGCGTTGAAGGTCGCAGGTGCGCTGAAATTGG 
O6        GTGAAGATCGTATCTCTCGACTGAAAGAGGCGTTGCGCGTTGCGGAGGCCTTGAAGCTGG 
O13       GTGAAGACCGCATCAATCGTTTGAAAGAAGCTTATCAAATAGCCGAGTCGCTGAAGTTGG 
O14       GTGAAGACCGCATCAATCGTTTGAAAGAAGCTTATCAAATAGCCGAGTCGCTGAAGTTGG 
O4        GGGAGGATACTATCTTGCGCCTGAGGGAAGCTCTGAAAATAGCCGAAGCCCTGAAGATTG 
O12       GAGAGGACCGCATTACTCAACTTCGTGAAGCTTTAAAGGTGGCCGACTCGTTGGGTTTGG 
O12b      GAGAGGACCGCATTACTCAACTTCGTGAAGCTTTAAAGGTGGCCGACTCGTTGGGTTTGG 
O11       GTGATGATAGGATTGCACGTTTGAAGGAGGCATTGCTGATTGCGGAGTCGCTCAAGATAG 
017       GTGATGATAGAATTGCACGTTTGAAGGAGGCATTGCTGATTGCGGAGTCGCTCAAGATAG 
O3        GCACTGACCGCATCGTTCGTCTGAAAGAAGCTTTGCAGGTTGCCGAAGCTGTTGGTGTAG 
O15       GCACTGACCGCATCGTTCGTCTGAAAGAAGCTTTGCAGGTTGCCGAAGCCGTTGGTGTAG 
O10       GTAATGATCGTATCGTCCGTTTGAAAGAGGCTCTGCAGGTTGCCAGAGCAGTGGGGGTAG 
O19       GTAATGATCGTATCGTCCGTTTGAAAGAGGCTCTGCAGGTTGCCAGAGCAGTGGGGGTAG 
 
 
O1        AAAAGCCTCCGATGATAAGTGGGCAGGTATCTGAGCAGCTTTCGGCTATCATGAACGGTA 
O9        TTAAGCCTCCTCTTGTGGAGGGACAGTCTGTCAAGCAGCTCTCTTCTATCATGGATGGGA 
O7        AAAAACCACCTCTTATTGGTCCCCAGGTTGATCAGCAGTTGTCCGCTATAATGGAAGGTA 
O8        AAAAACCACCTCTTATTGGTCCCCAGGTTGATCAGCAGTTGTCCGCTATAATGGAAGGTA 
O2        AGGAGCCTCCACTGATCAGTGGGCAATCCTCTGAGGAGCTCTCGGCTATCATGAATGGAA 
O5        AGGAGCCTCCACTGATCAGTGGGCAATCCTCTGAGGAGCTCTCGGCTATCATGAATGGAA 
018       AGGAGCCTCCACTGATCAGTGGGCAATCCTCTGAGGAGCTCTCGGCTATCATGAATGGAA 
O20       AGGAGCCTCCACTGATCAGTGGGCAATCCTCTGAGGAGCTCTCGGCTATCATGAATGGAA 
016       AGGAGCCTCCACTGATCAGTGGGCAATCCTCTGAGGAACTCTCGGCTATCATGAATGGAA 
O6        AAAATCCTCCGTTGATAGAAGGGCAGGTTGATCAACAGCTTTCCTCCATCATGGAAGGCG 
O13       AAAATCCCCCTTTGATTGGCGGGCAGATGGATCAGCAGCTTTCTTCTATCATGGAGGGAG 
O14       AAAATCCCCCTTTGATTGGCGGGCAGATGGATCAGCAGCTTTCTTCTATCATGGAGGGAG 
O4        AAAATCCACCCTCGTTTGAGGGGCAAACGGAGCGGCAGCTATCTTCGATCATGATCGGGG 
O12       AAAGACCTCCAATAATTAATGACCAGATGCCTGAGCAGCTCTCGGCAATAATGAGCGGTA 
O12b      AAAGACCTCCAATAATTAATGACCAGATGCCTGAGCAGCTCTCGGCAATAATGAGCGGTA 
O11       ATGGCCCGCCATTAATAGAAGGGGCGTCCGAGCAACAACTTTCCTCGATCATGGATGGTG 
017       ATGGCCCGCCATTAATAGAAGGGGCGTCCGAGCAACAACTCTCCTCGATCATGGATGGTG 
O3        AAAAGCCGCCACTCATTGGTTCGCAGATCGATCAGCAATTGTCGGCCATCATGGAAGGCA 
O15       AAAAGCCGCCACTCATTGGTTCGCAGATCGATCAGCAATTGTCGGCCATCATGGAAGGCA 
O10       AAAAACCTCCGCTTATAGGGGCACAGATTGATCAGCAACTGTCGGCAATCATGGAAGGCA 
O19       AAAAACCTCCGCTTATAGGGGCACAGATTGATCAGCAACTGTCGGCAATCATGGAAGGCA 
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O1        GCTTGATGTATATGCGGGGCAGCAAGGCGCTTAGAGGAGAGATCGAGGCTTTGGAAAGTC 
O9        GTCTGACCTACATGCGCGGTACCGAAGCGATTTCCGCGGAAATAAAAGCGTTGGAGTCTC 
O7        GTCTTATGTACATGCGTGGAACAAAAGCTTTGCGCGCCGAGATAAAGGCTTTGGAAGCGC 
O8        GTCTTATGTACATGCGTGGAACAAAAGCTTTGCGCGCCGAGATAAAGGCTTTGGAAGCGC 
O2        GTCTGATGTATATGCGTGGCAGTAAGGCGATTATGGCCGAGATTCAGACATTGGAGGCGC 
O5        GTCTGATGTATATGCGTGGCAGTAAGGCGATTATGGCCGAGATTCAGACATTGGAGGCGC 
018       GTCTGATGTATATGCGTGGCAGTAAGGCGATTATGGCCGAGATTCAGACATTGGAGGCGC 
O20       GTCTGATGTATATGCGTGGCAGTAAGGCGATTATGGCCGAGATTCAGACATTGGAGGCGC 
016       GTCTGATGTATATGCGTGGCAGTAAGGCGATTATGGCCGAGATTCAGACATTGGAGGCGC 
O6        GACTGATGTACATGCGTGGTGCCAAGGCTATTCGGGCAGAAATAAAAACGCTGCAAGATC 
O13       CATTGATGTATATGAGAGGTACCAAGGCCTTGCGGGCAGAAATCAGGGCTTTGGAAGAGC 
O14       CATTGATGTATATGAGAGGTACCAAGGCCTTGCGGGCAGAAATCAGGGCTTTGGAAGAGC 
O4        AACTTATGTATATGCGTGGGGCGAAAGCTCTGCGGGCAGAGATATCTAGTTTAGAGGCGC 
FO12      ATCTTATGTATATGCGAGGAAGTAAAGCATTGAAAGAGGAAATCCTGGTTCTGGAAGCGC 
O12b      ATCTTATGTATATGCGAGGAAGTAAAGCATTGAAAGAGGAAATCCTGGTTCTGGAAGCGC 
O11       ACTTGATGTACATGCGAGGAGCTAAGGCGCTGCGCGCTGAAATCAACAATCTTGAGTCGC 
017       ACTTGATGTACATGCGAGGAGCTAAGGCGCTGCGCGCTGAAATCAACAATCTTGAGTCGC 
O3        GCCTCATGTATATGAGGGGGTCGAGAGCTCTTAGGGCCGAGATAGAAGCTTTGGAGGCTC 
O15       GCCTCATGTATATGAGGGGGTCGAGAGCTCTTAGGGCCGAGATAGAAGCTTTGGAGGCTC 
O10       GTCTGATGTATATGAGAGGGACGAAAGCGCTGGAGGCTGAAATCAAAGCCTTGGAAAAAC 
O19       GTCTGATGTATATGAGAGGGACGAAAGCGCTGGAGGCTGAAATCAAAGCCTTGGAAAAAC 
 
 
O1        GTGTGTCAGATGATCCTTTCATCCCTGCTTTACGAACTCTGCAGGAGCAGGAAAAACTCT 
O9        GTGTTTCTGATGATCCATTTATTCCTCAGTTGAGAGGGCTGGAGGAGCGATACAAACTCT 
O7        GTACTTCGGATGATCCTTTTATACCTGCTTTACGTGGTCTGCAAGAACAATTGGCTCTCT 
O8        GTACTTCGGATGATCCTTTTATACCTGCTTTACGTGGTCTGCAAGAACAATTGGCTCTCT 
O2        GTAGCTCTGATGATCCTTTTATTCCGGCGTTGCGTACTCTTCAGGAGCAGCAGTTATTGC 
O5        GTAGCTCTGATGATCCTTTTATTCCGGCGTTGCGTACTCTTCAGGAGCAGCAGTTATTGC 
018       GTAGCTCTGATGATCCTTTTATTCCGGCGTTGCGTACTCTTCAGGAGCAGCAGTTATTGC 
O20       GTAGCTCTGATGATCCTTTTATTCCGGCGTTGCGTACTCTTCAGGAGCAGCAGTTATTGC 
016       GTAGCTCTGATGATCCTTTTATTCCGGCGTTGCGTACTCTTCAGGAACAGCAGTTATTGC 
O6        GTGTCTCCGATGATCCTTTCATTCCCGCATTACGAGGCTTGCAGGAGAAGTATGCTCTTC 
O13       GAACGTCGGACGATCCATTCATTCCTGCTTTGCGAAATTTGCAAGAAAAGCAAGCTATGT 
O14       GAACGTCGGACGATCCATTCATTCCTGCTTTGCGAAATTTGCAAGAAAAGCAAGCTATGT 
O4        GTGAGTCTGATGATTCTTTCATCGGCGGATTGAGAGCTTTGCAGGAAAGATATGCTCTTT 
FO12       GAACTTCGGATGATCCTTTTATTCCAGCTTTAAGGACTTTGCAGGAGTTGGAGTCGCTAT 
O12b      GAACTTCGGATGATCCTTTTATTCCAGCTTTAAGGACTTTGCAGGAGTTGGAGTCGCTAT 
O11       GTAGTGTAGATGCTCCATTCATTCCTGAGTTGAGAACTCTCCAAGAGAAACTATCTTGGA 
017       GTAGTGTAGATGCTCCATTCATTCCTGAGTTGAGAACTCTCCAAGAGAAACTATCTTGGA 
O3        GTACATCGGACGATCCATTCATTCCTGCGCTGCGTGGTCTGCAGGAGCAACTCGCTCTGT 
O15       GTACATCGGACGATCCATTCATTCCTGCGCTGCGTGGTCTGCAGGAGCAACTCGCTCTGT 
O10       GGACGTCGGATGATCCATTCATTCCCGCCTTGCGTGGTCTACAAGAGCAGCTTGCTCTTT 
O19       GGACGTCGGATGATCCATTCATTCCCGCCTTGCGTGGTCTACAAGAGCAGCTTGCTCTTT 
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O1        ATAGTAGTTTACGGGTAAACACCGACGAGGTTGCTGTGTTCCGTCAGGATGGTTCGGTTG 
RO9       ATGAGAACATGAGCCCGGAAGTGCAGCGTATAGCTGTATTCCGACAAGATGGCGCTGTGG 
O7        ATGAAAATGAAAAATTGAACTTCGATAGAGTCGCCGTCTTTCGACAAGATGGGGCTGTAG 
O8        ATGAAAATGAAAAATTGAACTTCGATAGAGTCGCCGTCTTTCGACAAGATGGGGCTGTAG 
O2        TGAGTAGCTTGCGTGTTAATTCGGAGCGGGTTTCTGTTTTTCGACAAGACGGTCCGATAG 
O5        TGAGTAGCTTGCGTGTTAATTCGGAGCGGGTTTCTGTTTTTCGACAAGACGGTCCGATAG 
018       TGAGTAGCTTGCGTGTTAATTCGGAGCGGGTTTCTGTTTTTCGACAAGACGGTCCGATAG 
O20       TGAGTAGCTTGCGTGTTAATTCGGAGCGGGTTTCTGTTTTTCGACAAGACGGTCCGATAG 
016       TGAGTAGCTTGCGTGTTAATTCGGAGCGGGTTTCTGTTTTTCGACAAGACGGTCCGATAG 
FO6       TGGAGGGGCTGACGCTGAATCTCGATAAAGTCGCTGTTTTTCGTCAGGATGGTACGATAG 
O13       ATTCTACTTTGAAATTGGACGTAAATAAGGTCGCGGTATTCAGGCAGGATGGAGTAGCCG 
O14       ATTCTACTTTGAAATTGGACGTAAATAAGGTCGCGGTATTCAGGCAGGATGGAGTAGCCG 
O4        ATACAAAACTATCTCCTGATGAAAGTCAAGTCTCTGTCTATAGAAAAGATGGGGTCGTTG 
O12       ACAGGGGGCTGAGTATCAAGTCTGAGCAGGTCGCAGTTTTTCGTCAGGATGGTGTAGTGG 
O12b      ACAGGGGGCTGAGTATCAAGTCTGAGCAGGTCGCAGTTTTTCGTCAGGATGGTGTAGTGG 
O11       ACTCCAGTTTGTCTGTGGATTCTGATGCGGTCGCTGTCTACAAGGAAGACGAGGGACTCT 
017       ACTCCAGTTTGTCTGTGGATTCTGATGCGGTGGCTGTCTACAAGGAAGACGAGGGACTCT 
O3        ATGAAAGCAAACAACTGAGTTTTGATAGAGTTGCGGTCTTCCGGCAGGACGGAAGCGTAG 
O15       ATGAAAGCAAACAACTGAGTTTTGATAGAGTTGCGGTCTTCCGGCAGGACGGAAGCGTAG 
O10       ATGAAAGTAAACAGTTGAATTTTGATAGAGTTGCGGTTTTTCGCCAAGATGGCGGTGTAG 
O19       ATGAAAGTAAACAGTTGAATTTTGATAGAGTTGCGGTTTTTCGCCAAGATGGCGGTGTAG 
 
 
O1        AGACGCCCGATTCTCCCGTGAAGCCGAAGAAGCTTTTACTCGTCATGATGGGGTTGTTGC 
O9        AAACACCCGATGTACCTGTTAAGCCAAATAAAGTAATGATTGTTTTTTTGGGTGGCGTGC 
O7        AAGCATCTGATGATCCGATTAAGCCGAGGAAAATTCTTATATTAGTTGTGGGAGTTATAT 
O8        AAGCATCTGATGATCCGATTAAGCCGAGGAAAATTCTTATATTAGTTGTGGGAGTTATAT 
O2        AAACGCCGGACTCACCAGTTCGTCCAAGGAGAGCGATGATTTTGATTTTTGGGTTGATAA 
O5        AAACGCCGGACTCACCAGTTCGTCCAAGGAGAGCGATGATTTTGATTTTTGGGTTGATAA 
018       AAACGCCGGACTCACCAGTTCGTCCAAGGAGAGCGATGATTTTGATTTTTGGGTTGATAA 
O20       AAACGCCGGACTCACCAGTTCGTCCAAGGAGAGCGATGATTTTGATTTTTGGGTTGATAA 
016       AAACGCCGGACTCACCAGTTCGTCCAAGGAGAGCGATGATTTTGATTTTTGGGTTGATAA 
O6        AGGTGCCAGATGATCCCGTCCGTCCAAGAAAAGGCATAGTGCTTATCCTAAGCATGCT-- 
O13       AAGTGCCGGATGATCCAGTTCGCCCGAAGAAGGGAATACTTCTAGTGCTGGGTGCGCT-- 
O14       AAGTGCCGGATGATCCAGTTCGCCCGAAGAAGGGAATACTTCTAGTGCTGGGTGCGCT-- 
O4        AAACTTCTGATAAGCCAATAAAGCCGAAGAAATTGATTAT------------AATTGTAC 
O12       AAGTACCTGATTTCCCCGTGAAGCCAAAAAAGCTATTGATCTTATTTGGCGGGGTGATGC 
O12b      AAGTACCTGATTTCCCCGTGAAGCCAAAAAAGCTATTGATCTTATTTGGCGGGGTGATGC 
O11       CTTTTTCAAATCAACCCATTAAGCCGAAGAAGATTCTTATAGTTACTATAGGTACTTTGG 
017       CTTTTTCAAATCAACCCATTAAGCCGAAGAAGATTCTTATAGTTACTATAGGTACTTTGG 
O3        AAACCCCCGATGACCCCATAAAACCGAGAAAGGTTCTCATTCTGGCCTTAGGTATTCTGG 
O15       AAACCCCCGATGACCCCATAAAACCGAGAAAGGTTCTCATTCTGGCCTTAGGTATTCTGG 
O10       AAATTCCTGACGACCCTATCAAGCCAAAAAAGGCTCTCCTCCTTGCTCTTGGTATTTTAG 
O19       AAATTCCTGACGACCCTATCAAGCCAAAAAAGGCTCTCCTCCTTGCTCTTGGTATTTTAG 
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O1        TCGGTGGTGCGGTTGGTGTCGTGACTGTCGTGTTT------------------------- 
O9        TGGGGTTCGTATTGGGGATGATGATTGCTCTCTTTTTGCATGTACTGAGGAAAAGTAGGG 
O7        TGGGCGGATTAATAGGCTGTGGAGTTGCTTTGCTAGGATTCCTCTACCGAGAAAAAAGTG 
O8        TGGGCGGATTAATAGGCTGTGGAGTTGCTTTGCTAGGATTCCTCTACCGAGAAAAAAGTG 
O2        TTGGTGGTGTGCTTGGTGGTTTTCTGGCGTTGTGC------------------------- 
O5        TTGGTGGTGTGCTTGGTGGTTTTCTGGCGTTGTGC------------------------- 
018       TTGGTGGTGTGCTTGGTGGTTTTCTGGCGTTGTGC------------------------- 
O20       TTGGTGGTGTGCTTGGTGGTTTTCTGGCGTTGTGC------------------------- 
016       TTGGTGGTGTGCTTGGTGGTTTTCTGGCGTTGTGC------------------------- 
O6        --------------------------------TGC------------------------- 
O13       --------------------------------CTC------------------------- 
O14       --------------------------------CTC------------------------- 
O4        TGGGTGCTGTATTTGGTAT----------------------TTTCCTGGGATGCTTGGTA 
O12       TGGGAGGAATGCTTGGTATGCTTTTTGTTGTAATTCGATTGTTTTATAGGCGAAATGCTA 
O12b      TGGGAGGAATGCTTGGTATGCTTTTTGTTGTAATTCGATTGTTTTATAGGCGAAATGCTA 
O11       CAGGATTGATAATTGGAATTCTACTCGCAGTGCTCGCTGGTTTTATAAGTAAGCTTCGTA 
017       CAGGATTGATAATTGGAATTCTACTCGCAGTGCTCGCTGGTTTTATAAGGAAGCTTCGTA 
O3        CTGGTGGTGTACTGGGTGTATTGGCCGCCTTGCTCCGTCTCCTGTTTCGTGAGAAGCGAC 
O15       CTGGTGGTGTACTGGGTGTATTGGCCGCCTTGCTCCGTCTCCTGTTTCGTGAGAAGCGAC 
O10       CCGGTGGTGTGTTTGGCGTATTGCTTGCCTTGCTCCGCCTATTGTTACGTGATGGGCGAA 
O19       CCGGTGGTGTGTTTGGCGTATTGCTTGCCTTGCTCCGCCTATTGTTACGTGATGGGCGAA 
 
 
O1        --AAT---------------------------------------------TCGCTCTATC 
O9        TCAGT---------------------------------------------TGACTCTGTT 
O7        TTGATAGTGGGGCTTGAGAA------------GTTTGTTGAGAAGTGGACTTGCTTATTT 
O8        TTGATAGTGGGGCTTGAGAA------------GTTTGTTGAGAAGTGGACTTGCTTATTT 
O2        ------------------------------------------------------------ 
O5        ------------------------------------------------------------ 
018       ------------------------------------------------------------ 
O20       ------------------------------------------------------------ 
016       ------------------------------------------------------------ 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        GGCCTGCTACGCATTGTGCA------------G--------------------------- 
O12       AGCTTTCCTAATATCG-------------------------------------------- 
O12b      AGCTTTCCTAATATCG-------------------------------------------- 
O11       GCGATGGCTCGCTTCGCTAA------------G--------------------------- 
017       GCGATGGCTCTCTTCGCTAA------------G--------------------------- 
O3        TCGATATAACGGGCTAAGGGTATTCCCGG---TAGGGTAAATAAAAGGACTTGATATGCA 
O15       TCGATATAACGGGCTAAGGGTATTCCCGG---TAGGGTAAACAAAAGGACTTGATATGCA 
O10       ACGGCATGGCGGACTTAAAGCATCCTATGACCAAGGATAAATGAAGGGATTCGATATGAG 
O19       ACGGCATGGCGGACTTAAAGCATCCTATGACCAAGGATAAATGAAGGGATTCGATATGAG 
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O1        GCAATAAGCGGTAAT-------------TATGGTTGGAATGGGCAGGGACGCCCTATCCG 
O9        CT--TGATGTGGCAT-------------TAGGGAAGAAAAGGGCAGGAA----------- 
O7        TCTTTAGGTGGATATGATCTGTGAGTTCTTTGTATAAAGAAGATAGGATAAGTTTGATTT 
O8        TCTTTAGGTGGATATGATCTGTGAGTTCTTTGTATAAAGAAGATAGGATAAGTTTGATTT 
O2        ------------------------------------------------------------ 
O5        ------------------------------------------------------------ 
018       ------------------------------------------------------------ 
O20       ------------------------------------------------------------ 
016       ------------------------------------------------------------ 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ----------------------------TTTAGGCGCTGAAGTAGCTGA----------- 
O12       ------------------------------TTGTCGGTAAGCTAACTGAGTTTTTGTTTT 
O12b      ------------------------------TTGTCGGTAAGCTAACTGAGTTTTTGTTTT 
O11       ----------------------------TTTTGATCTAAACCCTGATGG----------- 
017       ----------------------------TTTTGATCTAAACCCTGATGC----------- 
O3        GAAGTGAGTGGGTTTCCAGGCACGGTCTTCTCGTTGAAGAAGACCGTGCGTTGTTCTTTC 
O15       GAAGTGAGTGGGTTTCCAGGCACGGTCTTCTCGTTGAAGAAGACCGTGCGTTGTTCTTTC 
O10       GAAATGAACGCA-GTCTAGGTGCGGCCGT-TCGAACAAGAAGGCCGTTTGGTGTTTC--- 
O19       GAAATGAACGCA-GTCTAGGTGCGGCCGT-TCGAACAAGAAGGCCGTTTGGTGTTTC--- 
 
 
O1        GCTGTGCCTCTCATAAAATAAGCCATATCATTCGATATTTTCCCTTTATTTTCTTCGAGC 
O9        ----------------------------------GTAAATTCACTCTA------------ 
O7        CCCGGGCGGCTATTTTTTCTTCTGCTCTTTTGGTGTTGTCTAACTATTATTATCTCTATT 
O8        CCCGGGCGGCTATTTTTTCTTCTGCTCTTTTGGTGTTGTCTAACTATTATTATCTCTATT 
O2        ------------------------------------------------------------ 
O5        ------------------------------------------------------------ 
018       ------------------------------------------------------------ 
O20       ------------------------------------------------------------ 
016       ------------------------------------------------------------ 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ---------------TGGCATAACGCACATCAGGATTATGTC------------------ 
RO12      TTTGTTCGGGGGGAGGAGCTTGAAATGTATGGCGATAATGTCTCGAGGGTAATATGGTTG 
O12b      TTTGTTCGGGGGGAGGAGCTTGAAATGTATGGCGATAATGTCTCGAGGGTAATATGGTTG 
O11       -----------------------CACTTACTGGCATCAGGGT------------------ 
017       -----------------------CACTTACTGGCATCAGGGT------------------ 
O3        TTTTCGCGGATATCAATCAGATCCCCGGCTTATAGCTGTTTCAGGAGGGGCGCTGTTCGC 
O15       TTTTCGCGGATATCAATCAGATCCCCGGCTTATAGCTGTTTCAGGAGGGGCGCTGTTCGC 
O10       ---------GTGATAGTCACGGCCCTAACCTATAGCTGTGTTGGGGTGA--TTTGTTCGC 
O19       ---------GTGATAGTCACGGCCCTAACCTATAGCTGTGTTGGGGTGA--TTTGTTCGC 
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O1        CCATGGCCTT-------------------------------------------------- 
O9        --ATGGCCTG-------------------------------------------------- 
O7        TTTTAGAGTT-------------------------------------------------- 
O8        TTTTAGAGTT-------------------------------------------------- 
O2        ---CGGATTT-------------------------------------------------- 
O5        ---CGGATTT-------------------------------------------------- 
018       ---CGGATTT-------------------------------------------------- 
O20       ---CGGATTT-------------------------------------------------- 
016       ---CGGATTT-------------------------------------------------- 
O6        ---TGGTGGT-------------------------------------------------- 
O13       ---TGGACTC-------------------------------------------------- 
O14       ---TGGACTC-------------------------------------------------- 
O4        ----GATCTC-------------------------------------------------- 
O12       TTGAGCACCA-------------------------------------------------- 
O12b      TTGAGCACCA-------------------------------------------------- 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        GAATGGCGTTATAGATATTTTCGAGTGGGGCGGTAATGCGGAAGAAGACTCTTTGTGTGT 
O15       GAATGGCGTTATAGATATTTTCGAGTGGGGCGGTAATGCGGAAGAAGACTCTTTGTGTGT 
O10       GAGTGGTGTTATAGATATTGTCGAATGGGGCGGTAATGCGAAAGAAGACTCTTTGTGTGT 
O19       GAGTGGTGTTATAGATATTGTCGAATGGGGCGGTAATGCGAAAGAAGACTCTTTGTGTGT 
 
 
O1        ------------------------------------------------------------ 
O9        ------------------------------------------------------------ 
O7        ------------------------------------------------------------ 
O8        ------------------------------------------------------------ 
O2        ------------------------------------------------------------ 
O5        ------------------------------------------------------------ 
018       ------------------------------------------------------------ 
O20       ------------------------------------------------------------ 
016       ------------------------------------------------------------ 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        TTGGCACTCGGCCGGAAGCTATTAAGATGGCCCCAGTCACTCTGGCATTGGCTGGCGATG 
O15       TTGGCACTCGGCCGGAAGCTATTAAGATGGCCCCAGTCACTCTGGCATTGGCTGGCGATG 
O10       TTGGTACGCGGCCGGAGGCTATCAAAATGGCCCCGGTAACCCTGGCATTGGCGGACGATG 
O19       TTGGTACGCGGCCGGAGGCTATCAAAATGGCCCCGGTAACCCTGGCATTGGCGGACGATG 
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O1        ------------------------------------------------------------ 
O9        ------------------------------------------------------------ 
O7        ------------------------------------------------------------ 
O8        ------------------------------------------------------------ 
O2        ------------------------------------------------------------ 
O5        ------------------------------------------------------------ 
018       ------------------------------------------------------------ 
O20       ------------------------------------------------------------ 
016       ------------------------------------------------------------ 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        ACCGTTTCGAGGCGCGGGTGTGCGTTACCGGGCAACATCGCGAGATGCTTGATCAGGTCC 
O15       ACCGTTTCGAGGCGCGGGTGTGCGTTACCGGGCAACATCGCGAGATGCTTGATCAGGTCC 
O10       ATCGTTTCGAGGCGAGGGTATGCGTTACCGGCCAGCATCGTGAGATGCTTGACCAAGTCT 
O19       ATCGTTTCGAGGCGAGGGTATGCGTTACCGGCCAGCATCGTGAGATGCTTGACCAAGTCT 
 
 
O1        ------TTCTGGAAAA------------------------------------ATGTAAGC 
O9        ------CTGCGATGAAGGAGCGCT---------------------------CATATTGAG 
O7        ------CTCTCAGGGGGGCACCTCAGGTGCGGGATTGTTGGCTCTTGTTCGGGTGTTTGC 
O8        ------CTCTCAGGGGGGCACCTCAGGTGCGGGATTGTTGGCTCTTGTTCGGGTGTTTGC 
O2        ------TTTTGAAGAAGTATGCTCGTTAGGAAAGAGCTAGTTATTGAAGTGGTGACGCGT 
O5        ------TTTTGAAGAAGTATGCTCGTTAGGAAAGAGCTAGTTATTGAAGTGGTGACGCGT 
018       ------TTTTGAAGAAGTATGCTCGTTAGGAAAGAGCTAGTTATTGAAGTGGTGACGCGT 
O20       ------TTTTGAAGAAGTATGCTCGTTAGGAAAGAGCTAGTTATTGAAGTGGTGACGCGT 
016       ------TTTTGAAGAAGTATGCTCGTTAGGAAAGAGCTAGTTATTGAAGTGGTGACGCGT 
O6        ------TTTTTGGGGGTTGCGGTGGCTCTAGCCATCCTTATGGTGAGAGGTGGGTTTAGG 
O13       ------GTTTGGGGAGTGATGATTGCTTTCATCGTTATGGCCGTTAGAAG--------GT 
O14       ------GTTTGGGGAGTGATGATTGCTTTCATCGTTATGGCCGTTAGAAG--------GT 
O4        ------TGGAGCAGATTGAGCTGTGCCGATTTTTTTGAACTTATTTGCTTGAG---GGAT 
O12       ------ATGAAAGGTGTGTGCGGTTACGAATGTTGTGAAGTTGAAGGTTAAGATGCGAAG 
O12b      ------ATGAAAGGTGTGTGCGGTTACGAATGTTGTGAAGTTGAAGGTTAAGATGCGAAG 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        TAAATCTCTTCAAGATC-GTCCCTGACTTCGATCTCAATATTATGCGTACAGGTCAGGAT 
O15       TAAATCTCTTCAAGATCAGTCCCTGACTTCGATCTCAATATTATGCGTACAGGTCAGGAT 
O10       TGAATCTCTTCAAGATC-GTCCCTGACTTCGATCTCAATATCATGCGTTCGGGGCAGGAT 
O19       TGAATCTCTTCAAGATC-GTCCCTGACTTCGATCTCAATATCATGCGTTCGGGGCAGGAT 
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O1        ACTCCTTTTGTTAAG------------TAGGTGGAGAAGCTGGAACACTTTTCTATTGAA 
O9        ATCATTTTTATTTTG------------CGGGCG-----------------------TGTG 
O7        AGTATTTTTGCTGTGTTCACAACTTTTTAGGCCTGTTTTACGCAGTTCATTCAGGTTGGA 
O8        AGTATTTTTGCTGTGTTCACAACTTTTTAGGCCTGTTTTACGCAGTTCATTCAGGTTGGA 
O2        TGCACGTACTTTGGTCGAGTAATTTTGTGGAGTAGGTTTTCGTTGGGTGGCTCGATTGCT 
O5        TGCACGTACTTTGGTCGAGTAATTTTGTGGAGTAGGTTTTCGTTGGGTGGCTCGATTGCT 
018       TGCACGTACTTTGGTCGAGTAATTTTGTGGAGTAGGTTTTCGTTGGGTGGCTCGATTGCT 
O20       TGCACGTACTTTGGTCGAGTAATTTTGTGGAGTAGGTTTTCGTTGGGTGGCTCGATTGCT 
016       TGCACATGCTTTGGTCGAGTAATTTTGTGGAGTAGGTTTTCGTTGGGTGGCTCGATTGCT 
O6        CGCACGGTCGATGCTGCATGAGTTTTTTG------------------------------- 
O13       CTCGCGCAAAATAGTCTATATATTTACTG------------------------------- 
O14       CTCGCGCAAAATAGTCTATATATTTACTG------------------------------- 
O4        ATGGCTTGAGCTTGGCTAGGAATACTTTTTGGAACTTTTTAG-------------G---- 
O12       GGGGCATGTCTTAGCATCGGAAGGCCATTTGAGATTTTCTTGTGCTATCATAGTAA---- 
O12b      GGGGCATGTCTTAGCATCGGAAGGCCATTTGAGATTTTCTTGTGCTATCATAGTAA---- 
O11       -TTACTTGTTGTAGTTGTTGAATTGTATTAGGGGGTGTCGAGTAGAATGTCAATAA---- 
017       -TTACTTGTTGTAGTTGTTGAATTGTATTAGGGGGTATCGAGTAGAATGTCAATAA---- 
O3        CTGACTGATATCACTGTCGCCATTCTGCAAGGAATGAAAGAGGTTTTCGCCCAGTTCAAA 
O15       CTGACTGATATCACTGTCGCCATTCTGCAAGGAATGAAAGAGGTTTTCGCCCAGTTCAAA 
O10       CTGACTGATGTAACTGTTGCCATTCTGCAAGGAATGAAAGACGTTTTCTCTCAGTTCAAG 
O19       CTGACTGATGTAACTGTTGCCATTCTGCAAGGAATGAAAGACGTTTTCTCTCAGTTCAAG 
 
 
O1        GGGGATG----------------------------------------------------- 
O9        GGCGGTA----------------------------------------------------- 
O7        GGAGATA----------------------------------------------------- 
O8        GGAGATA----------------------------------------------------- 
O2        GAGGGGT----------------------------------------------------- 
O5        GAGGGGT----------------------------------------------------- 
018       GAGGGGT----------------------------------------------------- 
O20       GAGGGGT----------------------------------------------------- 
016       GAGGGGT----------------------------------------------------- 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        CCCGATATTATCCTTGTCCACGGCGATACAGCCACCACATTGGCTGCTAGCCTTGCGGCC 
O15       CCCGATATTATCCTTGTCCACGGCGATACAGCCACCACATTGGCTGCTAGCCTTGCGGCC 
O10       CCCGATATCGTTCTTGTCCATGGCGATACAGCCACGACGTTGGCTGCTAGCCTTGCTGCT 
O19       CCCGATATCGTTCTTGTCCATGGCGATACAGCCACGACGTTGGCTGCTAGCCTTGCTGCT 
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O1        ------------------------------------------------------------ 
O9        ------------------------------------------------------------ 
O7        ------------------------------------------------------------ 
O8        ------------------------------------------------------------ 
O2        ------------------------------------------------------------ 
O5        ------------------------------------------------------------ 
018       ------------------------------------------------------------ 
O20       ------------------------------------------------------------ 
016       ------------------------------------------------------------ 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        TATTACCATCAAATTCCTGTTGCCCATGTCGAAGCAGGTTTACGGACAGGGAACATGTAT 
O15       TATTACCATCAAATTCCTGTTGCCCATGTCGAAGCAGGTTTACGGACAGGGAACATGTAT 
O10       TATTATCATCAGATCCCGGTTGCCCATGTCGAGGCGGGATTGCGGACAGGGAACATGTAT 
O19       TATTATCATCAGATCCCGGTTGCCCATGTCGAGGCGGGATTGCGGACAGGGAACATGTAT 
 
 
O1        ------------------------------------AGCAGTGATCCTGCATTCATTTTC 
O9        ------------------------------------GGGCATGATCCTTGCTCGCCTTTC 
O7        ------------------------------------TTAGTTCTTGCTTTTCTGATTTTC 
O8        ------------------------------------TTAGTTCTTGCTTTTCTGATTTTC 
O2        ------------------------------------GAGAACGTTTCCATGCGGTGTTTC 
O5        ------------------------------------GAGAACGTTTCCATGCGGTGTTTC 
018       ------------------------------------GAGAACGTTTCCATGCGGTGTTTC 
O20       ------------------------------------GAGAACGTTTCCATGCGGTGTTTC 
016       ------------------------------------GAGAACGTTTCCATGCGGTGTTTC 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        TCGCCCTGGCCAGAGGAAGGTAATCGCAAATTAACCGGAGCCCTGGCCTGTCTCCATTTC 
O15       TCGCCCTGGCCAGAGGAAGGTAATCGCAAATTAACCGGAGCCCTGGCCTGTCTCCATTTC 
O10       TCTCCGTGGCCTGAAGAGGGCAATCGGAAATTAACTGGTGCCTTAGCCTGTCTTCACTTT 
O19       TCTCCGTGGCCTGAAGAGGGCAATCGGAAATTAACTGGTGCCTTAGCCTGTCTTCACTTT 
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O1        GCTCCGGATAACGTTGTTGAACGGATG--------------------------------- 
O9        GCGTCTGCTGA--ATGTGGGGTTGAGG--------------------------------- 
O7        GGGCTTCTTGTTATTTTGTTAAAGACGATGTTTAGCCAAGAAGGAGATTGGATGTATGTA 
O8        GGGCTTCTTGTTATTTTGTTAAAGACGATGTTTAGCCAAGAAGGAGATTGGATGTATGTA 
O2        CTCAGCTCTGTCTCCTGTGCCTTGGCTCCTTGAACGCAGAGGTTAACAGTTGAGCTGTGG 
O5        CTCAGCTCTGTCTCCTGTGCCTTGGCTCCTTGAACGCAGAGGTTAACAGTTGAGCTGTGG 
018       CTCAGCTCTGTCTCCTGTGCCTTGGCTCCTTGAACGCAGAGGTTAACAGTTGAGCTGTGG 
O20       CTCAGCTCTGTCTCCTGTGCCTTGGCTCCTTGAACGCAGAGGTTAACAGTTGAGCTGTGG 
016       CTCAGCTCTGTCTCCTGTGCCTTGGCTCCTTGAGCGCAGAGGTTAACAGTTGAGCTGTGG 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        GCTCCCACCGAGACCTCCAAAGACAATCTGCTCAGGGAAGGGATAGCGGCCGAACAGATC 
O15       GCTCCCACCGAGACCTCCAAAGACAATCTGCTCAGGGAAGGGATAGCGGCCGAACAGATC 
O10       GCTCCAACGGAGACTTCTAGGGACAACTTGCTTAGGGAAGGGATATCCGCCGAGCGAATT 
O19       GCTCCAACGGAGACTTCTAGGGACAACTTGCTTAGGGAAGGGATATCCGCCGAGCGAATT 
 
 
O1        ---------------GTAGCGCCTCTAGCGTCCAACGGGGAACGCTGGGGTCTAG----- 
O9        ---------------GCTGTAACCCTTATCTC--------------GAAGTTCGC----- 
O7        AATACCTTGATGTGCGCTATACCATTGTTACTTCTAAGGGTTCGCGAGAATTTGGCGCGA 
O8        AATACCTTGATGTGCGCTATACCATTGTTACTTCTAAGGGTTCGCGAGAATTTGGCGCGA 
O2        TTGTGGGTATGTGACGTCTGTTGCGGTGGTGTCTGGTTCCTGGTGTCGGGTGTGCGAGAA 
O5        TTGTGGGTATGTGACGTCTGTTGCGGTGGTGTCTGGTTCCTGGTGTCGGGTGTGCGAGAA 
018       TTGTGGGTATGTGACGTCTGTTGCGGTGGTGTCTGGTTCCTGGTGTCGGGTGTGCGAGAA 
O20       TTGTGGGTATGTGACGTCTGTTGCGGTGGTGTCTGGTTCCTGGTGTCGGGTGTGCGAGAA 
016       CTGTGGGTATGTGACGTCTGTTGCGGTGGTGTCTGGTTCCTGGTGTCGGGTGTGCGAGAA 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        GTTGTGACAGGAAATACCGTTATCGATGCATTGCTGAGTGTTGTCCAGCGATTAAGACAC 
O15       GTTGTGACAGGAAATACCGTTATCGATGCATTGCTGAGTGTTGTCCAGCGATTAAGACAC 
O10       CGTGTGACCGGAAATACTGTTATCGATGCCTTGTTAAATGTTGTGCAACGCTTGGAGCAA 
O19       CGTGTGACCGGAAATACTGTTATCGATGCCTTGTTAAATGTTGTGCAACGCTTGGAGCAA 
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O1        -------------------------------------------TCAATTTTTTGACTGTT 
O9        -------------------------------------------TCTTTTGTTTTTCCTTG 
O7        TTTA-------------------------------------TATTTTTCTTTGAGTGTTG 
O8        TTTA-------------------------------------TATTTTTCTTTGAGTGTTG 
O2        GATG-------------------------------------CCAAGTTGCCTGGCAGGTC 
O5        GATG-------------------------------------CCAAGTTGCCTGGCAGGTC 
018       GATG-------------------------------------CCAAGTTGCCTGGCAGGTC 
O20       GATG-------------------------------------CCAAGTTGCCTGGCAGGTC 
016       GATG-------------------------------------CCAAGTTGCCTGGCAGGTC 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        GATGTGGTGCTTGCTCGCCAAGCGGCGGCTCCGACCGAGTTTCTCGATTCCTCCCGCAAG 
O15       GATGTGGTGCTTGCTCGCCAAGCGGCGGCTCCGACCGAGTTTCTCGATTCCTCCCGCAAG 
O10       GATATGGAGCTTGCCAGCGAGGCGGCGGCTCCGACTGAGTTTCTTGACTCCTCACGCAGG 
O19       GATATGGAGCTTGCCAGCGAGGCGGCGGCTCCGACTGAGTTTCTTGACTCCTCACGCAGG 
 
 
O1        TCTGCGGTCAGTAGCCAGCAAGGCTGGGGCTCAATCATGGGATTCTTCCAGAGTCAAGCA 
O9        CTCGTTACCTCACGCCTACGGAGCTCGGGCT----------------------------- 
O7        CCTGCTTGTTTTGGTTCTTCAGGTTGTGGGTGAGTTTTTTATTTATTTCTATGGGAAGAG 
O8        CCTGCTTGTTTTGGTTCTTCAGGTTGTGGGTGAGTTTTTTATTTATTTCTATGGGAAGAG 
O2        GTTACGTGTCGTAGCCGTATTCGAAGCTCGGCAATCGCGGGGTGATTTACAGGACTGTGC 
O5        GTTACGTGTCGTAGCCGTATTCGAAGCTCGGCAATCGCGGGGTGATTTACAGGACTGTGC 
018       GTTACGTGTCGTAGCCGTATTCGAAGCTCGGCAATCGCGGGGTGATTTACAGGACTGTGC 
O20       GTTACGTGTCGTAGCCGTATTCGAAGCTCGGCAATCGCGGGGTGATTTACAGGACTGTGC 
016       GTTGCGTGTTGTAGCCGTATTCGAAGCTCGGCAATCGCGGGGTGATTTACAGGACTGTGC 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        TTCGTCCTCGTCACCGGTCATCGCCGCGAAAGCTTCGGAGGAGGTTTCGAGAGAATCTGC 
O15       TTCGTCCTCGTCACCGGTCATCGCCGCGAAAGCTTCGGAGGAGGTTTCGAGAGAATCTGC 
O10       TTCATTCTTGTCACTGGCCATCGCCGTGAAAGCTTTGGCGGAGGTTTCGAACGCATCTGT 
O19       TTCATTCTTGTCACTGGCCATCGCCGTGAAAGCTTTGGCGGAGGTTTCGAACGCATCTGT 
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O1        GCTTATCGAAGGAAGAGACTGTATATAATCGAACGGATTGGCG----------------- 
O9        ------------------------------GTATGGACTTTTA----------------- 
O7        TCTTTGGGAGAATAAGGCTTTTATCGGAGGGTTGGGGAATCCGTCGAGCTTTGGAATTCT 
O8        TCTTTGGGAGAATAAGGCTTTTATCGGAGGGTTGGGGAATCCGTCGAGCTTTGGAATTCT 
O2        TTAATACGGCGCAGGCTTGGTCAGGGTCGAGTCGGGTCTTCGGGTGTCAACTGGATCGTG 
O5        TTAATACGGCGCAGGCTTGGTCAGGGTCGAGTCGGGTCTTCGGGTGTCAACTGGATCGTG 
018       TTAATACGGCGCAGGCTTGGTCAGGGTCGAGTCGGGTCTTCGGGTGTCAACTGGATCGTG 
O20       TTAATACGGCGCAGGCTTGGTCAGGGTCGAGTCGGGTCTTCGGGTGTCAACTGGATCGTG 
016       TTAATACGGCGCAGGCTTGGTCAGGGCCGAGTCGGGTCTTCGGGTGTCAACTGGATCGTG 
O6        ---------------------------CTTGTAGGGTCGGCAGAAGTTTAT--------- 
O13       ---------------------------CTATTTGGATTTTTGGATATTCA---------- 
O14       ---------------------------CTATTTGGATTTTTGGATATTCA---------- 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        CGGGCCTTGGCCGAGGTCGCCAGAAATCACCCGGAGATCGATATCGTCTATCCGGTTCAC 
O15       CGGGCCTTGGCCGAGGTCGCCAGAAATCACCCGGAGATCGATATCGTCTATCCGGTTCAC 
O10       CAAGCACTGGGCGTGGTTGCAAGGAATCACCCAGAGATCGATATTGTTTATCCCGTTCAT 
O19       CAAGCACTGGGCGTGGTTGCAAGGAATCACCCAGAGATCGATATTGTTTATCCCGTTCAT 
 
 
O1        GTATGGCTCGTCTTGCCAGTGATGCTAGCTGTGACAAGGCAGGTAGGTTACCCTTTGCCT 
O9        GTGGCAGTCGTC------------------------------------------------ 
O7        TTGTGACTTGTTAATTGCCTATTTGTTGTTCTGGCGTAAAAAATCGTTTTATTCTTTCTT 
O8        TTGTGACTTGTTAATTGCCTATTTGTTGTTCTGGCGTAAAAAATCGTTTTATTCTTTCTT 
O2        CGAAAACCGGTTTCGTGGATGCTGATAAGCTCGGCTTGACTGGCAGTCCAGGGCGGTTAC 
O5        CGAAAACCGGTTTCGTGGATGCTGATAAGCTCGGCTTGACTGGCAGTCCAGGGCGGTTAC 
018       CGAAAACCGGTTTCGTGGATGCTGATAAGCTCGGCTTGACTGGCAGTCCAGGGCGGTTAC 
O20       CGAAAACCGGTTTCGTGGATGCTGATAAGCTCGGCTTGACTGGCAGTCCAGGGCGGTTAC 
016       CGAAAACCGGTTTCGTGGATGCTGATAAGCTCGGCTTGACTGGCAGTCCAGGGCGGTTAC 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        CTGAATCCGAACGTACGGGAACCAGTAAATCGGCTTCTCTCCGGTGTCGAGAATATTCAT 
O15       CTGAATCCGAACGTACGGGAACCAGTAAATCGGCTTCTCTCCGGTGTCGAGAATATTCAT 
O10       CTGAATCCGAATGTACGAGAGCCGGTCAATCGTCTACTTTCAGATGTTCAGAACATTCAT 
O19       CTGAATCCGAATGTACGAGAGCCGGTCAATCGTCTACTTTCAGATGTTCAGAACATTCAT 
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O1        AGCGGGGCGAGCCTTGTACTTCAAAG---------------------------------- 
O9        ----GCGTATGCTTTGTATTTTGTCG---------------------------------- 
O7        CGCATTTTTTTTATTGTGTGCTGGAGTCGTCATGACTAGCAGCATGCTGCCGGTGCTTCT 
O8        CGCATTTTTTTTATTGTGTGCTGGAGTCGTCATGACTAGCAGCATGCTGCCGGTGCTTCT 
O2        CAGGTCTGTGGAGGCGCAAAATGTATAGGAGCCTGCGTGAGCTGGGCAGGCTGAAGGCCT 
O5        CAGGTCTGTGGAGGCGCAAAATGTATAGGAGCCTGCGTGAGCTGGGCAGGCTGAAGGCCT 
018       CAGGTCTGTGGAGGCGCAAAATGTATAGGAGCCTGCGTGAGCTGGGCAGGCTGAAGGCCT 
O20       CAGGTCTGTGGAGGCGCAAAATGTATAGGAGCCTGCGTGAGCTGGGCAGGCTGAAGGCCT 
016       CAGGTCTGTGGAGGCGCAAAATGTATAGGAGCCTGCGTGAGCTGGGCAGGCTGAAGGCCT 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        CTAATAGAGCCTTTGGACTATCTGCCTTTCATCCACTTGATGAGCCGTGCCCATATCATC 
O15       CTAATAGAGCCTTTGGACTATCTGCCTTTCATCCACTTGATGAGCCGTGCCCATATCATC 
O10       CTTATAGAGCCGTTGGACTATCTCCCTTTCGTTCATTTGATGAGCCGTGCTCATGTTATT 
O19       CTTATAGAGCCGTTGGACTATCTCCCTTTCGTTCATTTGATGAGCCGTGCTCATGTTATT 
 
 
O1        ------------------------------GGCTAGCCTTGGAGTACAAGGCGCAAGCAG 
O9        ------------------------------GCTTCGATTT-------------------- 
O7        TTTGACTTTTATTACCGTTGCTTGGGGAATGCTTCGATCTGGGGTTAAATTTGCAATTCT 
O8        TTTGACTTTTATTACCGTTGCTTGGGGAATGCTTCGATCTGGGGTTAAATTTGCAATTCT 
O2        GCTCGAAAGCGAGTTAGCATTGTGGTCCGGAAGGGCATGGGTGGACCAGAGTGCCGTTCT 
O5        GCTCGAAAGCGAGTTAGCATTGTGGTCCGGAAGGGCATGGGTGGACCAGAGTGCCGTTCT 
018       GCTCGAAAGCGAGTTAGCATTGTGGTCCGGAAGGGCATGGGTGGACCAGAGTGCCGTTCT 
O20       GCTCGAAAGCGAGTTAGCATTGTGGTCCGGAAGGGCATGGGTGGACCAGAGTGCCGTTCT 
016       GCTCGAAAGCGAGTTAGCCTTGTGGTCCGGAAGGGCATGGGTGGACCAGAGTGCCGTTCT 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        CTCACCGATTCCGGTGGAATTCAGGAAGAAGCTCCCTCGTTGGGTAAGCCCGTTCTGGTT 
O15       CTCACCGATTCCGGTGGAATTCAGGAAGAAGCTCCCTCGTTGGGTAAGCCCGTTCTGGTT 
O10       CTCACCGATTCCGGTGGTATTCAGGAGGAAGCGCCTTCGTTAGGTAAGCCCGTTTTGGTC 
O19       CTCACCGATTCCGGTGGTATTCAGGAGGAAGCGCCTTCGTTAGGTAAGCCCGTTTTGGTC 
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O1        ATATCT------------------------------------------------------ 
O9        ------------------------------------------------------------ 
O7        TTGTCTTTCGGTGGCTCTCTTATTTATGGTTTTTTCTGATCAAATTTTAAGTGACCATCT 
O8        TTGTCTTTCGGTGGCTCTCTTATTTATGGTTTTTTCTGATCAAATTTTAAGTGACCATCT 
O2        GCACGGCAAAAGCCAACTTGCTCGGAGGTTCCCTAGCGCCTATGATTACGACGCCCTTCA 
O5        GCACGGCAAAAGCCAACTTGCTCGGAGGTTCCCTAGCGCCTATGATTACGACGCCCTTCA 
018       GCACGGCAAAAGCCAACTTGCTCGGAGGTTCCCTAGCGCCTATGATTACGACGCCCTTCA 
O20       GCACGGCAAAAGCCAACTTGCTCGGAGGTTCCCTAGCGCCTATGATTACGACGCCCTTCA 
016       GCACGGCAAAAGCCAACTTGCTCGGAGGTTCCCTAGCGCCTATGATTGCGACGCCCTTCA 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        ATGCGTGAGACGACTGAGCGACCCGAGGCGGTTGCCGCAGGGACCGTCAAGCTAGTCGGA 
O15       ATGCGTGAGACGACTGAGCGACCCGAGGCGGTTGCCGCAGGGACCGTCAAGCTAGTCGGA 
O10       ATGCGGGAGACGACGGAGCGCCCGGAGGCTGTTGCCGCAGGAACCGTCAAGTTGGTCGGG 
O19       ATGCGGGAGACGACGGAGCGCCCGGAGGCTGTTGCCGCAGGAACCGTCAAGTTGGTCGGG 
 
 
O1        ------------------------------------------------------------ 
O9        ------------------------------------------------------------ 
O7        TCGTTATAAGTTGGCATCAATGGTTGGGGTGATTGATGGTAGCCAAGCTGATTCATCGGC 
O8        TCGTTATAAGTTGGCATCAATGGTTGGGGTGATTGATGGTAGCCAAGCTGATTCATCGGC 
O2        TTTTTGGCCATTGCCGCCAGGTGCTGTGGAAAGCGACAGTATCCCTTCTTTATCGATCTT 
O5        TTTTTGGCCATTGCCGCCAGGTGCTGTGGAAAGCGACAGTATCCCTTCTTTATCGATCTT 
018       TTTTTGGCCATTGCCGCCAGGTGCTGTGGAAAGCGACAGTATCCCTTCTTTATCGATCTT 
O20       TTTTTGGCCATTGCCGCCAGGTGCTGTGGAAAGCGACAGTATCCCTTCTTTATCGATCTT 
016       TTTTTGGCCATTGCCGCCAGGTGCTGTGGAAAGCGACAGTATCCCTTCTTTATCGATCTT 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        ACGGAAGTCAAGAATATTGTGAATGAACTAGAACGTCTACTGACGGACGAGTCCGCTTAT 
O15       ACGGAAGTCAAGAATATTGTGAATGAACTAGAACGTCTACTGACGGACGAGTCCGCTTAT 
O10       ACAGAAATCAAGAATATAGTTAATGAGCTTGAGCGTTTACTGGTAGATGAATCTGCCTAT 
O19       ACAGAAATCAAGAATATAGTTAATGAGCTTGAGCGTTTACTGGTAGATGAATCTGCCTAT 
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O1        -----TGCTAGCCAGGTCAAAGATACCTGCATCCTGTCAAATGCGCTGTAAGGGAAACAG 
O9        -----------TTATGCATATAGCACGCGTGAAATGCTGAAGTCGCCAGAGGCAAAGCGT 
O7        GTCGGTGTCCGTCAGGGTGAAAATACATAAAGAGTATTTAGAATCTTTGGGGCGTGATGT 
O8        GTCGGTGTCCGTCAGGGTGAAAATACATAAAGAGTATTTAGAATCTTTGGGGCGTGATGT 
O2        GTGAAGATGTCGAGAGTGGTCGCAGAAAGGATTCACTCGACTGACGAATGAATCGTGGAA 
O5        GTGAAGATGTCGAGAGTGGTCGCAGAAAGGATTCACTCGACTGACGAATGAATCGTGGAA 
018       GTGAAGATGTCGAGAGTGGTCGCAGAAAGGATTCACTCGACTGACGAATGAATCGTGGAA 
O20       GTGAAGATGTCGAGAGTGGTCGCAGAAAGGATTCACTCGACTGACGAATGAATCGTGGAA 
016       GTGAAGATGTCGAGAGTGGTCGCAGAAAGGATTCACTCGACTGACGAATGAATCGTGGAA 
O6        --------------------------------------------------AGTCAATGGG 
O13       ------------------------------------------------------AGAGAG 
O14       ------------------------------------------------------AGAGAG 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        CTGCAAATGAGTTTTGCCCATAATCCATACGGTG-------------------------- 
O15       CTGCAAATGAGTTTTGCCCATAATCCATACGGTG-------------------------- 
O10       CGAAAAATGAGTTTTGCCCATAACCCTTACGGTG-------------------------- 
O19       CGAAAAATGAGTTTTGCCCATAACCCTTACGGTG-------------------------- 
 
 
O1        -----------------------------------------------------GGA---- 
O9        -----------------------------------------------------GGGCGTA 
O7        TCCAGGCTTTTTGTTTTATGGGTTTTCAGAACGCTATTATAATGGTGTGGATAGTCAGTT 
O8        TCCAGGCTTTTTGTTTTATGGGTTTTCAGAACGCTATTATAATGGTGTGGATAGTCAGTT 
O2        ------------------------------------------------------------ 
O5        ------------------------------------------------------------ 
018       ------------------------------------------------------------ 
O20       ------------------------------------------------------------ 
016       ------------------------------------------------------------ 
O6        ------------------------------------------------------------ 
O13       ------------------------------------------------------------ 
O14       ------------------------------------------------------------ 
O4        ------------------------------------------------------------ 
O12       ------------------------------------------------------------ 
O12b      ------------------------------------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        ----------------------------------------------ATGGAGAGGCATGC 
O15       ----------------------------------------------ATGGAGAGGCATGC 
O10       ----------------------------------------------ATGGAATGGCGAGT 
O19       ----------------------------------------------ATGGAATGGCGAGT 
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O1        ------GTGTCGGGTGGGTTTGG----------------------CTAGCGACTCCCTGT 
O9        TGTTACGAGATCAGCTGGTTTTG----------------------ACGGCTATTCTCTAT 
O7        GATTACATATCTTTCTAGCTTTGGTTTGTTGGCTTCGGGGGGCTTCTGGTTTTACGCTGT 
O8        GATTACATATCTTTCTAGCTTTGGTTTGTTGGCTTCGGGGGGCTTCTGGTTTTACGCTGT 
O2        ---------------------------------------------------------GAT 
O5        ---------------------------------------------------------GAT 
018       ---------------------------------------------------------GAT 
O20       ---------------------------------------------------------GAT 
016       ---------------------------------------------------------GAT 
O6        ---------------------------------------------------------ATT 
O13       ---------------------------------------------------------CTT 
O14       ---------------------------------------------------------CTT 
O4        ---------------------------------------------------------GGT 
O12       ---------------------------------------------------------GGT 
O12b      ---------------------------------------------------------GGT 
O11       ---------------------------------------------------------GGT 
017       ---------------------------------------------------------GGC 
O3        CAGCGTATTGTTCAGGCTTTGTTG------------------------------------ 
O15       CAGCGTATTGTTCAGGCTTTGTTG------------------------------------ 
O10       AAGCGAATCATTGACAGCCTCTTGGATGCGAAGAGAGGCGAGTAATAGATTGTAAGAGGT 
O19       AAGCGAATCATTGACAGCCTCTTGGATGCGAAGAGAGGCGAGTAATAGATTGTAAGAGGT 
 
 
O1        TCTGTAGTCATGATAACAGGTGGTTCATATAGGTCCTGTTACTACTTGCTGAGATGGAAA 
O9        CTGATTTTCATTCCA--------------------------------------------- 
O7        TTTATCTTTTTGTCGTTCTATTTTTAATTCCTCGCGTGCATCTATTTTTTTTGTTGTAGG 
O8        TTTATCTTTTTGTCGTTCTATTTTTAATTCCTCGCGTGCATCTATTTTTTTTGTTGTAGG 
O2        TTAAGTTCCCGTTGTGCGG--TCGCAGGCGCGGGCAGGTAAAATTGAGGTGAGTTGGA-- 
O5        TTAAGTTCCCGTTGTGCGG--TCGCAGGCGCGGGCAGGTAAAATTGAGGTGAGTTGGA-- 
018       TTAAGTTCCCGTTGTGCGG--TCGCAGGCGCGGGCAGGTAAAATTGAGGTGAGTTGGA-- 
O20       TTAAGTTCCCGTTGTGCGG--TCGCAGGCGCGGGCAGGTAAAATTGAGGTGAGTTGGA-- 
016       TTAAGTTCCCGTTGTGCGG--TCGCAGGCGCGGGCAGGTAAAATTGAGGTGAGTTGGA-- 
O6        TTCAGTTTTCAATCCATCGGATTTTGGTTGAGAACTGTTTTACATGAAGTGAGGTGCGCG 
O13       TACAATTCTGGTTTGGCT---TTATAGTTGGAGGTTCCTT-------------------- 
O14       TACAATTCTGGTTTGGCT---TTATAGTTGGAGGTTCCTT-------------------- 
O4        ACTGATTCC--------TTCCTTGGCGGCGTTGCCTGCTATCGGTTATCTGGCCAG---- 
O12       AATAATTTCGGTTCATTCGCTTGTGCAGAAGCGTTCGTTATCGATTGTTTAGGAAGGAAA 
O12b      AATAATTTCGGTTCATTCGCTTGTGCAGAAGCGTTCGTTATCGATTGTTTAGGAAGGAAA 
O11       GGGGCGTTTTCTACTCCGGTATATCCATGGGCAGCAACTATCTTTTGCC----------- 
017       GGGGCGTTTTCTACTCCGGTATATCCATGGGCAGCAACTATCTTTTGCC----------- 
O3        ---------------GTTTAAGTCTAAGTATTATTTT---------------GGAAAGGA 
O15       ---------------GTTTAAGTCTAAGTATTATTTT---------------GGAAAGGA 
O10       CTCAGAGTATCCGTTGTTTGAGCTTCTCTATGAGTTTTTAGGAATTATAATAGATAGGGA 
O19       CTCAGAGTATCCGTTGTTTGAGCTTCTCTATGAGTTTTTAGGAATTATAATAGATAGGGA 
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O1        TATGGAAAACCTGAGAGAAAAAGTTACTAGAAAGTTCAAGGATAAAGAGGCTCTTGTCGG 
O9        -----------------------------------------------TGTCTTTTGTCGA 
O7        TATTTTTATATTTATAATAGCTT------------------------TCTTGTTTAATAG 
O8        TATTTTTATATTTATAATAGCTT------------------------TCTTGTTTAATAG 
O2        --AAATGATAGATGTTAACACAGTGGTAGAGAAGTTCAAAAGCCGACAGGCCTTGATTGG 
O5        --AAATGATAGATGTTAACACAGTGGTAGAGAAGTTCAAAAGCCGACAGGCCTTGATTGG 
018       --AAATGATAGATGTTAACACAGTGGTAGAGAAGTTCAAAAGCCGACAGGCCTTGATTGG 
O20       --AAATGATAGATGTTAACACAGTGGTAGAGAAGTTCAAAAGCCGACAGGCCTTGATTGG 
016       --AAATGATAGATGTTAACACAGTGGTAGAGAAGTTCAAAAGCCGACAGGCCTTGATTGG 
O6        TTAAATGAAGGATCTGAA------------------------------------GGTTGC 
O13       -----TCATGGATATTAA------------------------------------GGCCGC 
O14       -----TCATGGATATTAA------------------------------------GGCCGC 
O4        ---------AGTTTTGGGGGTCGAGAATTTTGGGCT------------------------ 
O12       TATGAAAAAAGTTTTGGTTACTGGGGCGGATGGGTTTATTGGTTCACATCTCACGGAGTT 
O12b      TATGAAAAAAGTTTTGGTTACTGGGGCGGATGGGTTTATTGGTTCACATCTCACGGAGTT 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        TAGGTTGATGAGTTTCCAGAC---------------------------------TATTTC 
O15       TAGGTTGATGAGTTTCCAGAC---------------------------------TATTTC 
O10       TAAAT--ATGTCTTTCGATAC---------------------------------TATTTC 
O19       TAAAT--ATGTCTTTCGATAC---------------------------------TATTTC 
 
 
O1        GATCGTGGGGTTGGG-------------------CTATGTCGGACTCCCGCTTATGTTGC 
O9        TTTTCATTTTTAACC-------------------TTCTACCGTGGTCCTTTGTCTGGTGG 
O7        GATTCTTGATTATTA-------------------TCCTATGGCATTGTTTTTCTTTTTGA 
O8        GATTCTTGATTATTA-------------------TCCTATGGCATTGTTTTTCTTTTTGA 
O2        TATCGTGGGTCTGGG-------------------TTATGTCGGTTTACCACTGATGCTGC 
O5        TATCGTGGGTCTGGG-------------------TTATGTCGGTTTACCACTGATGCTGC 
018       TATCGTGGGTCTGGG-------------------TTATGTCGGTTTACCACTGATGCTGC 
O20       TATCGTGGGTCTGGG-------------------TTATGTCGGTTTACCACTGATGCTGC 
016       TATCGTGGGTCTGGG-------------------TTATGTCGGTTTACCACTGATGCTGC 
O6        AGTTGTTGGGCTAGG-------------------CTATGTTGGTCTTCCGCTT------- 
O13       TGTTGTCGGGTTGGG-------------------GTATGTTGGGCTACCTCTG------- 
O14       TGTTGTCGGGTTGGG-------------------GTATGTTGGGCTACCTCTG------- 
O4        ----------------------------------TCTGACCTTGTCTTTTGCCATCATTG 
O12       GTTGGTTGGTGAAGGCTATGAAGTAAAAGCTTTGTCTCAATATAATTCTTTTAACTATTG 
O12b      GTTGGTTGGTGAAGGCTATGAAGTAAAAGCTTTGTCTCAATATAATTCTTTTAACTATTG 
O11       ----------------------------------TCTTGCTGCGATTCCTTTTCTCACTA 
017       ----------------------------------TCTTGCTGCGATTCCTTTTCTCACGA 
O3        CGTAATTGGACTTGG-------------------TTACATAGGTCTTCCCACCGCAGCTG 
O15       CGTAATTGGACTTGG-------------------TTACATAGGTCTTCCCACCGCAGCTG 
O10       TGTAATTGGGTTGGG-------------------TTATATTGGTTTACCTACAGCTGCCG 
O19       TGTAATTGGGTTGGG-------------------TTATATTGGTTTACCTACAGCTGCCG 
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O1        GTT------------------ATAATTCAATCGGTTTTAG------------AGTGCTTG 
O9        TTT------------------CTGGCGTTGCTGGTGCTGG------------AACATT-- 
O7        TTTGCATGCTACCTTCGTCTCTTGACCTAAGTAGTCCGCG------------AAATGGTG 
O8        TTTGCATGCTACCTTCGTCTCTTGACCTAAGTAGTCCGCG------------AAATGGTG 
O2        GAT------------------ACAACGCCATTGGTTTCGA------------TGTCTTGG 
O5        GAT------------------ACAACGCCATTGGTTTCGA------------TGTCTTGG 
018       GAT------------------ACAACGCCATTGGTTTCGA------------TGTCTTGG 
O20       GAT------------------ACAACGCCATTGGTTTCGA------------TGTCTTGG 
016       GAT------------------ACAACGCCATTGGTTTCGA------------TGTCTTGG 
O6        --------------------------GCTGTTGAATTTGGTAAAAAACGAACCGTTGTCG 
O13       --------------------------GCTGTGGAGTTTGGAAAGAAGCGATCCGTCACAG 
O14       --------------------------GCTGTGGAGTTTGGAAAGAAGCGATCCGTCACAG 
O4        G--------------------------------------------ATATGCCAGTATATT 
O12       GGGTTGGCTTGAAGATGTTGCTTGTCTTAAGCAAATTGAAGTTTTAAATGGAGATGTACG 
O12b      GGGTTGGCTTGAAGATGTTGCTTGTCTTAAGCAAATTGAAGTTTTAAATGGAGATGTACG 
O11       G----------------------------------------------------------- 
017       G----------------------------------------------------------- 
O3        TTTTCGCTTCTCGACAGAAAAA------------------------------AGTGATTG 
O15       TTTTCGCTTCTCGACAGAAAAA------------------------------AGTGATTG 
O10       TTTTTGCTTCTCGTAGAAAACA------------------------------AGTGATAG 
O19       TTTTTGCTTCTCGTAGAAAACA------------------------------AGTGATAG 
 
 
O1        GCATTGATATCGACGCCGAAAAAGTTAGAA------------------------------ 
O9        --------------------GGAATCAAGA------------------------------ 
O7        GAATAGATAAGGGGATTGAGAAAATTTAAAAGGGTTATTTGCGTCTTAGATTCCTCCGTC 
O8        GAATAGATAAGGGGACTGAGAAAATTTAAAAGGGTTATTTGCGTCTTAGATTCTTCCGTC 
O2        GTATCGATATCGATGATGTCAAGGTTGACA------------------------------ 
O5        GTATCGATATCGATGATGTCAAGGTTGACA------------------------------ 
018       GTATCGATATCGATGATGTCAAGGTTGACA------------------------------ 
O20       GTATCGATATCGATGATGTCAAGGTTGACA------------------------------ 
016       GTATCGATATCGATGATGTCAAGGTTGACA------------------------------ 
O6        GTTTCGATATCAATCAGGGGCGAATCGCTG------------------------------ 
O13       GTTTCGATATAAATCATAGTCGTATTCGAG------------------------------ 
O14       GTTTCGATATAAATCATAGTCGTATTCGAG------------------------------ 
O4        TGACTTGGGTTTATCCAGAGCTGTTATCAG------------------------------ 
O12       CGATCCTCATTATTGCAAAAAAATTACAAA------------------------------ 
O12b      CGATCCTCATTATTGCAAAAAAATTACAAA------------------------------ 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        GTGTTGACGTCAATCAAGCGGCGGTTGATA------------------------------ 
O15       GTGTTGACGTCAATCAAGCGGCGGTTGATA------------------------------ 
O10       GGGTCGATGTAAACTCCAAAGCAGTTGAAA------------------------------ 
O19       GGGTCGATGTAAACTCCAAAGCAGTTGAAA------------------------------ 
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O1        -------GGCTGAATTCCGGTGAAAGCTATATTGAGCATATATCCGCGGAAAGCATTTCT 
O9        -------GGTT--------------------------ATGCGATTGTTGATTGCCTTGTC 
O7        TGACAGGGGCTATGCTTTGAAGATGCAATGGTTGAGTTTATGGCTATTTTAGTTGGGGTC 
O8        TGACAGGGGCTATGCTTTGAAGATGCAATGGTTGAGTTTATGGCTATTTTAGTTGGGGTC 
O2        -------AGCTTAATGCCGGGCAGTGCTATATCGAACATATTCCGCAAGCCAAAATTGCT 
O5        -------AGCTTAATGCCGGGCAGTGCTATATCGAACATATTCCGCAAGCCAAAATTGCT 
018       -------AGCTTAATGCCGGGCAGTGCTATATCGAACATATTCCGCAAGCCAAAATTGCT 
O20       -------AGCTTAATGCCGGGCAGTGCTATATCGAACATATTCCGCAAGCCAAAATTGCT 
016       -------AGCTTAATTCCGGGCAGAGCTATATCGAACATATTCCGCAAGCCAAAATTGCT 
O6        -------AACT---------GCGGCAAGGCATTGACTCTACTCTTGAAGTAGATGCGGCT 
O13       -------ATCT---------GCAGAAAGGGTATGATTCTACTCTTGAGGTCGAAAAGGAA 
O14       -------ATCT---------GCAGAAAGGGTATGATTCTACTCTTGAGGTCGAAAAGGAA 
O4        -----------------------------GGAGGTGGCTCTGAGTT-------------- 
O12       -----------------------------AGATGTTGATGTGGTTTTTCATCTTGCTGCT 
O12b      -----------------------------AGATGTTGATGTGGTTTTTCATCTTGCTGCT 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        -------CCATCAATCGAGGAGAGATTCATATCGTCGAACCTGATCTAGACATGGTGGTG 
O15       -------CCATCAATCGAGGAGAGATTCATATCGTCGAACCTGATCTAGACATGGTGGTG 
O10       -------CTATCAACCAGGGAAAGATTCATATCGTTGAACCGGACTTGGATATGCTCGTC 
O19       -------CTATCAACCAGGGAAAGATTCATATCGTTGAACCGGACTTGGATATGCTCGTC 
 
 
O1        CA---CGCTTGCTCTTCTGGTTTTGAAGCTACGACCGATTTCTCTCGGGCAAAAGAGTGC 
O9        TG---CGCCAACTCTTGCCGGATGGACATTG--------TTCTTCCGGTCAGCGGCTTGG 
O7        TG---TGGGGGCTCTTGTTTTATGGGTGTGC----------------------------- 
O8        TG---TGGGGGCTCTTGTTTTATGGGTGTGC----------------------------- 
O2        AA---GGCCCGTGCAAGCGGTTTCGAGGCTACGACCGATTTCAGCCGTGTCAGTGAATGT 
O5        AA---GGCCCGTGCAAGCGGTTTCGAGGCTACGACCGATTTCAGCCGTGTCAGTGAATGT 
018       AA---GGCCCGTGCAAGCGGTTTCGAGGCTACGACCGATTTCAGCCGTGTCAGTGAATGT 
O20       AA---GGCCCGTGCAAGCGGTTTCGAGGCTACGACCGATTTCAGCCGTGTCAGTGAATGT 
016       AA---GGCCCGTGCAAGCGGTTTCGAGGCCACGACCGATTTCAGCCGTGTCAGTGAATGT 
RO6       GAGTTGAAAGAAGCGTCCGAACTGAGCTTTACTTTCAATCTTCAGGACTTGCAAAAGTGC 
O13       GAGCTGGAAAGTGCTGTACATCTGAAATTTACTTCCACTCTGAGTGAGCTTCAAGAGTGT 
O14       GAGCTGGAAAGTGCTGTACATCTGAAATTTACTTCCACTCTGAGTGAGCTTCAAGAGTGT 
O4        -------------------------------CAGATAAAGGTTCGGAAGTCAACA----- 
O12       CTTATTGCTATTCCATATTCTTATGTGGCTCCGGATAGTTATTTGGAGACCAACGTTAAA 
O12b      CTTATTGCTATTCCATATTCTTATGTGGCTCCGGATAGTTATTTGGAGACCAACGTTAAA 
O11       ------------------------------------------------------------ 
017       ------------------------------------------------------------ 
O3        CATGCTGCCGTGACAGAGGGTTATCTGCGTGCGACCACCAATCCTGAGCCGGCCG----- 
O15       CATGCTGCCGTGACAGAGGGTTATCTGCGTGCGACCACCAATCCTGAGCCGGCCG----- 
O10       CATGCGGCTGTGACTAATGGGTACTTACGAGCAGTTTCTGTACCTGAGCCTGCTG----- 
O19       CATGCGGCTGTGACTAATGGGTACTTACGAGCAGTTTCTGTACCTGAGCCTGCTG----- 
 
Appendix Figure 10. Pseudomonas aeruginosa IATS O-antigen biosynthesis gene 
cluster alignments. Alignments were made with online Clustal W software. Sequences 
belonging to the same R-type are highlighted with the same color. Primer forward sites are 
denoted by F preceding the O type and reverse primer sequences are denoted by R preceding the 
O type. All sequences were retrieved from GenBank. 
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Verification of Group I Pilin Producing Strains 
 
 
  
 Appendix Figure 11. Group I pilO PCR screening assay of clinical isolates. PCR 
screening assay of clinical isolates using pilO specific primers. The first lane contains a DNA 
standard, the next two lanes contain a positive (strain 1244) and negative (strain PA103) control. 
Strains A190-A194 were screened for the presence of the group I specific gene, pilO. Band 
presence allowed for the assignment of group I pilin status. The gel is a 1% agarose gel made 
with 1x TBE and imaged using ethidium bromide and ultraviolet light.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       1244    PA103  A190    A191   A192    A193    A194      EMPTY 
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Appendix Table 2. Infection Type, Group I Status Verification Type, and Pilus Function of 
Children’s Hospital Isolates. Distribution of chronic, acute, and non-respiratory group I pilin 
producing isolates with pilO PCR and 5.44 western blot verification of group I status. Pilus 
function results of twitching motility. 
 
Infection Type Isolate # pilO PCR + 5.44 Western + Twitch + 
Chronic Respiratory A004 Y Y N 
 
A010 Y Y Y 
 
A011 Y Y Y 
 
A035 Y Y N 
 
A036 Y Y Y 
 
A062 Y Y Y 
 
A070 Y Y Y 
 
A085 Y N N 
 
A090 Y Y Y 
 
A093 Y Y N 
 
A127 Y Y N 
 
A136 Y Y N 
 
A137 Y Y Y 
 
A141 Y Y Y 
 
A144 Y Y Y 
 
A146 Y Y Y 
 
A153 Y Y N 
 
A158 Y Y N 
 
A159 Y N Y 
 
A164 Y Y Y 
 
A167 Y Y Y 
 
A172 Y Y Y 
 
A174 Y N N 
 
A175 Y N N 
 
A176 Y Y Y 
 
A178 Y Y N 
 
A181 Y N Y 
 
A185 Y Y Y 
 
A188 Y Y Y 
 
A189 Y N N 
 
A192 Y Y Y 
 
A198 Y Y N 
 
A200 Y N Y 
 
A201 Y N N 
 
A204 Y Y Y 
 
A206 Y N N 
 
A207 Y Y N 
 
A208 Y Y Y 
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Acute Respiratory A001 Y Y N 
 
A005 Y Y Y 
 
A027 Y Y N 
 
A058 Y Y Y 
 
A059 Y Y Y 
 
A060 Y Y Y 
 
A061 Y Y Y 
 
A064 Y Y Y 
 
A066 Y Y Y 
 
A068 Y Y Y 
 
A069 Y Y Y 
 
A074 Y Y Y 
 
A075 Y Y Y 
 
A076 Y Y Y 
 
A078 Y Y N 
 
A080 Y Y Y 
 
A081 Y Y Y 
 
A101 Y Y Y 
 
A107 Y Y Y 
 
A110 Y Y Y 
 
A115 Y Y Y 
 
A118 Y Y Y 
 
A132 Y Y Y 
 
A134 Y Y Y 
 
A145 Y Y Y 
 
A150 Y Y Y 
 
A194 Y Y Y 
 
A199 Y N Y 
Non-respiratory A020 Y Y y 
 
A021 Y Y y 
 
A024 Y Y Y 
 
A028 Y Y Y 
 
A029 Y Y Y 
 
A031 Y Y Y 
 
A032 Y Y Y 
 
A033 Y Y Y 
 
A038 Y Y Y 
 
A040 Y Y Y 
 
A041 Y Y Y 
 
A044 Y Y Y 
 
A048 Y Y Y 
 
A055 Y Y Y 
 
A057 Y Y Y 
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A082 Y Y Y 
 
A084 Y Y Y 
 
A091 Y N N 
 
A099 Y Y Y 
 
A103 Y Y Y 
 
A106 Y Y Y 
 
A108 Y Y Y 
 
A109 Y Y Y 
 
A113 Y Y N 
 
A114 Y Y Y 
 
A116 Y Y Y 
 
A117 Y Y Y 
 
A119 Y Y Y 
 
A122 Y Y Y 
 
A123 Y Y Y 
 
A125 Y Y N 
 
A128 Y Y Y 
 
A130 Y Y Y 
 
A131 Y Y Y 
 
A133 Y Y Y 
 
A168 Y Y N 
 
A170 Y Y Y 
 
A171 Y Y Y 
 
A180 Y Y Y 
 
A182 Y Y Y 
 
A190 Y Y Y 
 
A191 Y N N 
 
A196 Y Y Y 
 
A197 Y Y Y 
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 R-typing Verification of Group I Pilin Producing Strains 
 
 
 
Appendix Figure 12. R-typing PCR Screening Assay of Clinical Isolates. Control 
strains and clinical isolates were run with R4 and R5 PCR primers combined. Strain 577B: 
positive control for R4 type (O4 serotype), PAK: positive control for R5 (O6 serotype). Clinical 
isolates confirmed to be group I as per the pilO PCR assay were then run with the R4 and R5 
primer sets simultaneously. Band presence ~600bp indicate assignment to the R4 type while 
~450bp placed the isolate as R5 type. Lanes 2 and 18 contain 577B, Lanes 3 and 19 contain 
PAK, lane 4- A011, lane 5- A027, lane 6- A038, lane 7- A040, lane 8- A041, lane 9- A055, lane 
10- A060, lane 11- A061, lane 12- A064, lane 13- A075, lane 14- A125, lane 15- A128, lane 16- 
A131, lane 20- A164, lane 21- A167, lane 22- A172, lane 23- A174, lane 24- A176, lane 25- 
A180, lane 26- A181, lane 27- A185, lane 28- A191, lane 29- A196, lane 30- A198, lane 31- 
A200, lane 32- A208. The first lanes in the upper and lower gel contain a DNA size standard. 
 
 
 
 
 
 
 
 
 
 
 
 
       2      3     4    5      6     7    8      9   10    11  12    13   14   15   16 
      18   19   20   21   22   23   24   25   26   27   28   29   30   31   32 
600 bp 
400 bp 
600 bp 
400 bp 
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Appendix Table 3. Group I R-type Information. Group I PCR analysis data for Children’s 
Hospital isolates of R-type based on O-antigen biosynthesis cluster amplification of unique 
sequence regions. R-type with the equivalent O-antigen serotype. - = no reaction, + = slight 
reaction, ++ = moderate reaction, +++ = strong reaction, and ++++ = very strong reaction.  
 
Group I Strain 
R1= 
O1 
R2= 
O5/O2/O16/O18/O20 
R3= 
O3 
R4= 
O4 
R5= 
O6 
R6= 
O7/O8 
R7= 
O9 
R8= 
O10/O19 
R9= 
O11/O17 
R10= 
O12 
R11= 
O13/O14 
A001 - - - - +++ - - - - - - 
A004 - - - ++++ - - - - - - - 
A005 - - - - +++ - - - - - - 
A010 - - - ++++ - - - - - - - 
A011 - - - - - - ++++ - - - - 
A020 - - - - ++ - - - - - - 
A021 - - - - ++++ - - - - - - 
A024 ++++ - - - - - - - - - - 
A027 - - - - ++++ - - - - - - 
A028 - - - +++ - - - - - - - 
A029 - - - - - - - - + - - 
A031 - - - - ++ - - - - - - 
A032 - - - - +++ - - - - - - 
A033 - - - - ++++ - - - - - - 
A035 - - - - +++ - - - - - - 
A036 - - - - +++ - - - - - - 
A038 ++++ - - - - - - - - - - 
A040 - - - - ++++ - - - - - - 
A041 - - - - ++++ - - - - - - 
A044 - - - - ++++ - - - - - - 
A048 - - - - ++++ - - - - - - 
A055 - - - - +++ - - - - - - 
A057 - - - ++++ - - - - - - - 
A058 - - - - - - - +++ - - - 
A059 - - - - ++++ - - - - - - 
A060 - - - - - - - +++ - - - 
A061 - - - - +++ - - - - - - 
A062 - - - +++ - - - - - - - 
A064 - - - - ++++ - - - - - - 
A066 - - - - ++++ - - - - - - 
A068 - - - - ++++ - - - - - - 
A069 - - - - ++++ - - - - - - 
A070 +++ - - - - - - - - - - 
A074 - - - - ++++ - - - - - - 
A075 - - - - ++++ - - - - - - 
A076 - - - ++++ - - - - - - - 
A078 - - - - ++++ - - - - - - 
A080 - - - ++++ - - - - - - - 
A081 - - - ++++ - - - - - - - 
A082 - - - - ++++ - - - - - - 
A084 - - - - - - ++++ - - - - 
A085 - - - - - - ++++ - - - - 
A090 - - - - ++++ - - - - - - 
A091 ++++ - - - - - - - - - - 
A093 - - - - ++++ - - - - - - 
A099 - - - - ++++ - - - - - - 
A101 - - - - ++++ - - - - - - 
A103 - - - ++++ - - - - - - - 
A106 - - - - ++++ - - - - - - 
A107 - - - - ++++ - - - - - - 
A108 - - - - ++++ - - - - - - 
A109 - - - - - - +++ - - - - 
A110 - - - - +++ - - - - - - 
A113 - - - - ++++ - - - - - - 
A114 - - - - ++++ - - - - - - 
A115 - - - - ++++ - - - - - - 
A116 ++++ - - - - - - - - - - 
 181 
A117 - - - ++++ - - - - - - - 
A118 - - - - ++++ - - - - - - 
A119 - - - - ++++ - - - - - - 
A122 - - - - ++++ - - - - - - 
A123 - - - - ++++ - - - - - - 
A124 - - - - ++++ - - - - - - 
A125 - - - - ++++ - - - - - - 
A127 - - - - +++ - - - - - - 
A128 ++++ - - - - - - - - - - 
A130 - - - - +++ - - - - - - 
A131 ++++ - - - - - - - - - - 
A132 - - - - +++ - - - - - - 
A133 - - - - - - - +++ - - - 
A134 - - - - +++ - - - - - - 
A136 - - - - +++ - - - - - - 
A137 - - - - ++++ - - - - - - 
A141 - - - - ++++ - - - - - - 
A144 - - - - ++++ - - - - - - 
A145 - - - - +++ - - - - - - 
A146 - - - - +++ - - - - - - 
A150 - - - - ++++ - - - - - - 
A153 - - - - ++++ - - - - - - 
A158 - - - - - +++ - - - - - 
A159 - - ++++ - - - - - - - - 
A164 - - - - +++ - - - - - - 
A167 ++++ - - - - - - - - - - 
A168 - - - ++++ - - - - - - - 
A170 - - - - +++ - - - - - - 
A171 - - - - ++++ - - - - - - 
A172 - - - - - - - - +++ - - 
A174 ++++ - - - - - - - - - - 
A175 - - ++++ - - - - - - - - 
A176 - - - ++++ - - - - - - - 
A178 - - - - ++++ - - - - - - 
A180 ++++ - - - - - - - - - - 
A181 - - +++ - - - - - - - - 
A182 - +++ - - - - - - - - - 
A185 - - - +++ - - - - - - - 
A188 - - - - ++++ - - - - - - 
A189 - - - - ++++ - - - - - - 
A190 - - - - - ++++ - - - - - 
A191 - - - ++++ - - - - - - - 
A192 - - - - - - ++++ - - - - 
A194 - - - - ++++ - - - - - - 
A196 +++ - - - - - - - - - - 
A197 ++++ - - - - - - - - - - 
A198 - - - - ++++ - - - - - - 
A199 - - +++ - - - - - - - - 
A200 - - - - - - - +++ - - - 
A201 - - - - ++++ - - - - - - 
A204 - - - - ++++ - - - - - - 
A206 - - - - ++++ - - - - - - 
A207 - - - - ++++ - - - - - - 
A208 - - - - - ++ - - - - - 
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Appendix Table 4. Non-group I R-type information. Non-Group I PCR analysis data for 
Children’s Hospital isolates of R-type based on O-antigen biosynthesis cluster amplification of 
unique sequence regions. R-type with the equivalent O-antigen serotype. - = no reaction, + = 
slight reaction, ++ = moderate reaction, +++ = strong reaction, ++++ = very strong reaction, x = 
non-reactive. 
 
Non-
Group I 
Strain 
R1= 
O1 
R2= 
O5/O2/O16/O18/O20 
R3= 
O3 
R4= 
O4 
R5= 
O6 
R6= 
O7/O8 
R7= 
O9 
R8= 
O10/O19 
R9= 
O11/O17 
R10= 
O12 
R11= 
O13/O14 
Non-
reactive 
A002 - - - - - - - - - - - x 
A003 - - - - - - - - - - - x 
A006 ++++ - - - - - - - - - - 
 
A007 - - - - - - - - - - - x 
A008 - +++ - - - - - - - - - 
 
A009 - - ++++ - - - - - - - - 
 
A012 - - - - - - - ++++ - - - 
 
A013 - +++ - - - - - - - - - 
 
A014 - + - - - - - - - - - 
 
A015 - - ++++ - - - - - - - - 
 
A016 - - - +++ - - - - - - - 
 
A017 - - - - - - - - +++ - - 
 
A018 - - - - - - - +++ - - - 
 
A019 - - - - +++ - - - - - - 
 
A022 - ++++ - - - - - - - - - 
 
A023 - - - - - ++++ - - - - - 
 
A025 - - - - ++++ - - - - - - 
 
A026 + - - - - - - - - - - 
 
A030 - - - - ++++ - - - - - - 
 
A034 - ++++ - - - - - - - - - 
 
A037 - - - - - - - - + - - 
 
A039 - - - - - - - +++ - - - 
 
A042 - - - - - - - - + - - 
 
A043 - +++ - - - - - - - - - 
 
A045 - - - - - - - + - - - 
 
A046 - - - - - - - - ++++ - - 
 
A047 - - - - - - - +++ - - - 
 
A049 - - - - - - - - + - - 
 
A050 - - - - - - - - +++ - - 
 
A051 - - - - - - - ++ - - - 
 
A052 - - - - - - - - ++++ - - 
 
A053 - - - - - - - ++++ - - - 
 
A054 - - - - ++++ - - - - - - 
 
A056 - - - - ++++ - - - - - - 
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A063 - - - - - - - - ++++ - - 
 
A065 - - - - - - - +++ - - - 
 
A067 - - - - ++ - - - - - - 
 
A071 - ++++ - - - - - - - - - 
 
A072 - - - - - - - - - - - x 
A073 - +++ - - - - - - - - - 
 
A077 - ++++ - - ++ - - - - - - 
 
A079 - - ++++ - - - - - - - - 
 
A083 - - - - - - - - ++ - - 
 
A086 - - ++++ - - - - - - - - 
 
A087 - ++++ - - - - - - - - - 
 
A088 - - - - +++ - - - - - - 
 
A089 - - - - - - - - +++ - - 
 
A092 - - - - ++++ - - - - - - 
 
A094 - - ++++ - - - - - - - - 
 
A095 - - - - +++ - - - - - - 
 
A096 - - +++ - - - - - - - - 
 
A097 - - - - - - - - +++ - - 
 
A098 - - - - - - - - +++ - - 
 
A100 - - - - - - - - +++ - - 
 
A102 - - - - + - - - - - - 
 
A105 - - - - - - - - ++ - - 
 
A111 - ++ - - - - - - - - - 
 
A112 - - - - - - - - ++++ - - 
 
A120 - - - - - - - - + - - 
 
A121 - - - - - - - - + - - 
 
A126 - - - - - - - - + - - 
 
A129 - - - - - - - ++++ - - - 
 
A135 - ++++ - - - - - - - - - 
 
A138 - - - - - - - - ++ - - 
 
A139 - ++++ - - - - - - - - - 
 
A140 - - - - - - - - +++ - - 
 
A142 - - ++++ - - - - - - - - 
 
A143 - - - - - - - - ++ - - 
 
A147 - - - - - - - - +++ - - 
 
A148 - - - - ++ - - - - - - 
 
A149 - - - - - - - - + - - 
 
A151 - ++ - - - - - - - - - 
 
A152 - +++ - - - - - - - - - 
 
A154 ++++ - - - - - - - - - - 
 
A155 - - - + - - - - - - - 
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A156 - - - - - - - - - - - x 
A157 +++ - - - - - - - - - - 
 
A160 - + - - - - - - - - - 
 
A161 - - - - - - - - - - - x 
A162 - - - - - - - - + - - 
 
A163 - ++ - - - - - - - - - 
 
A165 - - - - - - - ++++ - - - 
 
A166 ++++ - - - - - - - - - - 
 
A169 - - - - +++ - - - - - - 
 
A173 - - - - ++++ - - - - - - 
 
A177 - - - + - - - - - - - 
 
A179 - - - - ++++ - - - - - - 
 
A183 - - +++ - - - - - - - - 
 
A184 - - ++ - - - - - - - - 
 
A186 - - - + - - - - - - - 
 
A187 - - - + - - - - - - - 
 
A193 - - - - - - - - - - - x 
A195 +++ - - - - - - - - - - 
 
A202 - - - - + - - - - - - 
 
A203 - - - - - - - - - - - x 
A205 - - - - - - +++ - - - - 
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Appendix Table 5. R5 group I dot blot reactions with anti-O6 antibodies. Dot blot 
verification for all PCR characterized R5 group I isolates. Anti-O6 monoclonal antibodies 
128.1.1, 2-34-3-7, and 7-72-1 were used against R5 typed strains. Y = reaction and N = no 
reaction. 
 
Strain 128.1.1 2-34-3-7 7-72-1 
A001 Y Y Y 
A005 Y Y Y 
A020 N N N 
A021 N N N 
A027 Y Y Y 
A031 N Y Y 
A032 Y Y Y 
A033 Y Y N 
A035 N N N 
A036 Y Y Y 
A040 Y Y Y 
A041 Y Y Y 
A044 Y Y Y 
A048 Y Y Y 
A055 Y Y Y 
A059 Y Y N 
A061 Y Y N 
A064 Y Y Y 
A066 Y Y N 
A068 Y Y N 
A069 Y Y Y 
A074 Y Y Y 
A075 Y Y Y 
A078 Y Y N 
A082 Y Y N 
A090 Y Y N 
A093 Y Y N 
A099 Y Y Y 
A101 Y Y N 
A106 Y Y Y 
A107 Y N Y 
A108 Y Y Y 
A110 N N N 
A113 Y Y N 
A114 Y Y Y 
A115 Y Y Y 
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A118 Y Y Y 
A119 Y Y N 
A122 Y Y Y 
A123 N N N 
A124 Y Y Y 
A125 Y Y N 
A127 Y Y Y 
A130 Y N Y 
A132 Y Y Y 
A134 Y Y Y 
A136 Y Y Y 
A137 Y Y N 
A141 Y Y N 
A144 Y N Y 
A145 Y N N 
A146 Y N N 
A150 Y Y N 
A153 Y Y N 
A164 Y Y Y 
A170 Y Y Y 
A171 Y Y Y 
A178 Y Y N 
A188 Y N N 
A189 Y N Y 
A194 Y Y Y 
A198 Y N Y 
A201 N N N 
A204 N N N 
A206 N N N 
A207 N N N 
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Appendix III- Chapter 4 Supplemental Images 
 
 
 Characterization of Non-glycosylated Group I Pilin Producing Clinical Isolates 
 
A) 
GGAGATATTCATGAAAGCTCAGAAGGGTTTTACTCTGATCGAACTGATGATCGTGGT
CGCGATCATCGGCATCCTGGCCGCCATTGCCATCCCGCAATACCAGGACTACACCGC
CCGTACCCAGGTGACCCGTGCCGTGAGTGAAATCAGCGCGTTGAAGACCGCTGCGG
AGTCGGCGATTCTGGAAGGCAAGAAGCTTGTTTCCAAGGATAATCCCGCGGATGGG
GAATATGATCTTGGTTTTACCAAGTCTACTTTGCTTGCTGGCAACGACGGTAAGGCA
CAGATCACCATCACTGGCGAAAGCAGTGCAACCCCGACCATTGCGGGGACTCTGGG
TAACTCTGCTGGTAAGGCCATCAGCGGTGCCGTTATCACCATCAAGCGTAGTGCTGA
GGGAGTCTGGACCTGCGCTATCAGTGGGTCTCCGGCCAACTGGAAAGCCAACTACG
CTCCGGCCAACTGCCCGAAACCCTAA 
 
B) 
MKAQKGFTLIELMIVVAIIGILAAIAIPQYQDYTARTQVTRAVSEISALKTAAESAILEGK
KLVSKDNPADGEYDLGFTKSTLLAGNDGKAQITITGESSATPTIAGTLGNSAGKAISGAV
ITIKRSAEGVWTCAISGSPANWKANYAPANCPKP 
 
Appendix Figure 13. pilA nucleotide and amino acid sequences for clinical isolate non-
glycosylated group I pilin producing mutant strain 3778. A) The nucleotide sequence of 3778 
pilA. Yellow- Shine-Dalgarno sequence, green- the pilA start, underlined- proline encoding 
sequence, red- pilA stop. B) Amino acid sequence for strain 3778 pilA showing the C-terminal 
proline residue highlighted in gray. 
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ATGCGAATGTGGCTAGCCTGGGAAAGAATGGATAGGGTGCTGCGTACTATTCTGTTA
TTGCTGATAAGCATTCTTCTGCTTTCTCCCATCGTTTATTGCGGGGTTTCCGATAACT
GGCATGACCAGCAGCGAATACTCCAACTGGTAGTGTTGAGTGGATCGTCACTCCTGC
TGCTCTTTTCTTTTCCTCTGCCGTTTGCCAGAAGGATGGTTCAGGTAACACTGTTGGT
TATCTTGGGCTAGCCCGCATTTCTCACAGCCCTGCGCATTGGGCCGTTTTGACGGAC
GCAGGTCGTCGCAGGTGGCGCAGGCTGCCGACAGCGCTGATTTCGGGCAAGCGCCT
GCGAGCGCGCTTGAACAAGGCGCTTGCGGCAGGGTGGACGGGGTGTGATGTGGAGG
GGGACGGTGGGTGTGCGGCTGTCAGCGCGCCGCGGCGCTCAAGACATCGAAGGCGT
GATCGAACACCTCCTGCTGCGGGAAGGCCGAACTCATGGCCACTTTGACCCGGCGC
ACGCTCACGGTGATGACCGCGCCGATCTTGAGCAGCTTCAGGCGGATGCTACCGGN
CGTGGCCTGGGCCAGTTCGGTCCCCGACAGCGCCAGCCTGCGCAGGCTTTCGAGCA
GCACGTANGCGAACGAGGACAGCCACAGCCGCAGCTGGTTGCTGCGCAGCGTCNCG
GTGGAGGTGCGGTCGGCGAACAGGTCGAGCTGACACTCCTTGATGCGGTTCTCCATC
TCGCCGCGCGCGCAGTAGAGATCCTCATACAGCGCCTTGTCCGGNCAGNCCCCGAC
CGCNAGCGTGGTCACNNCGAANCGTGGGTTGGTCTTGNCNNNNNAAGGCCTCGGNN
NNGGCCACCACCCGGCGCNNGGCGCTCCANCNTTTTCCTCGTGCNNNNGNGCANTN
CNTGGAACACCCNNGNCNGGGNNNTCCCGNCNCTTCNNACTNCGCNTGGGNCNNNC
GNNNGNTCNNNNNNNNNNNNCNNNNAAAANAGATCGNNGNNNAGATNNTCGATCA
TGCNNGNNNNCGGCNNGNATCTNGTGATAGCGCGAACNNNNNGCNCCTGNAAGCG
CTCCAGCCNGTTGAGCGTGCTCTTGCCGNCCAAGGGCGCACAGCGCGCACGTCCGG
ACTGCAGCTTGCCGATCACCGCGCCCAGCAGCGGGTCGTGGCGCAGTTGCTCGTGAT
CGTTGAGATCCTCGTAGCCCAGCGCGATGCCCATCACCCGCTGCGCCACCAGCGTGC
GCAGCGGAAACTCCACCGCCTCGGGCATCCGATCGTCCTGGAAACAGCCGNCCAGG
CGATCGAACAACCCCACCGCTTCATCGGTTTGTTTGAGCAGCAACGCGCCGCCATCC
GAACTCACCCGACCGCCATCAAATCCGGCTACCACCGCGCGCCGCCCCACCCCTGA
AAACGTGTACTGCTTCGGATTACACTGTGTCTGCATCGGGCCGCTCTCCGTTGTCGC
GCTAAATCGTTCTTTGCACAACAATTTTCGCGCATCCGACGGCCCGGTGCATCTCTTC
CTGTGAGAAATGCGGGCTAGGCAGCGTTTCCGCATTTCTCTCCGCCAATCCTTCCTG
GGCATTTAAGGAATGGTCGGTATTCGCCGGCCTGATGCTGTTTTCCTTCAATATATCC
GCCAGCCCAGAGTGGGTTCGCCGTATCGCCCTCTGGGGGCTGGTCGTGTTGGGAGGG
TTCTTCTGCTACCAGTTCCTGCTTTCCTATCTCGCGGCCTTCGTCAGCGGACTCCGTG
AGTTGAATCCCAGGGTTTTGCTCAGCGGCTTTTCCAACGTTCGGACCATGGGGCAGT
TCCAGGCCATGCTGCTGCCGCTGATGGCTGCGCTGGGGCTGTACCTGCGAGAGACCG
GGCGGTTCAGGCTGTCCCGGCTTGTCATGCTGCTGCTGGCCATTCAATGGTGCATCT
CCTTCGCCTTGGCTGGACGCGGGCTCTGGTTGGGTTTCGCCGTCGCGCATCTCGCGC
TTTGCTGGATCGGCCCCGTGGGGCGCCGCTTTTTGATCGTCCAGTTGTCCGCGGTATT
CGTCGGACTGGCGCTCTATTTCCTGCTAATGGTTGCCTTGCCGACCTGGCTCGGTATC
GACATGACCCTCATGTCCGGTATGCGCAGTGGTCTGTCTCTGCGCGACGTGTTGTGG
CGAGATGCCTGGGGCATGTTCGTAGCCCATCCTTTGCTTGGGGTCGGGCCCATGCAT
TTTTCGGCGGTGCCGAATAGCGTCGGTGCCCACCCGCACCAGATGCTGCTGCAATGG
TTCGCCGAATGGGGTGGGGTCGCTGGCCTTCTGGTGGTTGGGCTGATGATCCTTGGT
CTGCTTCGCGGCGCGCGTTACCTGCGTGAACAGGGCGATTCGATGGACGCCGGACT
GTGGCTGGCCCTTGTTTCGGTCCTGGTCCTGGCCCAGGTGGACGGCGTGTTCGTCAT
GCCCTTCACCCAGACCGTATTGGCCTTGCTGGTAGGCATCGCCATGGCACGCTGGTC
GAAGCCGGTCGCGCCGTCCCCCGCACAGCGCTGGCTCTGTCGGGGCCTGGCTGTCGT
TGTCATTGTCGTGCTGGGGCGCGTGCTGCTGCTCGAGGTGCCGGGGCTGACCGCGGC
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CGAGGAGCGCTACCTGGAAATCCACGGCGGCGGTGAGGCGCCACGTTTCTGGATTC
AGGGTTGGATTCCCATGTGA 
 
Appendix Figure 14. pilO nucleotide sequence of A031 with insertion. Nucleotide sequence 
for strain A031 pilO showing the start site (green), pilO DNA (yellow), sequence repeats 
(underline), insertion sequence (gray), and stop (red). 
 
 
TGCTATCCCTGATAGCGGCTATGCTGCTATCGACTGTAATTCATTATGGGGTTTCTCC
GAACTGGCACGACCAGCAACGCATATTCCAGTTGCTGTTGCTGAGTGGCTCGTCACT
GTTTTTTTTCTTGTATTTTCCTTCTTCGCTTATTAGGGATGGTCTGAAGTAGCCACGTA
TTTCTGGCCGACTACAGACCTCGCTGTTTTTTGAAGCGATCCATCGATCAAAAAGCG
CTCAGATCGTCGTCTTATGTAGGGTTTTTAGCCGCTACGCGTACCCCGTAGCGGCTAT
TCGCCGTGTTACAGGCGCACCTCTCCTGTGTTCGCGAGTAAATGCCGCCGCGCCATC
CACAGATTCGACAGCGCAAACAGCGTAATCAGTTGTGCGGTGTTCTTGGCCAGGCCA
CGGAAGCGCACCTTGGTGTAACCAAACTGGCGCTTGATCACCCGGAATGGATGTTCG
ACCTTGGCACGTACCTGCGCCTTGGCCTTCTCGATTTTGCGCTTGGCCTTGTACAGCG
GGCTGCGCTTGCTCAGTTGCTGGTAAGTGCTGCGCCGCGCCGCAATCTGCCAGATGA
CCGAGCGGCCTGCATGCTCGGCACGCTTCTCGACGCCGGTATAGCCGGCATCGCCGC
TGACCAGGTTCTCTTCGCCGTGCAGCAGCTTGTCCACCTGGGTGACATCGGCCACGT
TGGCCGCCGTGCCCACCACGCTGTGTACCAGGCCGGATTCGCTGTCGGCGCCGATGT
GCGCCTTCATGCCGAAGTAGTACTGGTTGCCCTTCTTGGTCTGGTGCATCTCGGGATC
GCGCTTGCCGTCCTTGTTCTTGGTCGAGCTCGGCGCATGGATCAGCGTGGCGTCGAC
GATGGTGCCCTGGCGCAGCGACAGGCCACGGTCGCCCAGGTAGCCATTGATCACCG
CCAGAATCCCGGCCGCCAGCTCGTGGCGCTCCAGCAGGCGACGGAAGTTGAGGATG
GTGGTTTCGTCGGGGATACGCTCCAGGCTCAGCCCGGCGAACTGGCGCAGGATGGT
CGTCTCGTACAGCGCTTCCTCCATCGCCGGGTCGCTGTAGCCGAACCAGTTCTGCAA
CAGATGCACGCGCAGCATCGCCATCAGCGGATAGGCGGGACGACCGCCTTCACCCT
TCGGGTAGTGCGGCTCGATCAGGGCGATCAGGCCCTGCCACGGCACCACCTGTTCCA
TTTCGATCAGGAACAGTTCCTTGCGGGTCTGCTTGCGCTTGCCGGCGTACTCGGCGT
CGGCGAAGGTCATCTGCTTCATCGGAAAGCTCTGCGGGTGAAGTCGGCGGATTTTGC
CAAATCAGGAAGTCTTTTTCAGAGTTTCCTTAGGCGAAAGGTTTTTGCCGCTCTATTG
TTGACTCTCGGGCTGGGTGTTTTTTCCTCCTTTCTTTCTGATAATTCTTCCTGGGCGCT
CAAGGAGTGGTCGGTATTCTCCGGCCTGATGCTGTTCTCCTTCAATATTTCCGTCAGT
CCCGAGTGGGTTCGCCGTGCCGCTATCTGGGGGCTGGTCGTGTTGGGAGGGTTCTTC
TGCTACCAGTTCCTGCTTTCCTATC 
 
Appendix Figure 15. pilO nucleotide sequence of 1631 with insertion. Nucleotide sequence 
for strain 1631 pilO showing pilO DNA (yellow), sequence repeats (underline), and insertion 
sequence (gray). 
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Appendix Table 6. Summary of mutant glycosylation pathway defects. + = no defect, - = 
defect. 
 
Isolate pilA structure(+/-) pilO structure(+/-) O-Ag synthesis(+/-) 
3778 - + + 
1631 + - + 
A031 + - + 
A107 + + - 
A033 + + - 
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 Verification of Complementation 
 
 
 
 Appendix Figure 16. Western blot showing pMBT7 (pMBT100) complemented 
1631. This image shows that the inducible promoter plasmid pMBT7 (pMBT100) provides the 
same level of complementation as the uninducible promoter plasmid pUCP26pilO in 
complemented 1631 cells. 
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 Appendix Figure 17. Western blot showing cell bound and sheared surface pili of 
pBADGrpilO complemented 1631. This image shows that both glycosylation and piliation are 
restored with the pilO
1244
 carrying inducible promoter plasmid, pBADGr. 
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 Verification of Glycosylation Loss of Engineered A074 PilO- Mutants 
 
 
 
Appendix Figure 18. Western blot showing glycosylated group I pilin producing 
clinical isolate, A074 and isogenic PilO- mutants. Whole cell lysates preparations of strain 
A074 and A074TK1-3 (A074 pilO knockout strains).  
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Appendix Figure 19. Complementation verification of pBADpilA
A074
 plasmid. 
Complementation verification of the functionality of strain 1244.47 containing the construct 
pBADpilA
A074 
with pUCP26pilO. A) Cell bound fractions. B) Sheared surface pili fractions. 
Duplicate lanes were cropped from the image.  
 
 
 
 
 
 
 
 
B.  A.  
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Appendix Table 7. Mercy Hospital Isolate Data. Information on strain, source, O-antigen 
serotype, pilin group PCR, antibody reaction with both group I and group II antibodies. 
 
Strain Source O-ag Group data 1244PAb Pep2 Pep1(LKT) 11.14 219 5.44 2.97 
3601 Sputum ? PCRI - - -  - -  
3855 Sputum O6 PCR?SeqIII - - - - - -  
3681 Sputum O6 PCRIWI + - -  + + - 
4051 Sputum O11 PCRIWI + + + - + + - 
3890 Sputum ? PCRIIWII - - -  - - + 
3829 Sputum O7? PCRIIWII + + -  - - + 
3614 Sputum ? PCRI - - -  - -  
9189 Sputum ? PCRIWI + + + - + + - 
8584 Sputum ? PCRIWI + - -  - - - 
7828 Sputum O11 PCRIWI + + -  + + - 
794 Sputum ? PCRIWI + - -  - -  
1017 Sputum O11 PCRIWI + - - - + + - 
1030 Sputum ? PCRI - - -  - -  
683 Sputum O11W WIIISeqIII - - -  - -  
1641 Sputum ?  - - -  - -  
736 Sputum O11 PCRIWI + + - - + + - 
560 Sputum ? PCRIWI + - -  - -  
4061 Sputum ? PCRIISeqIV - - -  - -  
8459 Urine O9 PCRIWISeqI + - -  + +  
2300 Urine ?  - - - - - -  
8437 Urine ? PCRIIWII - - -  - - + 
7256 Urine ?  PCRI - - -  - -  
1631 Urine ? PCRIWI + - -  + +  
1410 Urine O2 PCRIIWII - -   - - + 
6662 Ear ? PCRII - - -  - -  
8536 Ear O6 PCRIIWII - - -  - ? + 
8052 Ear ? PCRII - - -  - -  
3545 Ear NT PCRIIWII - - -  - - + 
3585 Ear ? PCRIWI + - -  - -  
1580 Ear O11 PCRIWI + + + - + + - 
4871 Leg O6 PCRIWI + + -  + + - 
3828 Leg O7 PCRIII  - -  - -  
6943 Leg ?  - - - - - -  
1185 Leg O5 SeqVI - - -  - - - 
3778 Eye O6W WISeqI + - -  - +  
7917 Eye 07 PCRI - - -  - -  
9260 Chest O6  - - - - - -  
3994 ? O6 WII - - -  - - + 
4073 ? ?  - - -  - -  
7604/8604 ? ? PCRI - - -  - - - 
1248 ? ? PCRIII - - -  - -  
2633 ? O6 PCRIWI + + -  - -  
2800 ? ? PCRIII - - -     
8928 ? O9 WISeqI - - -  + + - 
9053 ? O7? PCRIWI + + -  + + - 
9204 ? O11 PCRIWI + + -  + + - 
495 ? ? SeqIII - - -  - -  
846 ? ?  - - -  - -  
124A ? ? SeqIII - - -  - -  
 196 
7494 ? ?  - - - - - -  
8033 ? O2 PCRII        
8012 ? O6 PCRII        
5870 ? O13 SeqII        
4816 ? O10 WI      +  
7706 ? O20 SeqIII        
1136 ? ? SeqII        
5018 ? ?       -  
8848 ? O19 WI      +  
8433 ? ?       -  
8430 ? O20 PCRII        
4239 ? O16 PCRII        
6200 ? O6 WI      +  
6640 ? ? WISeqI      +  
5605 ? ? PCRII        
4271 ? O11 WI      +  
4923 ? O11 PCRII        
MHU0101 Urine        -  
501         -  
502         -  
024769   WI      +  
435012-
15297 
  WI      +  
650618         -  
371603         -  
558767-
15295 
  WI      +  
476675-
17495 
  WI      +  
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 Appendix Figure 20. Isoelectric focusing blot of controls and clinical isolates. Pilin 
protein from controls (1244, 1244G7, 653A, and 577B) and clinical isolates (A074, A059, A076, 
and A085) show varying isoelectric depending on the presence or absence (1244G7) of the pilin 
glycan.  
 
 
 
 
 
 Appendix Figure 21. Comparison of P. aeruginosa strain 1244 and A074 PilA 
primary amino acid sequences. The underlined residues show the only difference between the 
pilins of these two strains. This change provides the 1244 pilin with an overall negative charge at 
pH 7.0 while the A074 pilin exhibits a neutral state.  
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Appendix Figure 22. Cell bound and sheared pili fractions of pilA
1244
 in 1244.47 
cells. Expression of pilA
1244
 in 1244.47 cells show a potential increase in non-glycosylated pilin 
protein. 
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Upon first analysis of the initial 107 Children’s Hospital Clinical Isolates, data showed 
that there was a selection for non-glycosylated strains in the non-respiratory infection category, 
specifically the urinary tract isolates. Urinary tract infection isolates were then specifically 
requested in addition to the random isolates noted in Appendix Table 1. These samples were 
referred to as the B series and studied separately from the above sample set. Once more isolates 
were obtained, this initial finding because diluted out and was not statistically significant. 
Furthermore, western blot analysis showed that the majority 10/14 (71.4%) of the group I urine 
isolates produced glycosylated pilin which was the opposite of the expected results. This avenue 
of research was thus neglected to pursue more novel and significant results.  
Appendix Table 8. Urine isolates information. 
Pick-up Date Number Source Group I: WB 5.44 
 
Glycosylated 
 
2/24/2012 B001 urine Yes 
 2/24/2012 B002 urine 
  2/24/2012 B003 urine 
  2/24/2012 B004 urine Yes Yes 
4/6/2012 B005 urine 
  4/6/2012 B006 urine Yes Yes 
4/6/2012 B007 urine 
  4/6/2012 B008 urine Yes Yes 
4/6/2012 B009 urine Yes 
 4/6/2012 B010 urine Yes 
 4/6/2012 B011 urine 
  4/6/2012 B012 urine Yes 
 4/27/2012 B013 urine Yes Yes 
4/27/2012 B014 urine 
  5/17/2012 B015 Urine 
  5/17/2012 B016 Urine 
  6/13/2012 B017 Urine culture Yes Yes 
6/13/2012 B018 Urine culture Yes Yes 
6/13/2012 B019 Urine Yes Yes 
6/13/2012 B020 Urine 
  6/13/2012 B021 Urine culture 
  7/3/2012 B022 Urine 
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7/3/2012 B023 Urine 
  7/3/2012 B024 Urine Yes Yes 
7/3/2012 B025 Urine 
  7/3/2012 B026 Urine 
  7/3/2012 B027 Urine Yes Yes 
7/3/2012 B028 Urine 
  7/3/2012 B029 Urine Yes Yes 
 
 
